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I 
 
Abstract  
Individuals reporting chronic respiratory symptoms without airflow obstruction (AFO) were 
originally classified as “at risk” stage (GOLD Stage 0) of Chronic Obstructive Pulmonary 
Disease (COPD). However, this stage was removed due to lack of evidence regarding its 
progression to diagnosed COPD. There remain many such individuals in the population, 
including some already misdiagnosed with COPD despite not meeting required criteria. 
This thesis aims to clarify the uncertainty around the relevance of “GOLD Stage 0”. There are 
three systematic reviews examining the risk of developing COPD amongst GOLD Stage 0 
patients, their prognosis and the prognostic factors. The independent effect of respiratory 
symptoms versus AFO on quality of life is examined using data from the Health Survey for 
England. Baseline data from the Birmingham COPD Cohort Study are used for two cross-
sectional analyses, (1) comparing GOLD Stage 0 patients with those recently identified with 
COPD and (2) examining the characteristics of those “overdiagnosed” with COPD. 
GOLD Stage 0 patients showed a similar pattern of poor health outcomes to those diagnosed 
with COPD. Overdiagnosis of COPD was common, particularly among GOLD Stage 0 
patients. Obesity and restrictive disease were potential explanations for some overdiagnosed. 
The presence of chronic respiratory symptoms has a negative impact on patients’ health, 
regardless of the presence of diagnosed AFO. 
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1 INTRODUCTION 
 
1.1 Chronic Obstructive Pulmonary Disease (COPD) 
COPD is a complex heterogeneous disease (1, 2) consisting of a number of chronic 
respiratory disorders that progress gradually into airflow obstruction (3, 4). It is usually 
associated with chronic respiratory symptoms such as cough, sputum production, dyspnoea, 
and wheeze (5). The most widely used definition of COPD is that of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) committee, which defines COPD as ‘a common 
preventable and treatable disease, is characterized by persistent airflow limitation that is 
usually progressive and associated with an enhanced chronic inflammatory response in the 
airways and the lung to noxious particles or gases. Exacerbations and comorbidities 
contribute to the overall severity in individual patients’(6, 7).  
1.2 The Burden of COPD in the UK 
COPD is a major public health concern (8) and an important cause of morbidity and mortality 
worldwide (9-11). As a result of the demographic, environmental and socioeconomic changes 
over the last decades, the prevalence of COPD is markedly increasing (12), with the global 
burden of COPD predicted to escalate in the coming decades (12, 13). However in its early 
stages, COPD usually remains unrecognised or misdiagnosed (12, 14).  
1.2.1 Epidemiological Burden  
1.2.1.1 Prevalence 
According to the Quality Outcome Framework (QOF) statistical bulletin, the prevalence of 
diagnosed COPD in 2012/2013 was 1.74% of the UK population and increased to 1.78% in 
2 
 
2013/2014 with an estimation of approximately 1.5 million people diagnosed with COPD 
(15). However, the estimated number of people actually affected by COPD in the UK is three 
million (16), with about half remaining undiagnosed (7).  
1.2.1.2 Mortality 
Ascertainment of the COPD mortality rate is challenging; many patients with COPD die 
because of COPD-related causes, with their deaths certified as caused by these complications 
rather than COPD itself (7, 13). In 1990, the Global Burden of Disease Study ranked COPD 
as the sixth cause of death and it is predicted to become the third by the year 2020 (6, 13). In 
the UK, around 30,000 deaths each year are attributed to COPD (3, 7, 16).  
1.2.1.3 Morbidity 
Morbidity measures commonly include physician visits, emergency department visits and 
hospital admissions (6); however, COPD coexists with other tobacco-smoking-related 
diseases, such as cardiovascular diseases and lung cancer, with these comorbidities making 
COPD morbidity measures much more complicated (7). In the UK, there are approximately 
1.4 million COPD consultations within general practice each year—a figure four times greater 
than the number of angina consultations (7).  
1.2.2 Economic Burden  
COPD is a costly disease (7). Its direct cost to the UK healthcare system has been estimated at 
between £810 million and £930 million each year (7) with an annual average of £2,108 per 
patient (16). Moreover, the indirect costs of COPD are considerable due to its influence on 
annual productivity, which has been estimated at 24 million lost working days per year (7, 17, 
18), with a cost of more than £3.8 billion to employers and the UK economy (17).  
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1.3 Risk Factors 
Whilst cigarette smoking is known to be the main risk factor for COPD (6, 19), there are other 
factors which must be also considered (20), as epidemiological studies have consistently 
shown the development of COPD amongst non-smokers (6, 21). Other risk factors include 
occupational exposure (22), outdoor pollution (23), indoor pollution such as exposure to  
passive smoking (24) and biomass smoke (25), and some rare genetic syndromes such as 
alpha-1 antitrypsin deficiency (21).  
The presence of asthma and bronchial hypersensitivity are also found to be risk factors for 
COPD (21), although the evidence is not definitive (6). According to the “Dutch hypothesis”, 
bronchial hyper responsiveness, a distinctive feature of asthma, leads to the development of 
COPD (26). Results from previous studies have shown an overlap of up to 30% between 
patients who have a clinical diagnosis of COPD and asthma (26). Furthermore, airways hyper 
responsiveness has been found to be an independent risk factor for the accelerated decline in 
FEV1 (27) particularly among smokers (28). However, this hypothesis remains controversial 
due to lack of consistent supporting evidence (28, 29).  
Moreover, COPD results from a complex gene-environment interaction (6). Importantly, 
gender could affect a person’s smoking behaviour or exposure to occupational or 
environmental factors (6, 19), and low socioeconomic status is associated with many factors 
that increase the risk of developing COPD (26) such as crowding, poor nutritional status and 
higher smoking rates (26). Low socioeconomic status might also influence a child’s birth 
weight, which could, in turn, affect lung growth and predisposition to develop COPD (30, 
31). Furthermore, aging has the potential to result in a longer lifetime exposure to COPD risk 
factors (6).  
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1.4 Symptoms of COPD  
1.4.1 Cough and sputum  
Cough is usually the first symptom of COPD (18), starting intermittently before progressing 
to become persistent, with variable sputum production (3). The presence of chronic cough 
with regular sputum production for three months or more over two consecutive years has been 
the epidemiological definition of chronic bronchitis (CB) (18). However, this pattern of 
sputum production is not always seen in COPD, which usually has variable patterns (7, 18)  
1.4.2 Dyspnoea  
Shortness of breath is the most disabling symptom of COPD (3). It is usually the primary 
symptom that drives patients to seek medical advice (3, 18). The impact of breathlessness on 
patients is usually graded using the Medical Research Council (MRC) dyspnoea scale (Table 
1). This scale can be used to assist with treatment plans and also as a prognostic indicator (3).  
Table 1: MRC Dyspnoea Scale (3)  
Grade Degree of breathlessness related to activities 
 
1 Not troubled by breathlessness except on strenuous exercise 
 
2 Short of breath when walking or hurrying up a slight hill 
 
3 Walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath 
when walking at own pace 
 
4 Stops for breath after walking about 100 metres or after a few minutes on level ground 
 
5 Too breathless to leave the house, or breathless when dressing or undressing 
 
1.4.3 Wheeze  
Chest wheezing and tightness are non-specific and variable symptoms in COPD (6); the 
presence of these symptoms does not confirm the diagnosis of COPD and their absence does 
not exclude it (18).  
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1.4.4 Systematic symptoms  
In many patients, COPD may present with systematic manifestations (32). These may include 
cardiovascular compromise, malnutrition and weight loss, muscle wasting, anaemia, 
osteoporosis, and clinical depression (33-35).  
1.5 Diagnosis of COPD 
The diagnosis of COPD in the UK primary care setting follows the guidelines of the National 
Institute for Health and Care Excellence (NICE) (16). NICE recommends that a clinical 
diagnosis of COPD should be suspected in patients over 35-40 years of age, complaining of 
chronic cough with sputum and dyspnoea (7) and with a positive clinical history of exposure 
to COPD risk factors (7). However, spirometry is required to confirm the diagnosis (7). 
Currently, there is no international consensus on the best spirometric criteria for a clinical 
diagnosis of COPD (36); the presence of post-bronchodilator ratio of forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC) of <0.70 (FEV1/FVC<0.70) 
confirms COPD diagnosis according to the GOLD committee/current NICE guidelines (6, 7). 
Whilst a former criteria in the UK is that of the British Thoracic Society/NICE (2004) which 
requires a combination of the FEV1/FVC fixed ratio of less than 0.7 with a low FEV1 value of 
less than 80% of predicted (equivalent to COPD GOLD Stage 2) (36). However, the use of 
fixed ratio is recognised as potentially overestimating the prevalence of COPD amongst the 
elderly (37), because it does not account for normal age-related airflow limitation (38, 39) and 
may overestimate the effect of age by 50% (40). Therefore, the European Respiratory Society 
(ERS) and the American Thoracic Society (ATS) have adopted the Lower Limit of Normal 
(LLN) criteria to diagnose COPD (41), which categorises lung values below the 5
th
 percentile 
of the healthy non-smoking reference population as ‘abnormal’ following adjustment for age, 
sex, height and ethnicity (41, 42). 
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1.6 Management of COPD  
NICE guidelines have developed comprehensive management plans for patients with COPD 
(7). The following are some of the main components for managing stable COPD: 
1.6.1 Smoking cessation  
Smoking cessation is the most effective intervention in patients diagnosed with COPD (7). 
Evidence has shown that, stopping smoking in COPD patients slows the rate of FEV1 decline 
(43, 44) and improves patients’ symptoms (45), leading to slower disease progression rate and 
better survival (7). In the UK, smoking cessation services are widely accessible and have 
shown effective improvement in short term smoking cessation rates (53% in four weeks and 
15% in one year) (46).  
1.6.2 Pharmacotherapy  
COPD is usually treated with inhaled medications (7) including, short-acting beta agonists 
(SABA) and short-acting antimuscarinic antagonists (SAMA) for treating breathlessness and 
exercise restriction (7). Long-acting beta agonists (LABA) and long-acting antimuscarinic 
antagonists (LAMA) for treating severe stable COPD (16). Whilst inhaled corticosteroids 
(ICS) and combination inhalers are usually recommended by NICE for treating exacerbations 
or persistent breathlessness (7). Furthermore, COPD patients with exacerbations may also be 
prescribed oral antibiotics and corticosteroids (7). Long term oxygen therapy is recommended 
by NICE for patients with severe COPD as it has been shown to improve their survival (7, 
47). 
1.6.3 Pulmonary rehabilitation  
Pulmonary rehabilitation is ‘a multidisciplinary programme of care for patients with chronic 
respiratory impairment that is individually tailored and designed to optimise each patient’s 
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physical and social performance and autonomy’ (7). It becomes an increasingly effective 
management option of patients with moderate to severe COPD (usually with MRC dyspnoea 
scale grade three or higher) (7). Rehabilitation aims mainly to help patients to better cope with 
their disease (7). It has been shown to reduce patients’ breathlessness and fatigue (48), 
improves their psychological function (48) and quality of life (49) and reduce the hospital 
admissions and mortality risk following acute exacerbations (49).  
1.6.4 Immunisation 
According to the National policy, annual influenza vaccination should be provided to all 
patients with COPD regardless of the disease severity (7). Available evidence has shown that 
influenza vaccine significantly reduces the frequency of exacerbations among COPD patients 
(50) and significantly reduces COPD-related hospital admission rates (51). 
Pneumococcal vaccine is also recommended for all COPD patients (7), as Streptococcus 
pneumoniae is a common bacterial pathogen causing COPD exacerbation (52). However, 
evidence is inconclusive from previous randomised controlled trials regarding the 
effectiveness of Pneumococcal immunisation on reducing exacerbations, hospitalisation and 
mortality in COPD patients (53).      
1.6.5 Self-management and rescue packs   
Self-management can be described as ‘a set of skilled behaviours and refers to the various 
tasks that a person carries out for management of their condition’ (54). Although there is no 
consensus on the most effective method and the main components of self-management plans 
in COPD (7, 55), self-management interventions among COPD patients have been found to 
be associated with improved health related quality of life (HRQoL) and dyspnoea scores (56) 
and with reduced hospital admission rates (56, 57).   
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The primary aim of  self-management in COPD is to prevent exacerbations (55) by assisting 
patients to acquire the skills to respond to the early signs of exacerbations by starting or 
adjusting their medications (7, 58). Therefore, patients at risk of exacerbations should be 
provided with self-management plans and given a course of steroids and antibiotic (COPD 
Rescue Pack) to keep at home enabling them to respond earlier to the symptoms of 
exacerbation (7). However, the appropriate use of these medications must be monitored and 
patients must be advised to contact a healthcare professional if they do not improve (7).  
1.7 Overdiagnosis of COPD 
The problems of overdiagnosis and underdiagnosis of chronic diseases (including COPD) 
coexist in many healthcare settings in the developing and developed world (59), which pose 
challenges in daily practice with subsequent inappropriate patient management (36). 
However, a correct diagnosis of COPD is essential because of its specific therapeutic and 
prognostic consequences on diagnosed patients (60). The inappropriate use of COPD 
medications to treat patients who do not have the disease may not only result in under-
management of the true underlying aetiology that caused the patient’s symptoms (61) but also 
exposes patients to potentially harmful adverse effects of these medications (62, 63). For 
instance, ICS have been associated with an increased risk of pneumonia (64, 65) and LABAs 
may cause adverse cardiovascular effects (61, 66). Furthermore, COPD is associated with 
higher healthcare costs (61) and provision of COPD management to patients who do not have 
the disease is an inefficient use of healthcare resources with unnecessary expenditure (60, 62, 
67, 68). There are number of reasons why COPD may be overdiagnosed in primary care:    
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1.7.1 Primary care practitioners related factors  
1.7.1.1 Spirometry underuse 
Lack of spirometry confirmation, especially when General Practitioners (GPs) rely upon the 
nonspecific clinical respiratory symptoms and smoking history for COPD diagnosis (69), 
increases the risk of misdiagnosis of COPD, asthma or other comorbidities (Table 2) (68). All 
of which have different physiological mechanisms and thus different management strategies 
(68, 70). Some studies in the UK have found that approximately one third of practices had no 
spirometry available (71, 72) and in many practices that owned spirometry, nurses lacked 
adequate training and support to perform spirometry and interpret the results (71-73).  
Table 2: Other conditions that may present with similar symptoms as COPD (7)  
Common: 
 Asthma  
 Bronchiectasis  
 Congestive cardiac failure 
 Bronchial carcinoma  
Uncommon:  
 Obliterative bronchiolitis  
 Broncho pulmonary dysplasia  
 
1.7.1.2 Pre-bronchodilator spirometry for COPD diagnosis  
Relying upon pre-bronchodilator spirometry may lead to an overestimation of COPD 
prevalence (72) due to its higher rate of false positive diagnosis (74). Therefore, the GOLD 
and the current NICE (2010) guidelines specify the relevance of post-bronchodilator 
spirometry in diagnosing COPD (6, 7, 72). However, the previous NICE (2004) guidelines 
did not specify pre- or post-bronchodilator spirometry for COPD diagnosis (7). Despite 
guidelines, a recent internet-based survey in 12 countries including the UK, found that 22% of 
primary care practitioners and 15% of respiratory specialists reported the use of pre-
bronchodilator spirometry only in diagnosing COPD (75).  
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1.7.1.3 Lack of awareness and implementation of COPD guidelines  
Standard guidelines sometimes are not well implemented by many GPs in diagnosing and 
managing COPD (72, 76). Moreover, some studies have found that, in primary care, inhaled 
corticosteroids are commonly prescribed in patients with respiratory symptoms but who have 
not had a proper diagnosis or indication for this treatment (77, 78).  
1.7.2 COPD and asthma overlap 
One of the important differential diagnoses of COPD is asthma and both conditions often 
coexist (7). However, it is important to differentiate between both conditions to ensure correct 
treatment and the best possible outcome for the patient (76). Although there is similarity 
between COPD and asthma symptoms (78, 79) and both conditions are associated with 
inflammation and reduced pulmonary airflow, they have different underlying mechanisms and 
different medical history and clinical presentation (80, 81) (Table 3). Therefore, in most cases 
both conditions can be differentiated based on a proper history and clinical assessment (76). 
Furthermore, reversibility testing is beneficial in differentiating COPD and asthma in cases 
where there may be doubt (72). However, neither GOLD nor NICE guidelines recommends 
reversibility testing for diagnosis of COPD but recommends a differentiation between asthma 
and COPD based on clinical features (6, 7, 72), unless a diagnostic uncertainty remains, 
where only a significant reversibility of FEV1 of more than 400 ml confirms asthma diagnosis 
(7). However, the misclassification of asthma and COPD in primary care settings remains 
common (69, 80, 82, 83).  
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Table 3: Clinical features differentiating COPD and asthma (7, 76)  
 
Diagnostic features 
 
COPD  
 
Asthma  
 
Symptoms under age 35 
 
Rare 
 
Often 
 
Smoker or ex-smoker  
 
Nearly all 
 
Possibly 
 
Allergic hypersensitivity  
 
Rarely a factor  
 
Usually  
 
Chronic productive cough  
 
Common  
 
Uncommon and non-productive 
 
Breathlessness  
 
Persistent and progressive  
 
Variable and intermittent  
 
Nocturnal symptoms  
 
Uncommon except in severe stages  
 
Common  
 
Cause of exacerbations  
 
Bacterial/viral respiratory infection  
 
Allergens, exercise or cold air 
 
Response to bronchodilators 
 
Variable, PFT does not normalize 
but may show some improvement 
 
Quick response and PFT may 
significantly improve, e.g. FEV1 
may improve 400ml  
PFT: pulmonary function test 
1.7.3 Patient related factors 
Patients’ clinical factors such as age, sex, smoking, obesity and nasal obstruction secondary to 
allergic rhinitis and hay fever may lead to a clinical presentation with chronic respiratory 
symptoms and increase the possibility of over diagnosing those patients with COPD (60). 
Furthermore, patients with other chronic disease such as congestive heart failure (6), may 
present with similar respiratory symptoms of COPD (Table 2). Restrictive lung disease is 
another differential diagnosis of COPD (84) and it has different aetiological factors including, 
congestive heart failure, diabetes mellitus, obesity, muscular weakness and interstitial lung 
disease (85). However, evidence about patient related clinical factors associated with COPD 
overdiagnosis is limited. 
1.8 Chronic respiratory symptoms but normal lung function: COPD 
GOLD Stage 0  
The GOLD guidelines for COPD were first published in 2001 (86) and aimed to provide a 
standard global framework for COPD prevention and management (12, 86, 87). Five stages of 
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COPD severity were originally classified according to post-bronchodilator spirometric lung 
function measurements (Table 4). Many components of the original GOLD guidelines and 
staging system are controversial (86), particularly COPD GOLD Stage 0 (12), which has been 
defined by ‘the presence of chronic respiratory symptoms, such as cough and sputum 
production, but with preserved normal lung function (FEV1/FVC >70%)’ (86, 88). Patients at 
this stage were considered as being ‘at risk’ of developing COPD in the future (19, 89) and 
the main idea behind the inclusion of this stage was to allow for early intervention, prior to 
progression to Stage 1 or even more advanced stages of diagnosed COPD (90). However, due 
to lack of supporting evidence regarding this progression from GOLD Stage 0 to COPD 
Stages 1+, GOLD Stage 0 has been excluded from the GOLD staging scheme since 2006 
(91). However, the significance of the public health message that chronic respiratory 
symptoms are abnormal and their underlying causes must be identified remains unchanged 
(91). 
Table 4: 2001 GOLD classification of COPD Severity (88, 92) 
 Characteristics 
Post-bronchodilator spirometry Chronic respiratory symptoms 
 
GOLD Stage 0 (At risk) Normal spirometry  
(FEV1/FVC > 0.70) 
+ 
GOLD Stage I (Mild COPD) FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
± 
GOLD Stage II (Moderate COPD) FEV1/FVC < 0.70 
FEV1 < 80% but ≥ 50% predicted 
± 
GOLD Stage III (Severe COPD) FEV1/FVC < 0.70 
FEV1 < 50% but ≥ 30% predicted 
± 
GOLD Stage IV (Very Severe 
COPD) 
FEV1 ≤ 30% predicted or FEV1 < 
50% predicted plus chronic 
respiratory failure
1
 
± 
 
FEV1: forced expiratory volume in one second. FVC: forced vital capacity  
 
                                                 
1
Respiratory failure is defined as ‘arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without 
arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level’  
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1.8.1 COPD GOLD Stage 0: areas of controversy  
The main area of disagreement regarding GOLD Stage 0 is whether this stage has any 
prognostic significance (93). Previously published data have shown that an important 
proportion of patients with abnormal pulmonary function do not report respiratory symptoms 
(87). On the other hand, a large proportion of patients with normal lung function report 
respiratory symptoms but do not develop COPD (87). Another area of debate concerns the 
respiratory symptoms essentially required to define GOLD Stage 0, where most previous 
studies have used the MRC definition of CB of ‘the presence of productive cough for three 
months in two successive years in a patient in whom other causes of chronic cough, have been 
excluded’ (94). Importantly, few studies suggest a more sensitive definition of GOLD Stage 0 
by including a wider range of respiratory symptoms (cough, phlegm, wheeze, breathlessness), 
which are seen to occur on a recurrent basis (93, 95).  
1.8.2 Natural history of COPD GOLD Stage 0 
1.8.2.1 Earlier Epidemiology  
The Fletcher and Peto prospective 8 year cohort of working men aged 30 to 59 years in 
London (96), was the first study aimed to clarify the risk factors for developing COPD other 
than smoking (96). They studied the independent effect of chronic mucous hypersecretion 
(CMH) on FEV1 decline (96), finding no independent association between CMH and 
accelerated decline in FEV1 following adjustment for smoking and other potential 
confounders (96). The study concluded that smoking remains the main risk factor for COPD 
(96) and that CMH lacks any predictive value for developing of COPD (28). A similar 
conclusion was drawn from Kauffmann et al, in their 12 year cohort study of male chemical 
factory workers in Paris from 1960 to 1972 (97). They studied a wider range of respiratory 
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symptoms than Fletcher and Peto by including exertional dyspnea ‘even slight’ (97) with 
chronic cough and phlegm, finding a non-significant effect of respiratory symptoms on excess 
decline in FEV1 and that they lack any predictive value for subsequent development of COPD 
(97).  
1.8.2.2 More recent Epidemiology 
More recently, contradictory findings have been reported from studies which examined 
GOLD Stage 0. Some studies have found that GOLD Stage 0 is lacking any independent 
predictive value of increased risk of developing COPD (86), whereas other studies have found 
it to be associated with an increased risk of developing COPD (98, 99). Moreover, GOLD 
Stage 0, in some studies, has been recognised as associated with a higher healthcare utilisation 
(90, 100, 101), lower HRoQL (85, 100, 102) and increased risk of mortality (95, 103). On the 
other hand, other studies do not observe an association between GOLD Stage 0 and increased 
mortality risk (104).  
1.9 Rationale for studying GOLD Stage 0  
1.9.1 Insufficient evidence  
Generally, this condition of the presence of respiratory symptoms in the absence of airflow 
obstruction is an under-investigated area, with those patients representing a heterogeneous 
group with unclear aetiology and natural history (93). Moreover, the attention of researchers 
and clinicians is mainly focused on COPD (105), with most clinicians ignoring this condition 
and not managing it properly, assuming that it is benign since it is not currently classified as 
COPD (105). Furthermore, most previous research has focused on the coexistence of COPD 
and CB symptoms; unfortunately, however, such studies have failed to provide information 
for policy makers and healthcare providers concerning the relevance of the presence of 
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symptom even in the absence of diagnosed airflow obstruction (105). Moreover, sometimes 
symptomatic patients have been misdiagnosed as COPD based on their symptoms (60) and 
subsequently exposed to unnecessary medications that have been proven effective only in the 
case of COPD (60, 62).  
1.9.2 Uncertainty about the predictive value of GOLD Stage 0 on the risk of 
developing COPD 
Some studies have found that GOLD Stage 0 is associated with an increased risk of excess 
decline in FEV1 (86, 93) and development of COPD (19, 98). Conversely, other studies found 
that GOLD Stage 0 ‘is of little help in identifying subjects at risk of COPD’ (86).  
1.9.3 Uncertainty about the prognostic value of GOLD Stage 0 on longer term 
outcomes  
Although GOLD Stage 0 is no longer officially included in COPD staging scheme of the 
GOLD committee due to the inconsistent results from the previous studies (90), the presence 
of chronic respiratory symptoms could be an important predictor of long-term morbidity and 
mortality amongst affected subjects —even in the absence of diagnosed airflow obstruction 
(9).  
1.10 Thesis aim and objectives  
1.10.1 Aim  
This thesis aims to clarify the uncertainty around the relevance and impact of chronic 
respiratory symptoms in the absence of airflow obstruction on patients’ health in an effort to 
determine whether it is important to identify and target such patients with interventions.  
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1.10.2 Objectives  
1. To examine the risk of developing COPD amongst patients with chronic respiratory 
symptoms compared to the normal population (Chapter 2).  
2. To examine the overall prognosis and the prognostic factors of patients with chronic 
respiratory symptoms compared to diagnosed COPD patients (Chapter 3). 
3. To investigate the relative importance of the presence of chronic respiratory symptoms 
versus airflow obstruction on quality of life (Chapter 4). 
4. To compare the health-related characteristics and health outcomes of patients with 
chronic respiratory symptoms and those newly identified with COPD (Chapter 5). 
5. To describe the magnitude and factors associated with COPD overdiagnosis in the UK 
primary care setting (Chapter 6).  
1.11 Definition of GOLD Stage 0 
In this thesis, GOLD Stage 0 will be defined broadly by the presence of any respiratory 
symptoms that occur on a frequent basis (including CB symptoms, dyspnoea and wheeze), 
with preserved normal lung function and without previous diagnosis of other respiratory 
diseases including asthma.  
Cough and phlegm will be defined using the MRC definition of ‘their presence on most days 
for three or more consecutive months during the year for more than two years’, wheeze will 
be defined by ‘ever had wheezing or whistling in the chest in the last twelve months’ and the 
presence of dyspnoea will be defined as Grade two and above of MRC Breathlessness Scale 
‘troubled by shortness of breath when hurrying on the level ground or walking up a slight 
hill’. Although the term ‘COPD GOLD Stage 0’ no longer officially exists, for brevity it will 
be used in this thesis to refer to the study population of interest.  
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1.12 Thesis Structure  
There are seven chapters: Chapter 1 provides the study background; Chapter 2 is a systematic 
review of the literature examining the risk of developing COPD amongst patients with 
chronic respiratory symptoms compared to the normal population; Chapter 3 consists of two 
systematic reviews, the first of which examines the prognosis of patients with chronic 
respiratory symptoms compared to COPD patients, whilst the second investigates factors 
affecting the prognosis of such patients; Chapter 4 provides a cross-sectional analysis of 
respiratory data from the 2010 Health Survey for England (HSE) to examine the independent 
impact of the presence of chronic respiratory symptoms versus airflow obstruction on self-
assessed HRQoL; Chapter 5 is a cross-sectional analysis of the Birmingham COPD Cohort 
Study, comparing the difference in health-related characteristics and health outcomes of 
GOLD Stage 0 patients with a sample of recently identified COPD patients; Chapter 6 
describes the magnitude and the main factors associated with COPD overdiagnosis in the UK 
primary care setting by analysing data from the Birmingham COPD Cohort Study; Chapter 7 
provides a discussion of the main findings, the implications for research and clinical practice 
and the conclusion.  
1.13 Contribution to research and clinical practice  
This thesis will provide an evidence-base about the relevance of the presence of chronic 
respiratory symptoms in the absence of airflow obstruction and whether this condition 
warrants further attention. This research will also provide a platform for future health service-
related research on GOLD Stage 0 and it can be used as a reference to help inform developing 
clinical management strategies for patients with GOLD Stage 0 symptoms.  
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2 GOLD STAGE 0 AND THE RISK OF 
DEVELOPING COPD: A SYSTEMATIC 
REVIEW 
2.1 Abstract  
Background: The predictive value of GOLD Stage 0 on the risk of developing COPD is 
uncertain. In this review the evidence on the following question will be evaluated: Are people 
who have chronic respiratory symptoms but normal lung function at a higher risk of 
developing COPD compared to people who do not?  
Methods: Medline, Embase and other electronic databases (from inception to week 4 January 
2014) were searched for relevant studies that examined the risk of developing COPD among 
adults aged 40 years and over, who have chronic respiratory symptoms but normal lung 
function in comparison with the normal population. Cohort studies were preferred but cross-
sectional and case-control studies also accepted if they informed the review question. Two 
reviewers independently extracted data and assessed the quality of studies included. Analyses 
were descriptive. 
Results: 38 studies were identified as potentially relevant; of which ten studies were eligible 
for inclusion. GOLD Stage 0 was found to be associated with an accelerated FEV1 decline 
compared to the normal population. The findings from seven included cohort studies were 
contradictory regarding the risk of development of COPD among GOLD Stage 0 patients due 
to the instability of GOLD Stage 0 symptoms over time. Persistence of GOLD Stage 0 
symptoms showed a higher adjusted risk (IRR, 2.88; CI 95%, 1.44 to 5.79) for developing 
COPD.  
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Conclusion: Compared to the normal population, GOLD Stage 0 is associated with a higher 
risk of excess decline in FEV1. However, whether or not this necessarily leads to higher risk 
of developing COPD Stages 1+ remains unclear, although may be related to persistence of 
symptoms. 
2.2 Introduction 
The predictive value of the presence of chronic respiratory symptoms in the absence of 
airflow obstruction “GOLD Stage 0” has been a topic of argument (106) since the seminal 
study of Fletcher and colleagues (96). More recently, a wide range of views and some 
contradictory opinions have been observed, some studies have found it to be associated with 
an increased risk of developing COPD Stages 1+ in the future (98, 99), whilst other studies 
have found that GOLD Stage 0 lacks any predictive value of developing COPD (86). There 
has been no published systematic review studying the risk of developing COPD among 
GOLD Stage 0 patients. Therefore, this review aims at drawing together the currently 
available literature on Gold Stage 0 to provide an evidence-based summary and identify a 
scope for further research on this condition. These aims will be achieved by answering the 
following question: ‘Are people who have chronic respiratory symptoms but normal lung 
function at a higher risk of developing COPD compared to people who do not?’ 
2.3 Methods 
2.3.1 Protocol and registration  
The review protocol (Appendix A) for the present review and reviews 2 and 3 presented in the 
next chapter (Chapter 3), was prepared based on the guidelines of the Cochrane Collaboration 
(107) and the Centre for Reviews and Dissemination (108). The protocol was also registered 
with PROSPERO (Registration Number: CRD42014009146) (109).  
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2.3.2 Inclusion criteria 
In the three systematic reviews, GOLD Stage 0 was defined by the presence of any respiratory 
symptoms that occur on frequent basis (including CB symptoms, wheeze and dyspnoea) with 
normal lung function. Table 5 below summarises the selection criteria (PECOS) for the 
present review: 
2.3.2.1 Population 
Studies were sought included adults aged 40 years and older who had chronic respiratory 
symptoms but normal lung function. Studies of younger age groups were included only if 
self-reported asthma was excluded (to minimise the potential of diagnostic bias by 
misclassification of bronchial asthma as COPD). 
2.3.2.2 Exposure and comparator 
Studies were included if they measured the presence of any chronic respiratory symptoms 
(This is defined in some studies as more than three consecutive months a year for two 
consecutive years, although it may not always be defined this way), and compared GOLD 
Stage 0 patients to a normal population (asymptomatic with normal lung function).  
2.3.2.3 Outcome 
The outcomes of interest were the decline in crude and percent predicted FEV1 and the 
development of COPD. 
2.3.2.4 Study Design 
Ideally, cohort studies were sought; however, cross-sectional and case-control studies were 
also considered. Although cross-sectional studies do not allow causality to be proven or 
evaluation of prognosis, they may support the findings from the cohort studies.  
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Table 5: PECOS components of the review’s question 
Question components 
(PECOS) 
 
Inclusion criteria Exclusion criteria 
Population People aged 40 years and over with 
chronic respiratory symptoms  and 
preserved normal lung function 
Studies of younger age groups unless 
asthma excluded  
“Exposure” Any chronic respiratory symptoms  
Comparator “Normal population” (asymptomatic 
with normal lung function) 
 
Outcome 
 
Decline in FEV1% and development 
of COPD 
 
Study design Ideally cohort studies but cross-
sectional and case-control studies 
might be considered 
Reviews, editorials, case series and reports 
Types of publication All relevant studies with available full text, regardless of their publication status 
2.3.3 Search strategy 
Due to the limited number of epidemiological studies on GOLD Stage 0 and because it is a 
poorly indexed term, the search was designed to be comprehensive and thorough, combining 
the search for this review and reviews 2 and 3 together. A wide range of key and MeSH 
terms, synonyms and spelling alternatives were used. Furthermore, there were no language or 
time restrictions applied to the search. An expert Librarian and an information specialist were 
consulted regarding the search terms before the actual search was initiated.  
The electronic search for the three reviews was conducted by the first reviewer (HB) in 
February 2014, and initially involved searching the two key databases, Medline and Embase 
(from inception to week 4 January, 2014). The search terms used and different combinations 
with OR/AND, are presented in Table 43 (Appendix B). Thereafter, using the same search 
terms and combinations, the search also included CINAHL and databases for grey literature 
as Zetoc library, ETHOS library and SIGLE. The reference lists of identified relevant studies 
were also searched. The search was also supplemented by a database alert services 
subscription until April 2014.  
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2.3.4 Study selection 
The resulting records were screened for relevant studies by the two reviewers (HB and NA) 
independently. This began by scanning through the titles, which was done by the first 
reviewer (HB), followed by an independent screening by the two reviewers through abstracts 
and then the full text against the predefined eligibility criteria. All excluded studies were 
listed and documented with the respective reasons for exclusion.  
2.3.5 Data extraction 
Two reviewers independently extracted the data from included studies, using a simple form 
(Table 6) adapted from the STROBE (Strengthening the Reporting of Observational Studies 
in Epidemiology) checklist (110, 111) (Appendix C).The form was initially piloted on three 
articles.  
2.3.6 Methodological quality assessment  
Risk of bias assessment forms were generated from key quality assessment tools of non-
randomised studies (112, 113). The QUIPS (Quality in Prognosis Studies) tool (112) 
(Appendix D) was adapted for the included cohort studies and the Newcastle Ottawa Scale 
(113) (Appendix E) was adapted for cross-sectional studies. The risk of bias was judged 
independently by the two reviewers with ‘yes, partly, no and unclear’ for each perspective. 
However, no studies were excluded based on the risk of bias.  
2.3.7 Data synthesis process  
The analyses were descriptive only, describing and comparing the main findings from the 
included studies as a formal meta-analysis was deemed not appropriate (Appendix A, section 
8.5). There are clear difficulties involved with a formal meta-analysis of prognostic 
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systematic reviews, including high risk of publication bias, methodological quality and 
limitation in reporting quality of observational studies (114, 115).  
In the present review, there was high clinical and statistical heterogeneity among the included 
studies, different patient groups were targeted (younger age, middle aged, men only, 
occupational cohorts); there was a variation in cut-off points used to define COPD 
(FEV1/FVC<70% or FEV1/FVC<60%); some studies measured crude FEV1 values, others 
measured FEV1% predicted and sometimes FEV0.75 was measured. Moreover, the sample size 
in many studies was small; the analysis across studies adjusted for different variables (and 
sometimes was unadjusted) and in some cohort studies the completeness of follow-up was 
unknown.    
2.4  Results  
2.4.1 Study selection 
The electronic searches resulted in 16,636 records, of which 5,832 duplicates were removed 
(Figure 1). Of the resulting 10,804 unique records, 641 records were identified by the two 
reviewers (HB and NA) as potentially eligible from their titles/abstracts and 73 records were 
identified for full article analysis, including seven non-English articles (two French, one 
Spanish, two Romanian, one Turkish and one German), which also were assessed through 
their full text after translation to English. Out of the 73 articles, 38 were identified as 
potentially relevant for inclusion in this review; ten studies were found eligible for inclusion, 
and 28 were excluded and documented with the reasons for exclusion. The two reviewers 
disagreed on four studies for inclusion, on which the third reviewer (RJ) was consulted.  
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Figure 1: PRISMA flow diagram of study selection  
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meet GOLD Stage 0 
definition (n=7) 
 No comparator group (n=2) 
 Prevalence studies (n=8) 
Studies included in this 
systematic review 
 (n=10) 
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 (
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B
) 
 Records identified through 
Medline & Embase database  
(n=16,614) 
 
Records identified through 
search of other sources  
(n=22) 
 
 
 
Records screened for 
relevance (by abstracts)  
(n=641) 
 
 
 
 Excluded records 
(n=382) 
 More duplicates 
(n=186) 
 
Studies potentially eligibly 
for inclusion  
(n=38) 
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2.4.2 The study characteristics  
The characteristics and the main findings of the ten studies included are detailed in Table 6 
below:  
2.4.2.1 Study design and setting  
Of the included studies, eight were cohort (19, 86, 89, 93, 98, 99, 116, 117), two were cross 
sectional studies (118, 119) (Table 6) but no relevant case-control studies were identified. The 
length of follow-up in the cohort studies ranged from 3.5 to 40 years, whilst the sample size 
across all studies ranged between 121 and 13,108 participants. 
2.4.2.2 Population  
Most of the included studies targeted adults aged 40 years and over, except in the case of four 
cohort studies (86, 93, 98, 117) where younger age groups were also targeted. GOLD Stage 0 
patients who reported the presence of asthma were excluded in all of the included studies 
except in one study (19) (Table 6). 
2.4.2.3 Exposure  
In sex studies GOLD Stage 0 symptoms were defined using CB definition (86, 89, 93, 99, 
116, 117), while the other four studies (19, 98, 118, 119) included wheeze and breathlessness, 
in addition to the CB symptoms (Table 6).  
2.4.2.4 Comparator  
GOLD Stage 0 patients were compared in all of the included studies to a reference group 
drawn from the normal population (asymptomatic with normal lung function). Although one 
cohort study (116) did not clearly define the baseline lung function, both subgroups had no 
airflow obstruction at the baseline. 
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2.4.2.5 Outcome  
Amongst the cohort studies included, one study examined the effect of GOLD Stage 0 on rate 
of FEV1 decline (99), four studies examined the effect of GOLD Stage 0 on the risk of 
development of COPD (19, 89, 98, 117) and three studies assessed the effect of GOLD Stage 
0 on both of these outcomes (86, 93, 116). The included cross sectional studies examined the 
association between GOLD Stage 0 symptoms and absolute values of FEV1 (118, 119) (Table 
6). Incident COPD among GOLD Stage 0 patients was defined in all of the included studies 
using the GOLD committee fixed ratio definition (FEV1/FVC <70%), except in one study 
(116), which did not clearly define the development of COPD. With the exception of two 
studies (93, 118), all studies defined COPD based on pre- rather than post-bronchodilator lung 
function testing (Table 6). Note that defining COPD based on pre-bronchodilator lung values 
leads to an overestimation of its prevalence (72).  
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Table 6: Study characteristics and the main findings  
Vestbo et al., 1996 (116)  
Design Population of 
interest  
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Retrospective 
cohort study of 
two surveys 5 
years apart 
(Copenhagen 
City Heart 
Study) followed 
by 8-10 years 
follow-up of 
National Health 
Register for 
COPD 
development-
Denmark  
1,384 adults, 
aged 30-79 
years 
(mean=53 
years), reported 
CMH
2
 and free 
from self-
reported 
asthma 
 “The presence 
of cough and 
phlegm for at 
least 3 months 
for more than 
1 year” and 
further 
classified in 
to: 
1. CMH in 
the 1
st
 
survey but 
disappear 
in the 2
nd
  
2. No CMH 
at the 1
st
 
survey but 
appeared 
at the 2
nd
  
3. Persistent 
CMH in 
both 
surveys 
8,051 subjects 
without CMH  
 
The impact of 
CMH on excess 
decline in crude 
FEV1 and on a 
subsequent 
hospitalisation 
due to COPD  
 
 
 
 Smoking  
 Age 
 Height  
 Weight 
change 
 Sex  
 
 A steeper FEV1 decline in either 
groups with CMH than 
asymptomatic group, an excess 
FEV1 decline of 22.8 ml/year 
(95% CI, 8.2 to 37.4) in men and 
of 12.6 ml/year (95% CI, 0.7 to 
24.6) in women  
 Participants with persistent CMH 
over the study period showed a 
greater FEV1 decline than those 
with recently occurred and with 
disappeared symptoms; among 
men, the FEV1 decline was 18 
ml/year (3.3-32.7), 15.2 ml/year 
(3.0-27.5) and 16.0 ml/year (0.3-
31.8) respectively; among 
women, the decline was 7.9 
ml/year (-4.1-19.8), 8.8 ml/year (-
1.1-18.7) and 4.0 ml/year (-15.9-
7.9) respectively.  
 CMH was significantly associated 
with increased subsequent 
hospitalisation with COPD 
recorded as the main diagnosis 
among men and women, with 
RR= 5.3 (2.9-9.6) and RR= 5.1 
(2.5-10.3) respectively. 
 
 
The study did not 
clearly define the 
baseline lung 
function and the 
development of 
COPD  
 
                                                 
2 Chronic mucous hypersecretion (CMH) 
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Vestbo and Lange, 2002 (86) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Retrospective 
cohort study-
Denmark with 
15 years follow-
up (Copenhagen 
City Heart 
Study) 
766 GOLD 
Stage 0 adults, 
aged ≥20 years 
(mean=52 
years), reported 
the presence of 
productive 
cough, with 
FEV1/FVC 
>70% and free 
from asthma 
 “Productive 
cough for at 
least 3 months 
a year” 
10,441 normal 
adults 
(asymptomatic 
with normal 
lung function) 
 FEV1 Decline 
and 
progression 
from Stage 0 
to COPD 
Stages 1+.  
 COPD was 
defined and 
classified 
using the 
GOLD 
criteria 
  
 Age 
 Sex 
 Smoking 
 Inhalation 
habits  
 
 After 5 years, the difference in 
the development of COPD among 
both groups was not statistically 
significant  
 After 15 years, the progression to 
COPD was more common among 
GOLD 0 than normal subjects 
(p=0.01 for total population and 
p=0.02 for smokers) 
 In multivariate logistic regression, 
the effect of GOLD 0 on the 
development of COPD Stages 1+ 
was small after 5 and 15 years; 
OR 1.1 (95% CI, 0.9-1.5) & 1.2 
(95% CI, 0.8-1.5) respectively  
 The difference in the FEV1 crude 
decline between the baseline and 
after 5 years among normal and 
GOLD 0 subjects were 36.8 
ml/year and 59.6 ml/year 
respectively 
 Pre-BD3 values 
were used to 
define COPD  
 GOLD 0 
symptoms 
were unstable 
over time; after 
5 years, 39.6% 
of GOLD 0 
subjects 
resolved to no 
symptoms and 
after 15 years, 
about 49.4% 
were persistent 
GOLD Stage 0 
or developed 
COPD Stages 
1+ 
Lindberg et al., 2006 (19) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
7 years 
prospective 
cohort study-
Sweden 
963 adults, 
aged 46-77 and 
had chronic 
respiratory 
symptoms with 
normal lung 
 “Phlegm 
when 
coughing 
or phlegm 
which is 
difficult to 
Asymptomatic 
adults 
Incident COPD 
defined using two 
definitions: 
 GOLD I 
(FEV1/FVC<
0.70) 
 Gender 
 Age 
 Smoking 
 Family 
history of 
COPD 
 Incident cases of COPD reported 
significantly more respiratory 
symptoms at the baseline  
 The most significant symptoms 
preceding the development of 
COPD were sputum production 
 Only Pre-BD 
spirometry 
performed 
 Asthma was 
not excluded 
                                                 
3 Bronchodilator 
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function 
(FEV1/FVC 
>0.70%) 
 
bring up, 
most days 
during 
periods of 
at least 3 
months, 
during at 
least the 2 
last 
years” 
 Wheeze 
 Dyspnea  
 GOLD II 
(FEV1/FVC < 
0.70 and 
FEV1<80% 
predicted) 
and wheeze 
 In multivariable regression 
model, most of the symptoms 
were significant, or close to 
significant, as predictors of 
increased risk for incident COPD  
Pelkonen et al., 2006 (99) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Prospective 
cohort study 
with 40 years 
follow-up 
period- Finland  
488 men aged 
40- 59 years, 
had CB 
symptoms and 
free from other 
respiratory 
diseases  
 “Productive 
cough for at 
least 3 months 
a year”  
 
1,223 subjects 
without CB  
The effect of CB 
symptoms on the 
crude values of 
lung function 
measurements  
 
 Smoking 
habit 
 Occupation 
 The FEV0.75 was 252 ml (95% CI, 
211-293) lower in those with CB 
than subjects without CB 
 The FEV0.75 was 309 ml (95% CI, 
362-257) lower in subjects with 
persistent CB over the study 
period & 190 ml lower in subjects 
with non-persistent CB (95% CI, 
245-134) 
 The excess decline in FEV0.75 
attributable to the presence of 
CMH was 13.2 ml/year  
 FEV0.75 was 
measured 
instead of 
FEV1 
 Targeted men 
only 
 Different 
definitions of 
GOLD 0 were 
used over the 
study period 
 
de Marco et al., 2007 (98) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
11 years 
prospective 
cohort study-the 
European 
Community 
447 young 
adults aged 20–
44years, had 
respiratory 
symptoms with 
 “The 
presence 
of chronic 
cough/ 
phlegm on 
4,533 
asymptomatic 
adults  
The incident 
COPD, defined 
as: FEV1/FVC  
less than 70%  
 Sex 
 Age 
 Smoking  
 Education  
 The COPD incidence was 4 times 
greater in subjects who reported 
cough/phlegm at the end of 
follow-up than those never 
reported the presence of 
 Only Pre-BD 
spirometry 
performed 
 GOLD 0 
symptoms 
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Respiratory 
Health survey II  
normal lung 
function 
(FEV1/FVC 
>70%)  
and free from 
doctor-
diagnosed 
asthma  
most days 
for as 
much as 3 
months 
each 
year” 
 Dyspnea 
“even 
slight” 
cough/phlegm  
 Persistent symptomatic subjects 
had 3times greater risk for COPD 
(IRR, 2.88; 95% CI, 1.44-5.79) 
than asymptomatic after 
adjustment for confounders 
 Cough/phlegm was statistically 
significant independent predictor 
for incident COPD (IRR=1.85; 
95% CI, 1.17-2.93) after 
adjustment for smoking and other 
confounders 
 Dyspnoea was a poor predictor of 
incident COPD (IRR=0.98; 95% 
CI, 0.64-1.50) 
 
 
were unstable 
over time; 
among subjects 
reported the 
presence of 
symptoms at 
baseline, only 
38% reported 
the persistence 
of symptoms at 
the end of the 
study 
Guerra et al., 2009 (117) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Prospective 
Population-
based cohort 
study with 12 
years follow-
up-USA 
(Tucson 
Epidemiological 
Study of 
Airway Disease 
Study) 
97 white adults 
aged 21–80 
years (mean 
=50 years), had 
CB symptoms 
with 
FEV1/FVC 
≥70% and free 
from diagnosed 
asthma  
 “The presence 
of cough and 
sputum 
production on 
most days for 
at least 3 
months in at 
least 2 
consecutive 
years” 
1,315 
asymptomatic 
adults  
Incident COPD,  
defined as: 
FEV1/FVC <70%  
 Sex 
 Age  
 Pack-years 
smoking 
 Baseline 
FEV1/FVC  
 BMI  
 Education 
 
 At follow-up: 42% of GOLD 0 
subjects developed AFO
4
 
compared to 23% of 
asymptomatic subjects (p<0.001) 
 In univariate analyses, the effect 
of GOLD 0 symptoms on incident 
COPD was significant (HR=1.94; 
95% CI, 1.40-2.69). However, in 
multivariate model, this 
association became marginal 
(HR=1.37, 95% CI 0.98-1.92) 
 
 
 
 Targeted white 
adults only 
 Only Pre-BD 
spirometry 
performed 
 
 
                                                 
4 Airflow obstruction 
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Yamane et al., 2010 (89) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Prospective 
cohort study in 
Japan with 5 
years follow up 
period (between 
1993 and 2004) 
 
69 GOLD 
Stage 0 men 
aged 40-69 
years, had 
productive 
cough with 
normal lung 
function and 
free from any 
respiratory 
disease 
‘Phlegm when 
coughing, or 
have phlegm 
which is 
difficult to 
bring up, for 
periods of at 
least three 
months, 
during at least 
the last two 
years?’ 
536 normal 
subjects with 
normal lung 
function and 
without 
productive 
cough 
FEV1 decline and 
incident COPD, 
defined as: 
FEV1/FVC <0.70 
 
 
 Age 
 Height 
 FEV1% 
 Pack years 
of smoking 
 
 The cumulative COPD incidence 
rate was significantly higher 
among symptomatic men (10.1%) 
than asymptomatic (2.2%).  
 The COPD incidence rate was 
28.9/1000 person-years among 
symptomatic group and 7.5/1000 
person-years in asymptomatic 
group. 
 Current and ex-smoking 
individuals with productive cough 
had 1.8 times and 15.0 times 
higher risks for developing 
COPD, respectively compared to 
asymptomatic subjects  
 In multivariate analysis, 
productive cough was 
independent risk factor for the 
development of COPD in all 
subjects (HR=4.54, 95% CI 1.72-
12.0, p=0.002) and among former 
smokers (HR=25.4, 95% CI 3.17-
36.9, p=0.002) but not in current 
smokers (HR=0.49, 95% CI 0.05-
4.49, p=0.53)  
 The annual FEV1% decline was 
greatest among symptomatic 
subjects  
 Targeted a 
specified 
population 
(men only) 
Brito-Mutunayagam et al., 2010 (93) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
5 years 
prospective 
GOLD Stage 0 
Adults; 584 
 Cough Normal 
adults: 2,769 
FEV 1 decline and 
incident COPD, 
 Smoking  Persistent GOLD 0 symptoms  Performed pre 
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cohort study- 
Australia  
participants at 
baseline & 420 
participants at 
follow-up, aged 
≥18 years 
(mean=45.5 
years), reported 
the presence of 
cough/phlegm 
with post-BD 
FEV1/FVC 
>70% and free 
from asthma 
and restrictive 
disease 
 
without 
sputum 
 Productive 
cough “at 
least 
several 
table 
spoons 
per day on 
most or 
every day 
in the last 
3 months” 
participants at 
baseline & 
2,093 
participants at 
follow-up  
defined as post-
BD FEV1/FVC 
<70% 
 Age  
 Sex 
 BMI 
 
were associated with highest 
quartile of FEV1 decline per year 
(OR 2.1; 95% CI, 1.2-3.7) in men  
 GOLD 0 defined by cough 
without sputum: in non-smoker 
males, persistent GOLD 0 was 
significantly associated with the 
highest quartile of annual FEV1 
decline (OR 3.16; 95% CI, 1.46-
6.84), but this was not the case in 
non-smoker females. In current 
smokers, persistent GOLD 0 was 
associated with the highest 
quartile of annual FEV1 declines 
in women (OR 5 4.86; 95% CI, 
1.63-14.5) 
 GOLD 0 defined by cough & 
sputum: the mean annual decline 
in FEV1 was 76 mL greater 
compared with GOLD 0 defined 
by cough without sputum. 
 The effect of GOLD 0 symptoms 
on incident COPD was non-
significant (1.4%) among GOLD 
0 subjects and the asymptomatic 
& post-BD 
Spirometry 
 GOLD 0 
symptoms 
were unstable 
over time; 
39.8% of 
GOLD 0 
subjects had 
persistent 
symptoms at 
the follow-up 
and 58.5% 
resolved to no 
symptoms 
Shin et al., 2005 (119) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Cross-sectional 
study- Korea  
7,518 
symptomatic 
adults aged 40–
69 years, with 
normal lung 
function and 
free from other 
lung diseases  
Chronic 
cough, chronic 
phlegm, 
wheezing and 
dyspnoea 
Asymptomatic 
adults with 
normal lung 
function 
Difference in 
crude FEV1 value 
between both 
groups 
 
 
Age  In men, the age-adjusted mean 
FEV1 was lower among smokers 
and non-smokers with the 
presence of wheeze by 165 ml 
(95% CI 83-247, p<0.001) and 
133ml (95% CI 17-249, p<0.05) 
respectively, by 210 ml (95% CI 
38-382, p<0.05) among smokers 
Only Pre-BD 
spirometry was 
performed 
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  with dyspnoea and lower by 56 
ml (95% CI 5-107, p<0.05) 
among non-smokers with 
dyspnoea 
 In non-smoker women, the age-
adjusted mean FEV1 was 
significantly lower with the 
presence of wheeze: 89 ml (95% 
CI 44-134, p<0.001) and 
dyspnoea: 55 ml (95% CI 33-77, 
p<0.001).  
 There was no relationship 
between respiratory symptoms 
and FEV1 among smoker women. 
However, only small number of 
women smoked cigarettes (3.5%) 
 Chronic cough and phlegm 
showed non-significant effect on 
FEV1 
Komus et al., 2008 (118) 
Design Population of 
interest 
Definition of 
exposure 
Comparator Outcome Confounders 
adjusted for 
Results General 
observations 
Cross-sectional 
study-Turkey  
58 GOLD 
Stage 0 patients 
aged 40-95 
years, had 
chronic 
respiratory 
symptoms, 
with post-BD 
FEV1/FVC 
>0.70 and 
FEV1 ≥ %80 
and free from 
lung diseases  
Any symptom 
of cough, 
phlegm and 
dyspnoea for 
>3 months 
63 normal 
subjects  
Difference in 
absolute values of 
FEV1 between 
both groups  
 
 
None 
 
 Absolute and predicted values of 
FEV1 and FEV1/FVC were 
statistically significant lower 
among GOLD 0 group (p< 0.05):  
 Absolute FEV1: 2.39 ± 0.62L 
among GOLD 0 & 2.69 ± 0.67L 
among the healthy (p=0.01) 
 FEV1%: 87.36 ± 14.75 among 
GOLD 0 & 99.04 ± 18.23 among 
the healthy (p=0.00) 
 FEV1/FVC: 73.36 ± 3.6862L 
among GOLD 0 and 78.46 ± 5.42 
among the healthy (p=0.00) 
 Performed 
post-BD 
spirometry 
 Small sample 
size 
 This study was 
translated from 
Turkish to 
English  
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2.4.3 Methodological quality of the included studies  
The overall risk of bias in the cohort studies included is presented in Figure 2 (see Appendix 
F Table 44 for details of each study). All studies provided a clear description of study 
participants and the associated response rate. However, there was underreporting of study 
attrition in most of studies (n=7). Most studies accounted for the important confounders of 
age, sex and smoking in their analysis (n=7). Although the outcome of developing COPD was 
clearly defined in most of the studies (n=7), the measurement was not often reliable as lung 
function was tested only pre-bronchodilator (n=6). The methodological quality of the two 
included cross-sectional studies are detailed in Table 7 below; in one study there was a high 
risk of bias resulting from a poor study sample selection, whilst in the other, there was a lower 
risk of bias.  
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Figure 2: Overall risk of bias of the included cohort studies  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
There is no selective reporting of results
The selected statistical method is adequate for the design of the study
Sufficient presentation of data to assess the adequacy of the analytic strategy
Important potential confounders are accounted for in the analysis
Clear definitions of the important confounders
All important confounders are measured
The method and setting of outcome measurement is the same for all  participants
Method of outcome measurement used is adequately valid and reliable
A clear definition of the outcome is provided
No differences between participants completed the study and those who did not
Adequate description of participants lost to follow-up
Reasons for loss to follow-up are provided
Description of attempts to collect information on dropped out participants
Adequate response rate for study participants
Adequate description of inclusion and exclusion criteria
Adequate description of the period and place of recruitment
Description of the baseline study sample
Description of the source population
Adequate participation in the study
Yes
No
Partly
Unclear
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Table 7: Risk of bias assessment for the included cross-sectional studies (113) 
Study ID: (authors, year) Shin et al., 2005 Komus et al., 2008 
Domain Description Judgement  Judgement  
1. Selection    
 
Representativeness of the sample 
Truly representative sample of a target population  Y  U 
Full description of the sampling strategy is provided  Y N 
Sample size Justified and satisfactory Y U 
Non-respondents Full description of the response rate or the characteristics of the 
responders and the non-responders is provided  
Y N 
Ascertainment of the exposure  Validated measurement tool used  Y Y 
Detailed description of the measurement tool is provided  Y Y 
 
2. Comparability 
The subjects in different outcome groups are comparable, based on the 
study design or analysis 
Y Y 
 The most important confounding factors are controlled Y N 
3. Outcome    
Assessment of the outcome Fully described  Y Y 
 
Statistical analysis  
The statistical test used is clearly described and appropriate Y Y 
The measurement of the association is presented, including confidence 
intervals and p value 
Y Y 
(Y=yes, N=no, U=unclear)
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2.4.4 Main findings  
2.4.4.1 GOLD Stage 0 and the excess decline in FEV1  
Table 6 above presents in detail the main findings from the six studies that examined the 
effect of respiratory symptoms on excess decline in FEV1 (86, 93, 99, 116, 118, 119). All of 
these studies found that the presence of respiratory symptoms was significantly associated 
with excess FEV1 decline. Pelkonen et al. who targeted only men in their cohort study, 
observed an excess decline in lung function values among symptomatic participants. They 
used the FEV0.75 instead of FEV1 and observed that the FEV0.75 was 252 ml lower in subjects 
with symptoms at any point of the study period (95% CI, 211 to 293) than those without 
symptoms (99), 309 ml lower in subjects with persistent symptoms throughout the study 
period (95% CI, 257 to 362) but 190 ml lower in subjects with non-persistent symptoms (95% 
CI, 134 to 245) (99). By the end of their study, the excess decline in FEV0.75 due to the 
presence of chronic cough and phlegm was 13.2 ml/year (99).  
An excess decline in lung function associated with the presence of respiratory symptoms was 
also observed in two more studies by Vestbo et al. (86, 116). In their1996 paper, they 
observed a steeper FEV1 decline in subjects with symptoms compared to asymptomatic 
participants of both sexes (116). Amongst the three groups with symptoms; persistent, newly 
appeared and recovered symptoms, the FEV1 decline was greater among those with persistent 
symptoms (116). Furthermore, in their 2002 study Vestbo and Lange observed a significant 
difference in decline in the crude FEV1 value after 5 years follow-up between asymptomatic 
(36.8 ml/year) and GOLD Stage 0 subjects (59.6 ml/year) (86).  
Komus et al. completed a cross-sectional study that also observed significantly lower crude 
and predicted values of FEV1 and FEV1/FVC ratio amongst GOLD Stage 0 subjects 
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compared to the normal subjects (118). However, in this study the sample size was relatively 
small, and these findings need to be considered with caution. Brito et al. in a cohort study 
compared the effect of cough without phlegm with the effect of productive cough (with 
sputum) on the excess decline in FEV1 (93). Amongst those with productive cough, the mean 
annual excess decline in FEV1 was greater (76ml/year) than those with cough only 
(42ml/year) (93). On the other hand, Shin et al. in their cross-sectional study reported a non-
significant association between productive cough and age-adjusted mean FEV1 amongst 
smoking and non-smoking GOLD Stage 0 subjects (119). However, this association was 
significantly positive with dyspnoea and wheeze (119).  
2.4.4.2 GOLD Stage 0 and the risk of developing COPD  
Table 6 presents the main findings from the seven cohort studies that examined the effect of 
respiratory symptoms on the risk of developing COPD (19, 86, 89, 93, 98, 116, 117). The 
findings from these studies were conflicting. Vestbo et al. in 1996, after ten years’ follow-up, 
observed a statistically significant association between persistent respiratory symptoms and 
subsequent hospitalisation, with COPD recorded as the main diagnosis (116). Newly appeared 
CMH was also significantly associated with increased hospitalisation because of COPD (116). 
However, they acknowledged that there was potential for diagnostic bias due to the 
misclassification of other respiratory diseases or comorbid conditions as COPD in the hospital 
registers (116). In contrast, in their study of 2002, they concluded that ‘GOLD Stage 0 is of 
little help in identifying subjects at risk of COPD’ (86), because after 5 years follow-up, the 
difference in the development of COPD Stages 1+ amongst GOLD Stage 0 (12.4%) and the 
normal population (9.7%) was small (86). Although, after 15 years, the progression to COPD 
was significantly more frequent among GOLD Stage 0 than asymptomatic subjects (18.5% 
versus 13.2%, p=0.01) (86) . However, the adjusted effect of GOLD Stage 0 on the risk of 
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development of COPD Stage 1+ after 5 years (OR 1.1; 95% CI, 0.9 to 1.5) and 15 years (OR 
1.2; 95% CI, 0.8 to 1.5) was not statistically significant (86).  
Although incident COPD was not the main emphasis of the cohort study by Brito et al., they 
found that after five years follow-up, the rate of incident COPD was similar (1.4%) amongst 
GOLD Stage 0 and asymptomatic groups (93). On the other hand, Demarco et al. found that 
the incidence of COPD in a cohort of young adults was twice as great amongst GOLD Stage 0 
subjects as asymptomatic (98). After adjustment for potential confounders, chronic cough and 
phlegm were still statistically significant independent predictors of incident COPD 
(IRR=1.85; 95% CI, 1.17 to 2.93) (98). This was in agreement with Lindberg et al., (2006) 
and Yamane et al., (2010), who also found, respectively, a significant effect of respiratory 
symptoms as predictors of increased risk of COPD development (19) and a higher cumulative 
COPD incidence rate amongst symptomatics (10.1%) compared to asymptomatic (2.2%) (89). 
In another epidemiological study, Guerra et al. found that 42% of GOLD Stage 0 subjects 
developed COPD compared to 23% of asymptomatic subjects (P<0.001) (117). Although the 
unadjusted effect of GOLD Stage 0 on incident COPD was significant (HR=1.94; 95% CI, 
1.40 to 2.69), this became marginal after adjusted for potential confounders (HR=1.37; 95% 
CI, 0.98 to 1.92) (117).  
2.4.4.3 Instability of GOLD Stage 0 symptoms  
Although this was not a primary aim of this review, instability of GOLD Stage 0 symptoms 
over time has been highlighted in some of the included cohort studies (86, 93, 98, 116) as a 
potential determinant of the independent effect of GOLD Stage 0 symptoms on the 
subsequent risk of developing COPD. This feature of instability may explain to a large extent 
the contradictory results from different studies that examined GOLD Stage 0. Persistence of 
GOLD Stage 0 symptoms has shown to be associated with a highest quartile of annual FEV1 
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decline (OR 2.1; 95% CI, 1.2 to 3.7) (93) and also with a higher risk of developing COPD 
than newly appeared and recovered GOLD Stage 0 symptoms (116). De Marco et al. study 
found following an adjustment for confounders that, persistence of GOLD Stage 0 symptoms 
was associated with three times higher risk for developing COPD (IRR, 2.88; 95% CI, 1.44 to 
5.79) than asymptomatic subjects, compared to (IRR=1.40; 95% CI, 0.87 to 2.26) amongst 
those with newly occurred GOLD Stage 0 symptoms and (IRR=1.31; 95% CI, 0.71 to 2.43) 
amongst recovered GOLD Stage 0 subjects (98).  
Summary Box 1:  
1. GOLD Stage 0 and FEV1 decline:  
 The presence of GOLD Stage 0 symptoms is associated with excess FEV1 decline 
compared to the normal population (n=6 studies (4 cohort and 2 cross-sectional)).  
 The effect of symptoms on FEV1 decline was ‘dose dependent’ i.e. those with persistent 
symptoms showed higher decline followed by those with newly appeared then recovered 
symptoms (n=3 cohort studies) 
2. GOLD Stage 0 and the risk of developing COPD  
 4 out of 7 cohort studies found a higher risk of COPD amongst GOLD Stage 0 subjects 
than the normal population, while the other 3 cohort studies found a non-significant effect.  
 The effect of GOLD Stage 0 symptoms on the risk of developing COPD was also “dose 
dependent” (n=2 cohort studies).  
3. Instability of GOLD Stage 0 symptoms 
 This feature of instability was found to be the main determinant of the independent effect 
of GOLD Stage 0 symptoms on the excess FEV1 decline and on the risk of developing 
COPD Stages 1+ (n=4 cohort studies).  
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2.5 Discussion 
2.5.1 Summary of evidence  
This is the first systematic review examining the risk of developing COPD amongst GOLD 
Stage 0 patients compared to the normal population. The presence of GOLD Stage 0 
symptoms was found to be associated with an accelerated FEV1 decline; however, this 
association was most marked among participants with persistent symptoms over time, 
followed by those with newly appeared then recovered GOLD Stage 0 symptoms than the 
normal population. On the other hand, inconsistent results were observed amongst cohort 
studies regarding the independent effect of GOLD Stage 0 on the risk of developing of COPD 
compared to the normal population. Four of the seven cohort studies included (19, 89, 98, 
116) found a higher risk of COPD amongst GOLD Stage 0 subjects, whereas the other three 
cohort studies found no evidence of an effect of GOLD Stage 0 on the risk of developing 
COPD (86, 93, 117). However, the instability of GOLD Stage 0 could possibly contribute to 
these contradictory results.  
2.5.2 Limitations 
Undertaking a highly sensitive search strategy to retrieve articles for this review was complex; 
a broad spectrum of search terms was used. This subsequently resulted in a huge number of 
records, which was challenging and time consuming but was unlikely to have missed 
important studies. This review is also limited to being descriptive due to the high clinical and 
statistical heterogeneity amongst the studies included, resulting in practical difficulties for 
summarising and synthesising the data.  
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2.5.3 Implication for research and clinical practise 
It seems that patients with GOLD Stage 0 symptoms do have worse lung function decline 
over time. However, the main factor affecting the significance of GOLD Stage 0 symptoms on 
risk of developing COPD is the feature of instability of symptoms over time. This finding 
may help to clarify the ongoing debate about the relevance of GOLD Stage 0. Future studies 
must account for this feature when examining the risk of COPD amongst this group of 
patients. In clinical practice, GOLD Stage 0 patients with persistent symptoms may need to be 
targeted for COPD screening and management.  
2.5.4 Conclusion 
GOLD Stage 0 is associated with a higher risk of accelerated FEV1 decline than the normal 
population. However, whether or not this necessarily leads to a higher risk of developing 
COPD remains unclear. This could be explained by the instability of GOLD Stage 0 
symptoms over time, as persistence of GOLD Stage 0 was associated with a higher risk of 
developing COPD GOLD Stages 1+.  
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3 PROGNOSIS AND PROGNOSTIC FACTORS 
OF GOLD STAGE 0: SYSTEMATIC REVIEWS 
This chapter consists of two systematic reviews of literature, the first examining the prognosis 
of GOLD Stage 0 patients compared with established COPD patients and the second 
examining the main factors affecting GOLD Stage 0 patients’ prognosis.  
3.1 Abstract  
Background: Information on the prognosis of patients with chronic respiratory symptoms is 
limited and conflicting. Two systematic reviews in this chapter aim to answer the following 
questions: what is the prognosis of patients with chronic respiratory symptoms but normal 
lung function compared to established COPD patients? And what are the main factors that 
can affect the prognosis of patients with chronic respiratory symptoms but normal lung 
function?  
Methods: Medline, Embase and other bibliographic databases (from inception to week 4 
January, 2014) were searched for relevant studies that examined the prognosis and prognostic 
factors among adults aged 40 years and above who had chronic respiratory symptoms but 
normal lung function, in comparison with confirmed COPD patients. Cohort studies were 
sought. But for review (2), cross-sectional and case-control studies were also considered if 
they informed the review question. Two reviewers independently extracted data and assessed 
the quality of studies included. Analyses were descriptive. 
Results: There were 35 records identified as potentially relevant. Nine studies were eligible 
for inclusion in review (2), two cohort studies were eligible for inclusion in review (3) and 24 
studies were excluded. The presence of GOLD Stage 0 symptoms was associated with 
increased mortality risk, high healthcare utilisation and increased risk of difficulties in daily 
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activities compared to the normal population and similar to that measured among those with 
mild COPD. Review (3) found insufficient evidence about the prognostic factors of GOLD 
Stage 0. However, the persistence of GOLD Stage 0 symptoms was proposed as the main 
factor affecting the risk of developing COPD among GOLD 0 patients in Chapter 2 and this 
review found that the main factors associated with the persistence of symptoms were 
persistent smoking, male gender, older women and metabolic syndrome amongst men.   
Conclusion: GOLD Stage 0 is associated with increased risk of poor prognosis compared to 
the normal population and similar to those with mild COPD. However, the instability of 
symptoms over time was not fully accounted for and the effect of GOLD Stage 0 could 
therefore be underestimated. Prognostic factors affecting long-term morbidity and mortality 
among GOLD Stage 0 patients have not been entirely investigated and warrant more 
attention.  
3.2 Introduction  
GOLD Stage 0 had been excluded from the GOLD committee staging scheme of COPD since 
2006 due to the inadequate evidence regarding the progression from GOLD Stage 0 to 
diagnosed COPD Stages 1+ (9). However, the presence of chronic respiratory symptoms 
could be an important predictor of long-term morbidity and mortality amongst affected 
subjects, even in the absence of diagnosed airflow obstruction (9). The natural history of 
unexplained chronic respiratory symptoms of GOLD Stage 0 in the general population is an 
under-investigated area (101), with little attention being given to this condition (105), despite 
being a common health problem across the population, especially amongst smokers (9, 101).  
In Chapter two, review (1) found that GOLD Stage 0 was associated with higher risk of 
excess decline of FEV1 than the normal population. The risk of developing COPD among 
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GOLD Stage 0 population was not clear, although it might be related to persistence of 
symptoms. The following two systematic reviews of literature build on Chapter 2 and will be 
the first to gather the available evidence regarding the prognosis and prognostic factors of 
GOLD Stage 0 patients compared to confirmed COPD patients. In order to highlight gaps in 
knowledge and identify a scope for further research, the following two questions will be 
answered:  
1. What is the prognosis of patients with chronic respiratory symptoms but normal lung 
function compared to established COPD patients? 
2. What are the main factors affecting the prognosis of patients with chronic respiratory 
symptoms but normal lung function?  
3.3 Methods  
These reviews were conducted in parallel with systematic review (1), where there were shared 
methods for search strategy, study selection, data extraction and methodological quality 
assessment (See previous chapter for general review methods (Section 2.3). As it was the case 
with systematic review (1), the two reviews presented in this chapter are descriptive due to the 
practical difficulties involved with a formal meta-analysis of prognostic systematic reviews, 
including risk of publication bias, methodological quality and limitation in reporting quality 
of observational studies (114, 115).   
As with review (1), there was high clinical and statistical heterogeneity among the included 
studies in the present two reviews, different patient groups were targeted (younger age, 
middle aged, men only, occupational cohorts); there was a variation in cut-off points used to 
define normal lung function and studies measured different outcomes. Moreover, the sample 
size in many studies was small, the analysis across studies adjusted for different variables 
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(and sometimes was unadjusted) and in some cohort studies the completeness of follow-up 
was unknown.    
3.3.1 Inclusion criteria 
Table 8 below summarises the selection criteria for the present reviews (2) and (3):  
3.3.1.1 Population 
Both reviews sought studies that assessed middle-aged and elderly populations (40 years and 
above) who had chronic respiratory symptoms with normal lung function. 
3.3.1.2 Exposure and comparator 
The exposure in review (2) was the presence of any chronic respiratory symptoms and in 
review (3) was any factor that might affect the prognosis of GOLD Stage 0 patients 
(excluding genetic factors and childhood respiratory infection). The comparator group in 
review (2) was patients with a confirmed COPD diagnosis. 
3.3.1.3 Outcome 
For both reviews, studies examining any health outcome were included. 
3.3.1.4 Study Design 
For review (2), ideally cohort studies were included. However, cross-sectional and case-
control studies were also considered. Although cross-sectional studies do not allow causality 
to be proven or evaluation of prognosis, they may support the findings from the cohort 
studies. For review (3), only cohort studies were included.  
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Table 8: PECOS components for reviews 2 and 3 
Question components 
(PECOS) 
Review2: the prognosis of 
GOLD Stage 0  
Review3: prognostic 
factors of GOLD Stage 0 
Exclusion criteria 
Population 
 
People aged 40 years and 
above with chronic 
respiratory symptoms  
People aged 40 years and 
above with chronic 
respiratory symptoms and 
normal lung function 
Studies of younger age 
groups unless asthma 
excluded 
“Exposure” 
 
 
 
 
Chronic respiratory 
symptoms with normal 
lung function 
Any prognostic factor; for 
e.g. age, sex, smoking status, 
air pollutions, BMI, 
biomarkers, occupational 
exposure, FEV1 predicted 
and comorbidity 
 
Childhood respiratory 
infections 
 
Genetic factors 
 
Comparator COPD patients  None   
Outcome 
 
Any health outcome; for 
e.g. mortality, HRQoL, 
exacerbation and 
healthcare utilisation 
 
Any health outcome 
 
 
Study design Ideally cohort studies but 
case-control and cross-
sectional studies might be 
considered 
Cohort studies 
 
Reviews, editorials, case 
series and reports 
 
Types of publication All relevant studies with available full text, regardless of their publication status 
3.4 Results  
3.4.1 Study selection 
The results of the study selection process (Figure 3) are detailed under section 2.4.1 within 
review (1) in the last chapter. Of the 73 articles, 35 were identified as potentially relevant 
studies for answering review 2 and 3 questions; nine studies were found to be eligible for 
inclusion in review (2), whilst two were eligible for inclusion in review (3). Overall, 24 
studies were excluded with the reasons for exclusion documented. The two reviewers 
disagreed on four studies for inclusion in review (2), on which the third reviewer (RJ) was 
consulted.  
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Figure 3: PRISMA flow diagram of study selection  
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3.5 Review (2): What is the prognosis of patients with chronic respiratory 
symptoms but normal lung function compared to confirmed COPD 
patients? 
3.5.1  Results  
3.5.1.1 The study characteristics  
The characteristics and the main findings of the included nine studies are detailed in Table 9 
below:  
3.5.1.1.1 Study design and setting  
Nine studies were identified as eligible to answer this review question: six cohort studies (9, 
95, 100, 103, 104, 120), three cross-sectional studies (90, 101, 102) but no relevant case-
control studies were identified. The length of follow-up in the cohort studies ranged from 4 to 
30 years, whilst the sample size across all studies ranged between 115 and 15,440 
participants.  
3.5.1.1.2 Population  
Most of the studies targeted middle-aged subjects (40 years and above), with the exception of 
one cross-sectional study, where a younger age group (20–44 years) was studied (90). 
Although, in this study, asthma was not excluded in the initial analysis, subsequently it was 
excluded in a secondary analysis (90).  
3.5.1.1.3 Exposure 
GOLD Stage 0 symptoms were defined in most of the included studies using the MRC 
definition of CB—‘the presence of chronic cough and sputum production 3 months a year in 
the last 2 years’—with normal lung function (FEV1/FVC ≥ 70%), except in two studies, 
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which also included wheeze and dyspnoea (95, 101), and one study included dyspnoea (104), 
in addition to cough and sputum production. Only one study confirmed the presence or 
absence of airflow obstruction using post-bronchodilator spirometry (101). The remainder 
performed only pre-bronchodilator spirometry. 
3.5.1.1.4 Comparator 
GOLD Stage 0 patients were directly compared to confirmed COPD patients only in two 
studies (100, 101) while in the other seven studies, GOLD Stage 0 patients and COPD 
patients were both compared with a reference group of normal population (9, 90, 95, 102-104, 
120).  
3.5.1.1.5 Outcome  
Amongst the included cohort studies, four studies examined the risk of mortality amongst 
GOLD Stage 0 subjects (95, 103, 104, 120), one study assessed the rate of healthcare 
utilisation and the HRQoL (100), whilst one study examined the hospital admission rate (9). 
Amongst the included cross-sectional studies, one study (101) examined exacerbation-like 
events; one study assessed the rate of healthcare utilisation (90) and the third study (102) 
examined HRQoL.  
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Table 9: Study characteristics and the main findings (Review 2) 
Petty et al., 1976 (120) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations  
Prospective 
cohort study 
with 6-7 
years follow 
up period-
USA 
 
 67 GOLD 0 
subjects with a 
mean age of 47.1 
years and had 
CB symptoms 
 41 COPD 
patients as 
defined by 
FEV1/FVC 
<60% 
“Bringing up mucous 
from the chest in the 
morning and/or during 
the day for at least 3 
months of the year” 
 
111 healthy 
adults 
All-cause 
mortality 
rates 
None  
 
Mortality rate over the 
follow-up period among 
patients with CB was 
5.9% (with 
FEV1/FVC>75%) and 
10% (with 
FEV1/FVC=60-74%) with 
an average of 8.0% and 
among COPD patients 
was 19.5%  
 The study did 
not use the 
standard 
definition of 
COPD 
 Relatively small 
sample size 
 CB symptoms 
were unstable 
over the study 
period 
Ekberg-Aronsson et al., 2005 (103) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
Prospective 
cohort study 
in Sweden 
(1974-2003) 
 493 GOLD Stage 
0 subjects aged 
27-61 years 
(mean age=46.5 
years) and free 
from other 
comorbid 
conditions  
 3,356 COPD 
patients Stages 
1-4, classified 
according to the 
GOLD criteria 
1. “Daily cough lasting 
more than 3 months 
in more than 2 
years" 
2. "Ever symptoms of 
CB") 
3. “Phlegm coming up 
from chest daily for 
more than three 
months”  
4. "Recent symptoms of 
CB" 
Normal 
individuals  
All-causes 
mortality 
risks  
 Age  
 Sex  
 Smoking  
Inhalation habits  
 Compared to normal 
population, smoking men 
Stage 0 patients showed 
an increased mortality 
risk, HR=1.65 (1.32–
2.08) of similar 
magnitude to COPD 
Stage 2, HR=1.41 (1.31–
1.70) and higher than 
COPD Stage 1 HR=1.13 
(0.98–1.29).  
 No difference in mortality 
risk among GOLD 0 
smoking men defined as 
"ever symptoms of CB", 
HR=1.62 (1.25–2.12 
p<0.0001) or "recent 
 Was not clear 
whether asthma 
was excluded  
 Lack of follow 
up respiratory 
data did not 
allow to 
determine the 
stability of 
GOLD 0 
symptoms over 
the study period 
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symptoms of CB" 
HR=1.74 (1.13–2.68 p= 
0.012). 
 Among former and never 
smoker men, Stage 0 was 
associated with an 
increased mortality risk, 
but the number of deaths 
was small  
 Among smoking women, 
the HRs increased 
stepwise in Stage 1–4 (p 
for trend <0.0001). The 
HR was slightly increased 
in Stage 0, with a similar 
magnitude as in smoking 
men but of borderline 
significance 
 
Stavem et al., 2006 (104) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations  
25-27 years 
prospective 
cohort study 
in Norway 
 
 131 Gold Stage 0 
subjects with 
FEV1/FVC ≥ 
70% & free from 
known 
respiratory and 
non-respiratory 
comorbidity 
 265 COPD 
patients stages 1-
4. COPD defined 
& classified 
using the GOLD 
criteria  
 “Bring up phlegm on 
most days for as much as 
3 months each year”, 
“troubled by shortness of 
breath when hurrying on 
level ground or walking 
up a slight hill” and 
“short of breath walking 
with other people of your 
own age on level 
ground” 
1,223 normal 
reference 
Long term 
mortality 
(all-cause)  
 Age 
 Smoking 
habits  
 BMI 
 CVDs risk 
factors 
(systolic BP 
& serum 
cholesterol) 
 FEV1 
 Physical 
fitness  
 GOLD Stage 0 subjects 
had a non-significantly 
increased adjusted risk of 
death (HR=1.19; 95% CI 
0.91–1.57, p= 0.21) 
compared to the normal 
 GOLD Stage 1 patients 
(HR=1.30; 95% CI 1.0–
1.69, p= 0.05) and Stage 2 
(HR, 1.77; 95% CI 1.35–
2.32, p < 0.0001) showed 
increased all-cause 
mortality than the normal. 
 When GOLD 0 defined 
Targeted men only 
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broadly by the presence 
of any respiratory 
symptom, the HR for 
mortality became 
significant (HR, 1.35, CI; 
1.11–1.64 p=0.003)  
 In multivariate analysis, 
GOLD Stage 0 showed a 
better long-term 
prognosis than COPD 
patients Stages 1, 2, and 
3, with non-significant 
excess risk of long-term 
mortality 
 
Mannino et al., 2006 (95) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
11 years 
prospective 
cohort 
study-USA 
 
 2,244 GOLD 
Stage 0 subjects, 
aged 43–66 years 
 3,434 COPD 
patients 
classified into 4 
severity stages 
using the GOLD 
criteria 
  
“Presence of respiratory 
symptoms of cough, 
sputum, wheeze or 
dyspnoea in the absence 
of any lung function 
abnormality or disease” 
 
8,661 normal 
individuals 
Mortality 
risk  
 Age 
 Race 
 Sex 
 Smoking 
habit  
 Pack years 
 BMI 
 Education 
level  
 Following adjustment for 
confounders, all GOLD 
stages predicted a higher 
risk of death compared to 
normal population: 
GOLD 0 (HR=1.5; 95% 
CI, 1.3-1.8), GOLD 1 
(HR=1.4; 95% CI, 1.1-
1.6), GOLD 2 (HR=2.4; 
95% CI, 2.0-2.9) and 
GOLD 3 or 4 (HR=5.7; 
95% CI, 4.4-7.3) 
 At each GOLD stage, 
patients reporting at least 
one respiratory symptom 
had a higher risk of death 
than asymptomatic 
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Ekberg-Aronsson et al., 2008 (9) 
Design 
 
Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
Prospective 
cohort study 
in Sweden 
(1974-2002) 
 493 Gold Stage 
0 subjects with a 
mean age of 
46.5 years  
 3,356 COPD 
patients stages 
1-4 classified 
using the GOLD 
criteria 
“Chronic productive 
cough lasting more than 
3 months, for more than 
2 consecutive years” 
2,792 normal 
individuals 
All-causes 
hospital 
admission 
rates 
 Age 
 Gender  
 Smoking 
habits 
Compared to the normal, all-
causes hospital admission 
rates showed statistically 
significant increase for 
smoking GOLD 0 men and 
women, smoking men with 
COPD Stages 1-4 and 
smoking women with COPD 
Stages 2 and 4. The rates did 
not increase among ex and 
never smoking GOLD 0 
patients and COPD patients 
Stages 1–4  
 Some cohorts 
did not perform 
a spirometry  
 The study did 
not account for 
the instability of 
GOLD 0 
symptoms over 
the follow-up 
period 
De Marco et al., 2004 (90) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
Cross 
sectional 
study- the 
European 
Community 
Respiratory 
Health 
Survey  
 1,751 GOLD 
Stage 0 patients 
aged 20–44 
years (mean= 
33.2 years)  
 537 COPD 
patients Stages 
1-4 classified 
using the GOLD 
criteria  
 
 
 
 
 
 
 
“Cough and/or phlegm 
from the chest, usually in 
winter and on most days 
for as long as 3 months 
each year” 
 
12, 567 
normal 
population 
Healthcare 
utilisation  
 Smoking  
 Sex  
 Childhood 
respiratory 
infections 
 Occupation 
Socio-economic 
status  
 Compared to the normal, 
all Stages, including 
Stage 0, showed higher 
proportion of doctor visits 
(32.6% vs 18.4%, 
p<0.001), prescribed 
medication (24.1% vs 
14.0%, p<0.001), had at 
least one emergency 
department attendance/or 
hospital admission 
(10.8% vs 5.1%, p<0.001) 
because of respiratory 
problems 
 Following exclusion of 
patients with coexisting 
asthma, the relative 
 Does not 
separate out 
GOLD 0 
patients in the 
results of 
healthcare 
utilisation   
 Asthma was not 
excluded in the 
initial analysis 
but 
subsequently 
excluded in the 
secondary 
analysis  
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pattern of utilisation 
remained unchanged 
Joo et al., 2008 (100) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
4 years 
prospective 
cohort study 
-USA 
 
23 GOLD Stage 0 
adults, aged 25-87 
years (mean =71.5 
years)  
The presence of chronic 
cough and sputum 
production  
49 COPD 
patients 
classified as 
GOLD Stages 
1–2 and 44 
patients as 
Stage 3–4 
HRQoL & 
Healthcare 
utilization 
among 
both 
patients 
groups  
 Age  
 Smoking 
status 
 
 There was a statistically 
significant gradient of 
effect on HRQoL from 
GOLD Stage 0 through 
GOLD Stage 4. However, 
effects were not 
significantly different 
between GOLD Stage 0 
and GOLD Stages 1 and 2     
 GOLD 0 group had 
higher averages of 
outpatient visits/year of 
14.4 (SD = 30.5), 
hospitalisations/year of 
0.3 (SD = 0.8) and all-
cause inpatient visits of 
1.89 (SD = 1.36) than 
COPD patients, but the 
difference was not 
statistically significant 
 98% of GOLD 0 
group were 
males 
 Small sample 
size  
 
Kanervisto et al., 2010 (102) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
Cross-
sectional 
study- 
Finland 
 630 GOLD 
Stage 0 patients 
aged ≥30 
years277 COPD 
patients Stages1-
4 classified 
using the GOLD 
criteria 
“Chronic cough and 
sputum production 3 
months a year or in the 
last 2 years without 
airways obstruction” 
3,811 normal 
population 
HRQoL  Age 
 Gender 
 BMI 
 Socio-
economic 
status 
 Smoking 
Compared with the normal:  
 COPD patients and 
GOLD 0 patients had 
poorer adjusted activities 
in daily living (OR= 4.52 
(3.33 to 6.15) and 
OR=2.01 (1.55 to 2.60)), 
respectively), reduced 
Was not clear 
whether asthma was 
excluded 
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habits 
 FEV1% 
 Comorbid 
conditions 
 
instrumental activities in 
daily 
living(OR=3.81(2.82 to 
5.16) and OR= 2.15 (1.70 
to 2.72), respectively)  
 GOLD 0 patients had 
difficulties in experiences 
of day to day life (OR= 
1.58, 95%CI, 1.31 to 
1.90), while COPD 
patients did not (OR= 
1.11, 95%CI, 0.83 to 
1.49)  
 GOLD 0  patients had 
fewer hobbies (OR= 1.38, 
95%CI, 1.12 to 1.70) 
while COPD patients had 
not (OR= 1.24, 95%CI, 
0.92 to 1.66) 
Tan et al., 2014 (101) 
Design Population  Definition of exposure Comparator  Outcome Confounders 
adjusted for 
Results General 
observations 
Cross-
sectional 
multisite 
population-
based study 
in Canada  
658 GOLD Stage 0 
subjects aged ≥ 40 
years and free from 
diagnosed respiratory 
diseases  
“Chronic cough or 
phlegm not occurring 
during a ‘cold’ and on 
most days for as much as 
3 months each year for 2 
years”, or ‘episodes of 
wheezing or whistling in 
the chest associated with 
feeling of shortness of 
breath, in the past 1 year 
not occurring during a 
cold” or dyspnoea of 
MRC grade ≥ 2 
838 COPD 
patients, 
defined using 
the GOLD 
committee’s 
definition 
 
Exacerbati
on like 
events  
 
 Age 
 Gender 
 BMI 
 Education 
 Ever 
smoking 
 Comorbid 
conditions 
 Pulmonary 
function 
 
Exacerbation in the last year 
were reported by 3.9% of 
GOLD 0 subjects compared 
with 8.2% of COPD patients 
(p<0.001). However the 
impact on healthcare 
utilisation was similar; among 
GOLD 0 group, 68% of 
exacerbations needed doctor 
visit and among COPD group, 
62% needed a doctor visit 
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3.5.1.2 Methodological quality of the included studies  
The overall risk of bias in the included cohort studies is presented in Figure 4 (see Appendix 
F Table 45 for details of each study). Most studies provided a clear description of study 
participants and the associated response rate (n=5). Although all studies provided reasons for 
loss to follow-up, the description of participants lost to follow-up was inadequate in most of 
them (n=4). Most studies accounted for the important confounders in their analysis (n=5) and 
the outcome was clearly defined and accurately measured in most of these studies (n=5). The 
methodological quality of the three included cross-sectional studies is detailed in (Table 10). 
The overall risk of bias was low.  
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Figure 4: Overall risk of bias of the included cohort studies (Review 2) 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
There is no selective reporting of results
The selected statistical method is adequate for the design of the study
Sufficient presentation of data to assess the adequacy of the analytic strategy
Important potential confounders are accounted for in the analysis
Clear definitions of the important confounders
All important confounders are measured
The method and setting of outcome measurement is the same for all  participants
Method of outcome measurement used is adequately valid and reliable
A clear definition of the outcome is provided
No differences between participants completed the study and those who did not
Adequate description of participants lost to follow-up
Reasons for loss to follow-up are provided
Description of attempts to collect information on dropped out participants
Adequate response rate for study participants
Adequate description of inclusion and exclusion criteria
Adequate description of the period and place of recruitment
Description of the baseline study sample
Description of the source population
Adequate participation in the study
Yes
No
Partly
Unclear
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Table 10: Risk of bias assessment for the included cross-sectional studies in review 2 (113)  
Study ID: (authors, year) De Marco et al., 2004 Tan et al., 2014 Kanervisto et al., 2010 
Domain Description Judgement  Judgement  Judgement 
1. Selection      
Representativeness of the sample Truly representative sample of a target population  Y  Y  Y  
Full description of the sampling strategy is provided  Y Y  Y  
Sample size Justified and satisfactory Y  Y Y  
Non-respondents Full description of the response rate or the characteristics of 
the responders and the non-responders is provided  
P 
  
Y  P  
 
Ascertainment of the exposure  
Validated measurement tool used  Y  Y  Y 
Detailed description of the measurement tool is provided  Y  
  
Y  Y  
 
2. Comparability 
The subjects in different outcome groups are comparable, 
based on the study design or analysis 
Y  
  
Y  Y  
 The most important confounding factors are controlled Y  Y  Y  
3. Outcome     
Assessment of the outcome Fully described  Y  Y  Y  
Statistical analysis  The statistical test used is clearly described and appropriate Y  
  
Y  Y  
The measurement of the association is presented, including 
confidence intervals and p value 
Y  
  
Y  Y  
(Y=yes, N=no, P=partly) 
60 
 
3.5.1.3 The main findings 
3.5.1.3.1 GOLD Stage 0 and the risk of mortality  
Four cohort studies examined the risk of mortality amongst GOLD Stage 0 subjects (95, 103, 
104, 120) (Table 9). Mannino et al. (2006) cohort study found that compared with the normal 
population, the presence of GOLD Stage 0 respiratory symptoms was associated with an 
increased risk of mortality (HR=1.5, 95% CI; 1.3 to1.8) to a similar extent to COPD Stage 1 
(HR=1.4, 95% CI; 1.1 to 1.6) (95). COPD GOLD Stage 2 (HR=2.4, 95% CI; 2.0 to 2.9) and 
COPD Stages 3 or 4 (HR= 5.7, 95% CI; 4.4 to 7.3) had a higher risk of mortality (95).  
The second cohort study (103) observed that GOLD Stage 0 was associated with a higher risk 
of mortality than the normal population, especially among current smoking men (HR=1.65, 
CI; 1.32 to 2.08) (103). This figure was comparable to that of COPD Stage 2 (HR=1.4, CI; 
1.31 to 1.70) (103) and greater than that observed amongst COPD Stage 1 subjects (HR=1.13, 
CI; 0.98 to 1.29) (103).  Similar effects were observed even with modified definitions of 
GOLD Stage 0 ‘ever symptoms of CB’ (HR=1.62, CI; 1.25 to 2.12) or ‘recent symptoms of 
CB’ (HR=1.74, CI; 1.13 to 2.68) (103). Amongst current smoking women, the HR was 
increased in GOLD Stage 0 compared with the normal population, demonstrating a similar 
magnitude to that observed amongst men but showing borderline statistical significance (103). 
Moreover, GOLD Stage 0 was associated with an increased risk of mortality amongst never 
and former smokers of both sexes (103), but the number of deaths was very small (103). 
However, in this study, there were no follow-up data on respiratory symptoms and it was not 
possible to determine the stability of GOLD Stage 0 symptoms over the study period. 
Therefore, the effect of symptoms on the risk of mortality might be even underestimated 
(103).  
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Although they did not adjust for the potential confounders, Petty et al., (1976), when 
comparing the risk of death amongst GOLD Stage 0 and COPD patients compared to a 
healthy reference group showed that the mortality rate over a follow-up period of 7 years was 
19.5% amongst COPD patients, and amongst patients with CB symptoms was lower, with an 
average of 8.0% (120). Stavem et al., (2006), who targeted men only, also found compared to 
a normal population that GOLD Stage 0 subjects did not have a statistically significant 
increased adjusted risk of mortality (HR=1.19, 95% CI; 0.91 to 1.57), whilst GOLD 1 and 2 
showed a statistically significant increased risk of death (HR=1.30, 95% CI; 1.00 to 1.69 and 
HR=1.77, 95% CI; 1.35 to 2.32, respectively) (104). However, GOLD Stage 0 patients 
showed a statistically significant increased mortality risk similar COPD Stage 1 risk 
(HR=1.35, CI; 1.11 to 1.64) when a broadened definition of GOLD Stage 0 was used (by the 
presence of any phlegm or any breathlessness) (104).  
3.5.1.3.2 Exacerbation-like events 
One cross-sectional study examined the exacerbation like events amongst GOLD Stage 0 
patients with persistent symptoms, compared to those with confirmed COPD (101). It found 
that the proportion of GOLD Stage 0 subjects who experienced exacerbations defined as “a 
period of worsening of breathing problems that got so bad that it interfered with usual daily 
activities or caused the individual to miss work” was lower (3.9% versus 8.2%, p<0.001) than 
amongst COPD patients (101). However, the influence on healthcare utilisation was equal or 
slightly greater amongst GOLD Stage 0 subjects, with 68% of exacerbations requiring a 
doctor consultation compared to 62% amongst COPD group (101). Furthermore, this study 
found that GOLD Stage 0 and COPD patients shared common predictors for respiratory 
exacerbation events (101) (Table 9).  
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3.5.1.3.3 HRQoL 
Two studies examined HRQoL amongst GOLD Stage 0. The cohort study of Joo et al., (2008) 
compared HRQoL amongst GOLD Stage 0 with those diagnosed with COPD (100). 
Following adjustment for the confounding of age and smoking, it was found that GOLD Stage 
0 subjects had statistically significant better HRQoL scores than those with COPD Stages 1–2 
and 3–4 (mean total score 29.14, 36.00 and 52.92, respectively, p<0.001) (100).  
The cross-sectional work of Kanervisto et al., (2010), found that compared to the normal 
population, both GOLD Stage 0 participants  experienced a poorer physical functioning in 
daily living (OR=2.01; 95% CI, 1.55 to 2.60) than the normal population but better than 
COPD patients (OR=4.52; CI, 3.33 to 6.15). (102). However, GOLD Stage 0 subjects 
reported more difficulties in experiences of day to day life (OR=1.58; CI, 1.31 to 1.90) (102), 
whilst COPD patient did not (OR=1.11; CI, 0.83 to 1.49) (102).Furthermore, GOLD Stage 0 
patients reported fewer hobbies (OR=1.38; CI, 1.12 to 1.70), whilst COPD patient did not 
(OR=1.24; CI, .92 to 1.66) (102).  
3.5.1.3.4 Healthcare utilisation  
Healthcare utilisation was examined in three studies, where the cohort study of Joo and 
colleagues (2008)  suggested that GOLD Stage 0 subjects had a higher rate of all cause-
inpatient visits, with an average of 1.89 (SD=1.36) visits per patient-year than COPD patients  
(100) and had a higher rate of all cause outpatient visits, with an average of 14.40 (SD=30.79) 
visits per patient-year (100) compared to an averages of 10.50 (SD=13.53) amongst COPD 
patients Stages 1–2 and 10.73 (SD=14.24) amongst COPD patients Stages 3–4 subjects (100). 
However, the differences between subgroups were not statistically significant (p=0.308) 
(100). The utilisation of respiratory medications in this study was higher among COPD 
patients (26% amongst GOLD Stage 0 subjects, 59% amongst COPD patient Stages 1–2 and 
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91% amongst COPD Stages 3–4) (100). However, due to the small sample size of this study, 
these findings should be viewed with caution.  
The cross-sectional study by De Marco et al., (2004) stated that, the use of healthcare 
resources, including physician visits, prescribed medications, emergency department visits 
and one or more hospital admission due to respiratory problems was similar amongst GOLD 
Stage 0 patients and those with COPD Stages 1+ (Table 9) and the trend remained unchanged, 
even after excluding those with self-reported asthma (90). The Ekberg-Aronsson et al., (2008) 
cohort reported generally increasing gradient of hospital admissions amongst current smokers 
from GOLD Stage 0  through COPD patients Stages 1–4 compared to the normal population 
(9). However, the rates did not increase amongst ex and never smoking GOLD Stage 0 
patients (9) (Table 9). However, in this study, there were no follow-up data on respiratory 
symptoms; thus, the instability of GOLD Stage 0 symptoms over the study period was not 
accounted for (9).  
Summary Box 2:  
1. GOLD Stage 0 and the risk of mortality  
 Compared to normal population, GOLD Stage 0 patients showed a similar adjusted mortality 
risk to those with COPD Stage 1 (n=1 cohort study) and current smoking GOLD Stage 0 men 
showed a similar risk to COPD Stage 2 patients (n=1 cohort study).  
 Conversely in 2 other cohort studies, the mortality risk tended to be higher amongst 
confirmed COPD patients but not amongst GOLD Stage 0 patients compared to normal 
population.   
 However, using a broader definition of GOLD Stage 0 was associated with a higher mortality 
risk similar to COPD Stage 1 patients (n=1 cohort study).  
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2. GOLD Stage 0 and exacerbation events 
 GOLD Stage 0 subjects experienced fewer exacerbations but similar healthcare utilisation to 
COPD patients (n=1 cross-sectional study).  
3. HRQoL amongst GOLD Stage 0 patients  
 Compared to COPD patients, GOLD Stage 0 subjects tended to have better total HRQoL 
scores (n=1 cohort study), although GOLD 1 and 2 did not show significant difference from 
GOLD 0.  
 Compared to normal population, GOLD Stage 0 and COPD subjects experienced a worse 
physical functioning, with the confirmed COPD patients tending to have worse outcomes 
(n=1 cross-sectional study).  
4. Healthcare utilisation amongst GOLD Stage 0  
 Compared to confirmed COPD patients, GOLD Stage 0 subjects tended to have a higher rate 
of healthcare utilisation than COPD patients, although was not statistically significant (n=1 
cohort study).  
 Compared to the normal, increased all-cause hospital admission rate showed a gradient of 
effect from GOLD Stage 0 through to diagnosed COPD patients (n=1 cohort study).  
 Healthcare utilisation due to respiratory problems amongst GOLD Stage 0 was similar to 
those with mild COPD (n=1 cross-sectional study).  
5. None of the studies included accounted for the instability of GOLD Stage 0 symptoms over time.  
3.5.2 Discussion  
3.5.2.1 Summary of evidence  
This is the first systematic review of literature to examine the prognosis of GOLD Stage 0 
patients compared to those with confirmed COPD diagnosis. Generally there was a gradient 
of effect with increased risk of mortality, poor HRQoL and increased healthcare utilisation 
from the normal population through to diagnosed COPD patients. GOLD Stage 0 patients 
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have worse prognosis than the normal population but have similar outcomes to COPD Stages 
1 and similar to COPD Stage 2 among smokers. Overall, GOLD Stage 0 patients tended to 
have similar mortality risk, better HRQoL, fewer exacerbations and similar consumption of 
healthcare resources to patient with mild COPD.  
3.5.2.2 Limitations  
The main limitation of this review is the paucity of cohort studies that examined the prognosis 
of GOLD Stage 0 patients and the inclusion of cross-sectional studies which does not allow 
for prognostic evaluation. However, the search was comprehensive and it was unlikely to 
have missed important cohort studies. Another limitation is the lack of studies that directly 
compared GOLD 0 patients with COPD patients, which resulted in the inclusion of studies 
that compared both patients groups with the normal population.   
3.5.2.3 Implication for research and clinical practise 
The findings from this review suggest that the GOLD Stage 0 could be associated with 
increased risk of poor prognosis and healthcare utilisation to a similar extent as mild COPD. 
However, there is limited evidence and the instability of GOLD Stage 0 symptoms was not 
fully accounted for when examining prognosis. Therefore, future studies must consider the 
instability of GOLD Stage 0 symptoms to fully examine their effects. Furthermore, a 
sensitivity analysis based on the different definitions of GOLD Stage 0 needs to be considered 
in future studies, in order to establish a consensus definition of this condition.  
3.5.2.4 Conclusion  
GOLD Stage 0 is associated with increased risk of poor prognosis compared to the normal 
population and similar to those with mild COPD. GOLD Stage 0 population showed a higher 
mortality risk to an extent which may be similar to patients with mild COPD, particularly 
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when broader definition of GOLD Stage 0 was used. Despite better reported HRQoL, GOLD 
Stage 0 patients tended to have similar restriction in daily activities and similar healthcare 
consumption to patients with mild COPD. However, the instability of symptoms over time 
was not fully accounted for and the effect of GOLD Stage 0 could even be underestimated.
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3.6 Review (3): What are the main factors that can affect the prognosis of 
patients with chronic respiratory symptoms but normal lung function?  
3.6.1  Results  
3.6.1.1 The study characteristics  
The characteristics and the main findings of the included two studies are detailed in Table 11:  
3.6.1.1.1 Study design and setting  
Two cohort studies were included. The length of the follow-up period ranged from 3 to 5 
years, whilst the sample sizes ranged from 56 participants in one study (121) to 3,206 
participants in the second (93).  
3.6.1.1.2 Population  
One study targeted middle-aged GOLD Stage 0 subjects (121), whilst in the other study, a 
younger age group was also studied (93). Patients reporting the presence of asthma were 
excluded. GOLD Stage 0 symptoms were defined in both studies using the MRC definition of 
CB.   
3.6.1.1.3 Exposure and outcome  
One cohort study (121) examined factors affecting the rate of FEV1 decline including age, 
duration of CB symptoms, initial degree of airflow obstruction reversibility and the initial 
level of FEV1. The second cohort study (93) investigated factors affecting the persistence of 
GOLD 0 symptoms over time including age, sex, smoking status, metabolic syndrome and 
body mass index (BMI).  
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Table 11: Study characteristics and the main findings (Review 3) 
 
Barter et al., 1974 (121) 
Design Population of interest Exposure Outcome Results General observations  
4.5 years 
prospective 
cohort study-
Australia  
56 Ex-servicemen with 
CB symptoms, aged 
40- 68 years, had pre 
and post-BD FEV1 of > 
60% predicted and free 
from asthma and other 
lung diseases  
 Age 
 Initial degree 
of reversible 
bronchospasm  
 Duration of CB 
 Initial level of 
FEV1 
Factors affecting 
the annual decline 
rate of FEV1  
 
 FEV1 annual decline rate showed a significant 
positive correlation with the initial degree of 
reversible bronchospasm and with the duration of 
CB symptoms (p<0.05) but showed a non-
significant correlation with the initial value of FEV1  
 Age was weakly but significantly related to the 
FEV1 annual decline (p<0.05) 
 There was an individual variation in FEV1 decline 
rate; the highest decline was 0.23L/year 
 
 Small sample size 
 The used cut off of ≥ 
60% define moderate 
AFO according to 
the GOLD 
 Targeted a specified 
population 
 
Brito Mutunayagam et al., 2010 (93) 
Design Population of interest Exposure Outcome Results General observations 
3.5 years 
prospective 
cohort 
Study-
Australia  
 
 
584 GOLD Stage 0 
adults, aged ≥18 years 
(mean=45.5 years) and 
free from asthma and 
restriction (the total 
study sample was 
3,206 participants) 
 
 
 Age 
 Sex  
 Smoking status 
 BMI 
 Metabolic 
syndrome  
Factors affecting 
the persistence or 
resolution of 
symptoms 
 Persistence of GOLD 0 symptoms at follow-up was 
associated with persistent smoking (men: OR 11.9, 
95% CI, 6.4-22.1; women: OR 4.0, 95% CI, 2.1-
7.4), depressive symptoms (men: OR 3.8, 95% CI, 
1.9-7.6; women: OR 3.2, 95% CI, 1.7-5.9), with 
highest quartile of annual FEV1 decline (mL) (OR 
2.1, 95% CI, 1.2-3.7) and with metabolic syndrome 
in men (OR 5 1.7, 95% CI, 1.01-3.0) and with older 
age in women 
 Resolving of GOLD 0 symptoms was associated 
with smoking cessation (OR 13.7; 95% CI, 4.6-
40.1), FEV1 decline (mL) per year below the median 
(OR 2.0; 95% CI, 1.1-3.5), normal BMI (OR 1.8; 
95% CI, 1.03-3.13), and younger age groups 
 
Relatively short follow-
up period 
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3.6.1.2 Methodological quality of the included studies  
The overall risk of bias in the included two cohort studies is presented in Figure 5 (see 
Appendix F Table 46 for details of each study). Both studies provided a clear description of 
study participants and the associated response rate. However, description of study attrition 
and participants lost to follow-up was generally underreported in both studies. The prognostic 
factors examined were adequately defined and reliably measured in both studies included. 
Furthermore, both studies accounted for the important confounders in their analysis and the 
outcome was clearly defined and measured.   
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Figure 5: Overall risk of bias of the included two cohort studies (Review 3)
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
There is no selective reporting of results
The selected statistical method is adequate for the design of the study
Sufficient presentation of data to assess the adequacy of the analytic strategy
Important potential confounders are accounted for in the analysis
Clear definitions of the important confounders
All important confounders are measured
The method and setting of outcome measurement is the same for all  participants
Method of outcome measurement used is adequately valid and reliable
A clear definition of the outcome is provided
Adequate proportion of the study sample has complete data for the PF
The method and setting of measurement of PF is the same for all study participants
Method of PF measurement is adequately valid and reliable
A clear definition or description of the PF is provided
No differences between participants completed the study and those who did not
Adequate description of participants lost to follow-up
Reasons for loss to follow-up are provided
Description of attempts to collect information on dropped out participants
Adequate response rate for study participants
Adequate description of inclusion and exclusion criteria
Adequate description of the period and place of recruitment
Description of the baseline study sample
Description of the source population
Adequate participation in the study
Yes
No
Partly
Unclear
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3.6.1.3 The main findings  
3.6.1.3.1 Factors affecting the rate of FEV1 decline  
The cohort study of Barter et al., (1974) (121) found that increasing age (p<0.05) and the 
greater initial degree of airway obstruction reversibility (p=0.001) were the main factors that 
showed a significant relationship with the increasing rate of FEV1 decline among GOLD 
Stage 0 patients (121). Another observation from this study was that the longer duration of 
CB symptoms has been found to be a significant predictor of FEV1 decline (p<0.05) (121). 
Furthermore, there was also an individual variation in FEV1 decline rates observed in this 
study, some of GOLD Stage 0 subjects had an annual decline in FEV1 of 0.23L, many 
subjects had a negligible FEV1 decline and few subjects had an annual increase of 0.06L 
(121). The effect of baseline initial level of FEV1 on the annual rate of its decline was also 
examined in this study, which suggested a possible correlation with FEV1 annual decline rate, 
although this was not statistically significant (r=0.16) (121). However, the sample size of this 
study was relatively small (56 Ex-servicemen) and these findings need to be considered with 
caution (Table 11). 
3.6.1.3.2 Factors affecting the persistence of GOLD Stage 0 symptoms 
Systematic review (1) in the previous chapter suggested that the feature of instability of 
GOLD Stage 0 symptoms over time is possibly the main determinant of the independent 
predictive value of GOLD Stage 0 on the risk of developing COPD (please refer to section 
2.4.4.3).  
The present review identified one cohort study by Brito et al., (2010) (93), which investigated 
the main factors affecting the persistence of GOLD Stage 0 symptoms over time. Brito et al., 
found that persistent smoking and male gender (smoking men: OR=11.9; 95% CI, 6.4 to 22.1; 
smoking women: OR=4.0, 95% CI, 2.1 to 7.4) (93), older age in women and the presence of 
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metabolic syndrome amongst men (OR=51.7; 95% CI, 1.01 to 3.0) were the main factors 
associated with the persistence of GOLD Stage 0 symptoms (93). While smoking cessation, 
normal BMI and younger age were the main factors associated with a resolution of GOLD 
Stage 0 symptoms (93) (Table 11).  
Summary box 3:  
1. Factors affecting FEV1 decline rate (n=1 cohort study): 
 Increasing age  
 The higher initial degree of airway obstruction reversibility 
 The longer duration of CB symptoms 
 An individual variations  
2. Factors affecting the persistence of GOLD Stage 0 symptoms (n=1 cohort study): 
 Persistent smoking 
 Male gender 
 Older women  
 Metabolic syndrome amongst men   
 
3.6.2 Discussion  
3.6.2.1 Summary of evidence  
This is the first systematic review to examine the main factors affecting the prognosis of 
GOLD Stage 0 patients. However, only two cohort studies were identified relevant to answer 
the review’s question and therefore this systematic review draws attention to the lack of good 
data on the prognostic factors of this condition of GOLD Stage 0 and that reliable answer to 
this question requires more evidence and better studies.  
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This review confirmed through one cohort study (93) that the persistence of GOLD Stage 0 
symptoms was more common among those who were persistent smokers, amongst males, 
older females and males with metabolic syndrome (93). Through the other included cohort 
study (121), this review found that increasing age, the longer duration of CB symptoms and 
the presence of airway obstruction reversibility were the main factors associated with excess 
decline in FEV1 (121). However, the sample size of the latter study was small and a specified 
population was targeted (56 Ex-servicemen).  
3.6.2.2 Limitations  
Undertaking a comprehensive search strategy was challenging but unlikely to have missed 
important studies. However, the main limitation of this review was the lack of enough 
evidence to answer the review question, with only two cohort studies identified relevant. This 
makes it difficult to draw a conclusion with certainty.  
3.6.2.3 Implication for research and clinical practise 
Future longitudinal studies are required in order to explore the main factors affecting the 
prognosis of GOLD Stage 0 patients. However, as recommended in the last two reviews, 
factors affecting the instability of GOLD Stage 0 symptoms over time need to be explored 
through future studies. This will allow for developing interventions targeting GOLD Stage 0 
adults at a higher risk of persistence of their symptoms; for instance, strengthening of the 
smoking cessation programmes.  
3.6.2.4  Conclusion  
This systematic review found insufficient evidence to answer its question on the factors that 
could affect the individual’s susceptibility to poor prognosis among GOLD Stage 0 patients. 
Therefore, these factors warrant further attention and future studies are needed. Particularly, 
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on the factors affecting the persistence of GOLD Stage 0 symptoms over time, which may in 
part be moderated by persistence of smoking.  
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4 CHRONIC RESPIRATORY SYMPTOMS 
VERSUS AIRFLOW OBSTRUCTION: THE 
EFFECT ON PATIENT’S QUALITY OF LIFE—
THE HEALTH SURVEY FOR ENGLAND (2010) 
4.1 Abstract  
Background: The severity of airflow obstruction is considered to be inadequate in capturing 
the eventual COPD-related adverse health outcomes and patient’s perception of ill health. The 
primary aim of this study was to compare the independent impact of respiratory symptoms 
and obstructive lung function on patients’ HRQoL, with a secondary aim to explore those 
symptoms that contribute most to patients’ general health.  
Methods: Cross-sectional analysis of the 2010 data of the HSE on 2,046 adult participants 
classified into four groups according to the presence or absence of respiratory symptoms and 
the presence or absence of airflow obstruction as based on the LLN criteria. Logistic 
regression analysis adjusted for age, sex, smoking, BMI and comorbidity was used to quantify 
the effects of symptoms on HRQoL.  
Results: Patients with chronic respiratory symptoms had significantly poorer HRQoL across 
a number of measures than the normal population, and those with symptoms and airflow 
obstruction were even more affected. Conversely, asymptomatic patients with airflow 
obstruction only showed no significant differences from the normal population.  
Conclusion: These results emphasise the importance of the effect of respiratory symptoms on 
patients’ quality of life, regardless of the presence of airflow obstruction, which may not 
capture the entire picture of COPD. 
76 
 
4.2 Introduction  
Patients with COPD usually have poor HRQoL that worsens over time (122), with the main 
determinants requiring identification in order to develop intervention strategies which could 
improve patients’ HRQoL (122). Most existing guidelines for COPD management and 
monitoring are primarily based on the degree of airflow obstruction (123). However, COPD is 
a multidimensional systematic syndrome (123), with this approach considered inadequate in 
terms of capturing the multiple components of COPD (26, 124, 125). Moreover, the severity 
of airflow obstruction does not adequately predict the eventual COPD-related adverse health 
outcomes (125); therefore, calls for considering multidimensional indices of COPD—such as 
the BODE index (comprising BMI, airflow obstruction, dyspnoea and exercise tolerance), 
ADO index (age, dyspnoea and airflow obstruction) and many other indices are increasing 
(123).  
HRQoL has become an important outcome measure for chronic diseases, including COPD 
(126) and improvement of the HRQoL of affected patients is an important goal of their 
management (122). Previously published studies that examined the HRQoL among COPD 
patients have reported that the degree of severity of airflow obstruction is the main contributor 
to poor HRQoL (127, 128). However, few studies have examined the effects of symptoms on 
HRQoL among COPD patients (94, 122, 126, 129-131). Therefore, it has not yet been 
clarified whether poor HRQoL in COPD is attributed to the degree of airflow obstruction, to 
the presence of symptoms, or to both. Furthermore, evidence is inadequate and has shown 
conflicting results regarding the impact of respiratory symptoms in the absence of airflow 
obstruction on HRQoL, that is the group formerly defined as COPD GOLD Stage 0 (100, 
102). Additionally, in previously published studies, patients with diagnosed asthma and other 
respiratory conditions were not always excluded among GOLD Stage 0 group and the 
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presence of these conditions was not accounted for in examining the impact of symptoms on 
HRQoL (supplementary Table 19).  
This population-based study is the first to compare the independent impact of respiratory 
symptoms and obstructive lung function as measured using the LLN criteria on different 
measures of patients’ HRQoL amongst three groups of “exposure” of the English population 
compared to healthy reference group, with a secondary aim to explore in more details those 
symptoms that contribute most to patients’ self-assessed general health.  
4.3 Methods 
4.3.1 Study design  
Cross-sectional analysis of respiratory data from the 2010 HSE (132).  
4.3.2 Study setting 
The 2010 HSE was the twentieth annual cross-sectional health survey carried out in the UK as 
a part of the NHS Information Centre for Health and Social Care surveys programme (132). 
The HSE provides annual data at a national level, using a representative sample of the UK 
general population, chosen through multistage stratified random sampling, made up of 8,736 
addresses of private households across England (132). The 2010 HSE was mainly focused on 
respiratory health and lung diseases (132). More detailed information on the HSE is available 
at: http://www.hscic.gov.uk/pubs/hse10trends.  
4.3.2.1 Sampling strategy 
In the 2010 HSE, a multistage stratified random sampling strategy was used (132). The 
sampling frame was the small user Postcode Address File (132). At the first stage, a random 
sample of 840 primary sampling units was selected based on the postcode sectors (132). In the 
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second stage, a random sample of postal addresses (known as delivery points) was then drawn 
from within each selected primary sampling unit (132). Within each selected household, all 
adults (up to a maximum of ten adults) were selected to take part in the survey (132). 
4.3.2.2 Measurements and data collection  
During the first stage of the HSE, eligible adults who gave consents to participate undertook a 
standard computer-assisted interview including questions on general health, smoking status, 
and respiratory health (132). The interview also included a self-completion questionnaire, 
including a shortened 12-item general health questionnaire (GHQ12) and the EQ-5D. Height 
and weight measurements were also taken at the interview (132). Stage 2 involved nurse visits 
to the participants’ houses, during which the spirometry testing was performed.  
4.3.2.2.1 Pulmonary function tests 
Pre-bronchodilator spirometry was performed to measure the three key lung function 
parameters: FEV1, FVC and FEV1/FVC ratio (132). Participants were excluded from 
performing the spirometry if they were pregnant, were currently being treated for 
tuberculosis, had a resting pulse rate of more than120 beats per minute, had been admitted to 
hospital with a heart complaint during the preceding month, or if they had had a heart attack, 
detached retina or major surgery on their chest, abdomen, ears, eyes or brain in the preceding 
three months (132). However, detailed information on the measurement protocol for 
spirometry is given in Volume two of the HSE report available at: 
www.ic.nhs.uk/pubs/HSE10report 
4.3.3 Study Population  
This study considered the 2010 data of the HSE adult participants who were aged 40 years 
and above, of white ethnicity, free from asthma and other doctor-diagnosed respiratory 
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conditions and who had valid spirometry results available. The eligible participants were then 
classified into four “exposure” groups according to the presence or absence of any respiratory 
symptoms and the presence or absence of airflow obstruction based on the LLN criteria: 
normal population (asymptomatic with normal lung function), AFO only group 
(asymptomatic but had obstructive lung function), symptoms only group “GOLD Stage 0” 
(reported the presence of chronic respiratory symptoms but had normal lung function) and 
symptomatic AFO group (reported the presence of chronic respiratory symptoms and had 
obstructive lung function).  
4.3.4 Definitions  
4.3.4.1 Chronic Respiratory Symptoms 
The presence of respiratory symptoms of cough, sputum, dyspnoea and wheezing was 
assessed using the MRC questionnaire (132). Cough and phlegm were defined by the positive 
response to the question ‘Do you usually cough or bring up phlegm on most days for three 
consecutive months or more during the year?’ (132). Wheeze was defined by a positive 
response to the question ‘Have you had wheezing or whistling in the chest in the last 12 
months?’ (132). Dyspnoea was defined as grade two or above of the MRC breathlessness 
scale ‘Short of breath when hurrying or walking up a slight hill’ (132).  
4.3.4.2 Airflow obstruction  
Airflow obstruction was defined based on the LLN criterion using the Stanojevic (2009) all-
ages equations (132), as FEV1/FVC ratio below the 5
th
 percentile of predicted value for age, 
sex, height and ethnicity (41). However, at the time at which the HSE was conducted, the all-
age reference equations were available only for white ethnicity and those for other ethnicities 
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were not yet developed (132); therefore, this study considered participants of white ethnicity 
only. 
4.3.4.3 Covariates  
Participants were categorised according to their smoking status (current, former, never). BMI 
was estimated by dividing patient weight in kilograms by the square of their height in metres 
(132) and further categorised using the World Health Organisation (WHO) BMI classification 
standard into: underweight (BMI less than 18.5 kg/m²), normal (BMI= 18.5 to 24.9 kg/m²), 
overweight (BMI=25 to 29.9 kg/m²) and obese (BMI ≥ 30 kg/m²). Doctor diagnosed long 
standing comorbidities were assessed using self-completed questionnaires, which included 
cardiovascular diseases (CVDs), cancer, diabetes and mental illnesses. Multiple comorbidities 
were defined by the presence of three or more of these comorbidities.  
4.3.4.4 HRQoL 
HRQoL was examined using self-completion questionnaires (132) on:  
4.3.4.4.1 Self-reported general health  
General health was investigated by asking participants to rate their general health on a five 
point Likert scale as either: very good, good, fair, bad or very bad (132).  
4.3.4.4.2 GHQ12 
The GHQ12 contains twelve items that capture information on psychosocial health, such as 
depression, anxiety, sleep disturbance and ability to cope over the recent few weeks (132). 
The twelve items are graded on a four points response scale, where a score of 0 is given to 
responses such as those stating the symptom as present ‘not at all’ or ‘no more than usual’, 
whilst a score of 1 is given to responses such as ‘rather more than usual’ or ‘much more than 
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usual’ (132). A GHQ12 score of 4 or higher is indicated as a ‘High GHQ12 score’, 
demonstrating probable psychological disturbance or ill mental health (132).  
4.3.4.4.3 Three level EQ-5D  
The EQ-5D has two components, the first of which is a descriptive system including five 
different dimensions, namely pain/discomfort, anxiety/depression, self-care, ability to perform 
usual activities, and mobility (132). Participants were asked to indicate whether they had no 
problems, some problems or severe problems (132). The second component is the EQ visual 
analogue scale (EQ VAS), which records participant’s self-assessed health through the use of 
a vertical visual scale, where endpoints are categorised as ‘Best imaginable health state’ (100) 
and ‘Worst imaginable health state’ (0) (132).  
4.3.5 Statistical Analysis 
STATA v.13 was used for all statistical analyses. In order to account for the complex 
sampling design and to minimise bias from individual non-response within households, the 
survey dataset was weighted using individual level weights provided by the HSE, which were 
a combination of the household weight and a component that adjusted for the sample 
technique (132). Due to the way in which the questions were formulated, missing data on 
respiratory symptoms were treated as the absence of symptoms. Descriptive data were 
presented as mean and standard error (SE) for continuous variables and as frequency and 
percentage for categorical variables.  
In order to examine the independent effect of respiratory symptoms and airflow obstruction 
on HRQoL amongst the three groups of “exposure” compared with normal population, linear 
and multiple logistic regression were undertaken and associations presented as the odds ratios 
(ORs), with 95% confidence interval (CI) and p value. Age, sex and smoking status were 
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defined as potential confounders and adjusted for in an initial model. To account for the 
clinical significance of BMI and comorbidity and their potential influence on the association, 
further adjustment with BMI, cardiovascular comorbidity and the number of comorbidities 
was performed in a second model.  
Due to the small numbers of observations in level 3, the domains of the EQ-5D were 
dichotomised in the regression model combining levels 2 and 3. In order to examine the 
respiratory symptom that had the most significant effect on general health, symptoms were 
examined individually using multiple logistic regression adjusted as above  and further the 
symptoms were adjusted for each other.  
4.3.5.1 Statistical power of the analysis  
There were 2,046 participants with data available for this analysis (see results section 4.4.1). 
This would provide 85% power to observe an odds ratio of 2.0 for the proportion of non-
normals (combined symptoms only, AFO only and both) reporting bad to very bad health, 
assuming that 3% of the normal population reports bad to very bad health. This assumes that 
the population sizes are 1,369 for normals, 68 for AFO only, 522 for symptoms only and 87 
for presence of both (see next section).    
4.4 Results  
4.4.1 Study sample 
There were 2,303 HSE participants who met the inclusion criteria for this study. Of those, 
2,046 participants (88.8%) had spirometry data available and were included (Figure 6). 
Among those included, 1,369 participants were classified as “normal”, 68 classified as “AFO 
only”, 522 classified as symptoms only “GOLD Stage 0”, and 87 classified as “AFO with 
symptoms". 
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Figure 6: Flow diagram of patient selection procedure 
4.4.2 Description of patient characteristics 
4.4.2.1 Socio-demographics and clinical characteristics  
Compared with the normal group (mean age 56.9 years), GOLD Stage 0 patients and those 
with AFO only were significantly older (both groups mean age 60.2 years) and those with 
both symptoms and AFO were the oldest (64.3 years, p<0.0001). Patients with both AFO and 
symptoms were more likely to be males than the normal group (66.7% versus 47.3%, 
p<0.0001). All groups were more likely to be current smokers than the normal group, but 
participants with AFO were most likely to be current smokers. Participants with both AFO 
and symptoms were also more likely to be ex-smokers than normal (51.7% versus 33.7%, 
p<0.0001). Overall, participants with AFO were much more likely to be ever smokers (Table 
12).  
8,420 HSE adult participants  
2,303 eligible participants  
Included participants 
(n=2,046)  
Normal population 
(n=1369) 
AFO only 
 (n=68) 
Symptoms only 
(n=522) 
Symptomatics with 
AFO  
(n=87)  
Excluded with missing 
spirometry data  
(n=257 )                                                                                          
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Compared to the normal, GOLD Stage 0 participants were more likely to be obese (37.5% 
versus 22.2%, p<0.0001). GOLD Stage 0 participants showed similar trends to those with 
both AFO and symptoms in the higher rates of the following self-reported diagnosed 
comorbidities than the normal group: cardiovascular diseases (24.7% and 23.0%, respectively, 
versus 10.8%), high blood pressure (45.2% and 46.0%, respectively, versus 29.9%), diabetes 
(11.3% and 9.2%, respectively, versus 4.4%), mental health comorbidities (5.4% and 5.7%, 
respectively, versus 2.0%) and multiple comorbidities of two conditions (21.1% and 25.3%, 
respectively, versus 10.5%) or three or more conditions (12.5% and 14.9%, respectively, 
versus 3.7%). Participants with AFO only showed similar comorbidity profiles to the normal 
group, except for the neoplasm (7.4% versus 2.1% among the normal) (Table 12). 
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Table 12: Univariable socio-demographics and clinical characteristics by groups of “Exposure” compared 
to the normal population 
 Normal 
population 
(n=1369) 
AFO only (n=68) GOLD Stage 0 
(n=522) 
AFO with symptoms 
(n=87) 
 
Age−Mean (SE) 
 
56.9 (0.3) 
 
60.2 (1.6); P=0.05  
 
60.2 (0.5); P<0.0001  
 
64.3 (1.2); P<0.0001  
 
Sex
1
  
Males 648 (47.3%) 30 (44.1%)  244 (46.7%) 58 (66.7%) 
Females  721 (52.7%) 38 (55.9%) 278 (53.3%) 29 (33.3%) 
P value - P=0.6  P=0.8  P< 0.0001  
 
Smoking status
2
  
Current smokers 119 (8.7%) 23 (33.8%) 117 (22.4%) 32 (36.8%) 
Ex-smokers 462 (33.7%) 21 (30.9%) 189 (36.2%) 45 (51.7%) 
Never smokers 788 (57.6%) 24 (35.3%) 216 (41.4%) 10 (11.5%) 
P value - P<0.0001  P<0.0001  P<0.0001 
 
BMI
3
  
Normal  365 (26.7%) 23 (33.8%)  85 (16.3%) 32 (36.8%) 
Underweight   5 (0.4%)  0    1 (0.2)   2 (2.3%) 
Overweight  594 (43.4%) 27 (39.7%) 186 (35.6%) 29 (33.3%) 
Obese  304 (22.2%) 11 (16.2%) 196 (37.5%) 17 (19.5%) 
P value - P= 0.1  P< 0.0001  P=0.03  
 
Self-reported doctor diagnosed comorbidities 
CVDs 148 (10.8%)   8 (11.8%); P=0.7  129 (24.7%); P<0.0001  20 (23.0%); P<0.0001  
Heart failure      0    0     4 (0.8%)   2 (2.3%) 
High blood pressure  410 (29.9%) 16 (23.5%); P=0.2  236 (45.2%); P<0.0001  40 (46.0%); P=0.002  
Neoplasm    28 (2.1%)   5 (7.4%); P=0.01    21 (4.0%); P=0.01    7 (8.1%); P=0.001  
Diabetes    60 (4.4%)   3 (4.4%); P=0.9    59 (11.3%); P<0.0001    8 (9.2%); P=0.05  
Mental    27 (2.0%)   1 (1.5%); P= 0.3    28 (5.4%); P<0.0001    5 (5.7%); P=0.006  
 
Number of comorbid conditions
4
  
No comorbidity  812 (59.3%)  39 (57.4%) 202 (38.7%) 23 (26.4%) 
1 comorbidity 363 (26.5%) 18 (26.5%) 145 (27.8%) 29 (33.3%) 
2 comorbidities 144 (10.5%)   6 (8.8%) 110 (21.1%)  22 (25.3%) 
≥ 3 comorbidities   50 (3.7%)  5 (7.4 %)   65 (12.5%) 13 (14.9%) 
P value - P=0.7  P<0.0001  P<0.0001  
 Normal population is the reference group for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories: 1=male, 2=current smokers, 3= normal BMI and 4=No comorbidity 
 P value is for the difference between each patient group and the normal population 
4.4.2.2 Profile of individual respiratory symptom  
The relative prevalence of individual respiratory symptoms was compared in the two groups 
with any symptoms. For each of the individual symptoms, prevalence was significantly higher 
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amongst participants with AFO than those with normal lung function except for dyspnoea 
MRC Grade two (Table 13). 
Table 13: Self-reported respiratory symptoms by lung function 
 GOLD Stage 0 (n=522) 
 
AFO with symptoms (n=87) P value 
Chronic cough 175 (33.5%) 45 (51.7%) <0.0001 
Chronic phlegm   97 (18.6%) 24 (27.6%) <0.0001 
Wheeze 188 (36.0%) 53 (60.9%) <0.0001 
Dyspnoea     
MRC Grade 2  212 (40.6%) 24 (27.6%) <0.0001 
MRC Grades 3-5    99 (19.0%) 27 (31.0%) <0.0001 
Values presented are numbers with percentages unless otherwise stated 
4.4.2.3 Measures of HRQoL 
Table 14 below shows the distribution of HRQoL between subgroups. In unadjusted analyses, 
compared to the normal, participants with both symptoms and AFO and GOLD Stage 0 
participants were significantly more likely to report bad to very bad general health (16.1% and 
10.5%, respectively, versus 2.9%) and worse GHQ12 (4+) scores (16.1% and 18.0%, 
respectively, versus 9.3%).  
Within the EQ-5D, the frequency of moderate anxiety was higher amongst GOLD Stage 0 
group (27.0%), followed by the AFO only group (20.6%) and the symptoms with AFO group 
(18.4%). GOLD Stage 0 participants (44.8%) and those with both symptoms and AFO 
(43.7%) showed higher frequencies of mild to moderate problems with pain compared to 
(28.9%) in the normal group. Similar patterns were observed for self-care, usual activities and 
mobility. There was also a similar gradient of scores observed with the EQ-5D VAS general 
health scale, with the worst scores amongst the group reporting both symptoms and AFO. 
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Table 14: Univariable measures of HRQoL by groups of “Exposure” compared to the normal population 
 Normal 
population 
(n=1369) 
AFO only 
(n=68) 
GOLD Stage 0 
(n=522) 
AFO with 
symptoms 
(n=87) 
P value 
 
Self-assessed general health  
 
<0.0001 
Very good to good  1,174 (85.8%) 53 (77.9%) 309 (59.2%) 46 (52.9%)  
Fair    155 (11.3%) 15 (22.1%) 158 (30.3%) 27 (31.0%)  
Bad to very bad      40 (2.9%)   1 (1.5%)   55 (10.5%) 14 (16.1%)  
 
Psychosocial wellbeing (GHQ12 score)  
 
<0.0001 
Score 0    915 (66.8%) 47 (69.1%) 279 (53.5%) 47 (54.0%)  
Score 1-3    275 (20.1%) 11 (16.2%) 113 (21.7%) 20 (23.0%)  
Score 4+    128 (9.3%)   8 (11.8%)   94 (18.0%) 14 (16.1%)  
 
EQ-5D dimensions 
 Anxiety/depression <0.0001 
Not anxious/depressed 1,093 (79.8%) 51 (75.0%) 337 (64.6%) 61 (70.1%)  
Moderately anxious    203 (14.8%) 14 (20.6%) 141 (27.0%) 16 (18.4%)  
Extremely anxious      15 (1.1%)    0   11 (2.1%)   3 (3.5%)  
 Pain/discomfort  <0.0001 
No pain/discomfort     898 (65.6%) 43 (63.2%) 237 (45.4%) 39 (44.8%)  
Moderate pain    396 (28.9%) 24 (35.3%) 234 (44.8%) 38 (43.7%)  
Extreme pain      34 (2.5%)   0   34 (6.5%)    4 (4.6%)  
 Self-care <0.0001 
No problems  1,287 (94.0%) 64 (94.1%) 456 (87.4%) 71 (81.6%)  
Some problems with washing 
or dressing  
     34 (2.5%)   3 (4.4%)   45 (8.6%)   8 (9.2%)  
Unable to wash or dress my 
self  
       1 (0.1%)  0     1 (0.2%)   0  
 Usual activities <0.0001 
No problems 1,168 (85.3%) 59 (86.8%) 374 (71.6%) 54 (62.1%)  
Some problems    146 (10.7%)   9 (13.2%) 113 (21.6%) 24 (27.6%)  
Unable to perform usual 
activities 
    13 (0.9%) 0   16 (3.1%)   4 (4.6%)  
 Mobility  <0.0001 
No problems 1,265 (92.4%)  60 (88.2%) 370 (70.9%) 52 (59.8%)  
Some problems    180 (13.2%) 11 (16.2%)  179 (34.3%) 30 (34.5%)  
Severe problems        7 (0.5%)   0     1 (0.2%)    0  
EQ-5D VAS −Mean (SE)   82.8 (0.4) 81.9 (1.8) 74.7 (0.7) 71.4 (1.9) <0.0001 
 
Values presented are numbers with percentages unless otherwise stated 
4.4.3 The independent effect of symptoms and airflow obstruction on HRQoL  
4.4.3.1 Self-assessed general health  
Following an adjustment for age, sex and smoking status, the risk of self-assessed ‘bad to 
very bad’ general health was significantly higher amongst symptomatic participants with 
AFO (OR=4.1; 95% CI, 2.1 to 7.9) and GOLD Stage 0 group (OR=3.3; 95% CI, 2.1 to 5.1) 
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compared to the normal group. On the contrary, the AFO only group showed a lower risk than 
the normal population. Similar patterns were observed following further adjustment for the 
confounding of the BMI, cardiovascular comorbidity and the number of comorbidities (Table 
15).   
Table 15: The adjusted difference in general health between “Exposure” groups compared to the normal 
population 
 Bad to very bad self-assessed general health 
Number (%) Unadjusted OR 
(95% CI) 
Adjusted OR
1
  
(95% CI) 
Adjusted OR
2
  
(95% CI) 
 
Normal population 
 
40 (2.9%) 
 
1.0 
 
1.0 
 
1.0 
 
AFO only 
 
  1 (1.5%) 
 
0.2 (0.02 to 1.3) 
 
0.13 (0.02 to 0.9) 
 
0.1 (0.01 to 0.9) 
 
GOLD Stage 0 
 
55 (10.5%) 
 
3.9 (2.6 to 5.9) 
 
3.3 (2.1 to 5.1) 
 
2.1 (1.3 to 3.4) 
 
AFO with Symptoms 
 
14 (16.1%) 
 
6.5 (3.5 to 11.9) 
 
4.1 (2.1 to 7.9) 
 
2.5 (1.1 to 5.5) 
 Normal population is the reference group for all comparisons 
 Reference category: good/very good to fair general health 
 OR1:Adjusted for age, sex and smoking status 
 OR2: Adjusted for age, sex and smoking status, BMI, CVDs and the number of comorbidities 
4.4.3.2 Self-assessed Psychosocial Wellbeing 
The adjusted risk of worse GHQ12 (4+) scores was significantly higher amongst participants 
with both symptoms and AFO (OR=2.4; 95% CI, 1.3 to 4.4) and GOLD Stage 0 participants 
(OR=2.3; 95% CI, 1.7 to 3.2) compared to the normal group. Conversely, the AFO only group 
showed non-significant difference from the normal group. Similar patterns were observed 
following further adjustment for the confounding of the BMI, cardiovascular comorbidity and 
the number of comorbidities (Table 16).   
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Table 16: The adjusted difference in psychosocial wellbeing between ‘Exposure’ groups compared to the 
normal population 
 Psychosocial wellbeing (GHQ12 scores 4+) 
Number (%) Unadjusted OR 
(95% CI) 
Adjusted OR
1
 (95% 
CI) 
Adjusted OR
2
 (95% 
CI) 
 
Normal population 
 
128 (9.3%) 
 
1.0 
 
1.0 
 
1.0 
 
AFO only 
 
    8 (11.8%) 
 
1.3 (0.6 to 2.7) 
 
1.3 (0.6 to 2.7) 
 
1.2 (0.5 to 2.6) 
 
GOLD Stage 0 
 
  94 (18.0%) 
 
2.2 (1.7 to 2.9) 
 
2.3 (1.7 to 3.2) 
 
1.9 (1.4 to 2.7) 
 
AFO with Symptoms 
 
 14 (16.1%) 
 
2.0 (1.1 to 3.5) 
 
2.4 (1.3 to 4.4) 
 
1.6 (0.8 to 3.2) 
 Normal population is the reference group for all comparisons 
 Reference category: GHQ12 scores 0-3 
 OR1:Adjusted for age, sex and smoking status 
 OR2: Adjusted for age, sex and smoking status, BMI, CVDs and the number of comorbidities 
4.4.3.3 EQ-5D  
Table 17 below presents the adjusted risks for each domain of the EQ-5D. Compared to the 
normal, the risk of moderate to extreme anxiety was higher amongst GOLD Stage 0 
participants (OR=2.3; 95% CI, 1.8 to 2.9). Moreover, participants with both AFO and 
symptoms (OR=1.8; 95% CI, 1.1 to 2.8) and GOLD Stage 0 participants (OR=2.1; 95% CI, 
1.7 to 2.6) showed a higher risk of moderate to extreme pain and discomfort. Similar patterns 
were confirmed for moderate to severe problems with self-care, usual activities and mobility. 
The lower mean EQ-5D VAS scores were also significantly associated with the presence of 
symptoms. Similar patterns were observed following further adjustment for the confounding 
of the BMI, cardiovascular comorbidity and the number of comorbidities (Table 17).   
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Table 17: The adjusted difference in the EQ-5D domains between “Exposure” groups compared to the 
normal population 
 EQ-5D 
Number (%) Unadjusted OR 
(95% CI) 
Adjusted OR
1
 (95% 
CI) 
Adjusted OR
2
 (95% 
CI) 
Moderate/extreme anxiety and depression
1
 
Normal population 218 (15.9%) 1.0 1.0 1.0 
AFO only   14 (20.6%) 1.3 (0.7 to 2.5) 1.3 (0.7 to 2.4) 1.2 (0.6 to 2.3) 
GOLD Stage 0 152 (29.1%) 2.3 (1.8 to 2.9) 2.3 (1.8 to 2.9) 2.0 (1.5 to 2.6) 
AFO with Symptoms   19 (21.9%) 1.6 (0.9 to 2.6) 1.6 (0.9 to 2.8) 1.3 (0.8 to 2.3) 
Moderate/extreme pain and discomfort
2
  
Normal population 430 (31.4%) 1.0 1.0 1.0 
AFO only   24 (35.3%) 1.2 (0.7 to 1.97)  1.02 (0.6 to 1.8)  1.0 (0.6 to 1.8) 
GOLD Stage 0 268 (51.3%) 2.4 (1.9 to 2.9) 2.1 (1.7 to 2.6) 1.5 (1.2 to 1.9) 
AFO with Symptoms   42 (48.3%) 2.2 (1.4 to 3.4) 1.8 (1.1 to 2.8) 1.2 (0.7 to 2.1) 
Moderate/severe problems with self-care
3
  
Normal population   35 (2.6%) 1.0 1.0 1.0 
AFO only     3 (4.4%) 1.9 (0.6 to 5.4) 1.4 (0.5 to 3.9) 1.3 (0.4 to 5.0) 
GOLD Stage 0   45 (8.8%) 3.7 (2.4 to 5.6) 3.0 (1.9 to 4.7) 1.9 (1.1 to 3.3) 
AFO with Symptoms     8 (9.2%) 4.4 (2.1 to 8.9) 2.9 (1.3 to 6.2) 1.7 (0.8 to 3.9) 
Moderate/severe problems with usual activities
4
 
Normal population 159 (11.6%) 1.0 1.0 1.0 
AFO only     9 (13.2%) 1.2 (0.6 to 2.3) 0.95 (0.5 to 1.9) 0.8 (0.3 to 1.5) 
GOLD Stage 0 129 (24.7%) 2.5 (1.97 to 3.2) 2.2 (1.7 to 2.9) 1.4 (1.0 to 1.9) 
AFO with Symptoms   28 (32.2%) 3.8 (2.4 to 6.0) 3.0 (1.8 to 4.8) 1.6 (1.0 to 2.8) 
Moderate/severe problems with mobility
5
 
Normal population 187 (13.7  1.0 1.0 1.0 
AFO only   11 (16.2%)  1.2 (0.6 to 2.3) 0.9 (0.5 to 1.9) 1.0 (0.5 to 2.2) 
GOLD Stage 0 180 (34.5%)  2.3 (2.6 to 4.1) 2.8 (2.2 to 3.6) 1.8 (1.4 to 2.4) 
AFO with Symptoms   30 (34.5%)  3.9 (2.5 to 6.1) 2.7 (1.7 to 4.4) 1.9 (1.1 to 3.3) 
 
EQ-5D VAS (Best/worst imaginable health state)  
 Mean (SE) Unadjusted 
regression 
coefficient (95% 
CI) 
Adjusted regression 
coefficient
1
 (95% 
CI) 
Adjusted regression 
coefficient
2
 (95% 
CI) 
Normal population 82.8 (0.4)    1.0 1.0 1.0 
AFO only 81.9 (1.8)   -0.8 (-4.4 to 2.7)  0.2 (-3.3 to 3.7) 0.9 (-2.2 to 3.9) 
GOLD Stage 0 74.7 (0.7)   -8.1 (-9.7 to -6.4) -7.4 (-9.1 to -5.7) -4.0 (-5.5 to -2.4) 
AFO with Symptoms 71.4 (1.9) -11.3 (-15.1 to -7.5) -9.5 (-13.3 to -5.7) -6.4 (-9.9 to -2.8) 
 Normal population is the reference group for all comparisons 
 Reference categories:1= not anxious/depressed, 2= no pain/discomfort, 3, 4 and 5= no problems  
 OR1:Adjusted for age, sex and smoking status 
 OR2: Adjusted for age, sex and smoking status, BMI, CVDs and the number of comorbidities 
4.4.4 The effect of individual symptoms on self-assessed general health  
The effect of individual symptoms was explored on participants’ perception of general health. 
In unadjusted analyses, the risk of bad to very bad general health was significantly associated 
with each individual symptom except for chronic phlegm which showed similar direction but 
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did not reach statistical significance. After adjustment for age, sex and smoking status, the 
associations remained similarly significant, although after further adjustment for 
cardiovascular comorbidity, BMI and each other, only dyspnoea (OR=4.5; 95% CI, 2.2 to 9.4) 
and wheeze (OR=3.3; 95% CI, 1.3 to 8.7) remained statistically significant (Table 18).  
Table 18: The adjusted individual effect of respiratory symptoms on general health 
 Bad to very bad general health 
Unadjusted OR 
(95% CIs) 
 
Adjusted OR
1 
(95% CIs)
 
Adjusted OR
2 
(95% CIs)
 
Adjusted OR
3 
(95% CIs) 
Chronic cough 1.7 (1.1 to 2.7) 1.7 (1.1 to 2.7) 1.3 (0.7 to 2.3) 1.7 (0.8 to 3.6) 
Chronic phlegm 1.5 (0.9 to 2.2) 1.4 (0.9 to 2.2) 1.2 (0.7 to 2.1) 1.0 (0.5 to 1.8) 
Wheeze 2.9 (2.1 to 4.3) 2.8 (1.9 to 4.0)  1.9 (1.2 to 3.1) 3.3 (1.3 to 8.7) 
Dyspnoea (MRC grade ≥2) 6.3 (5.0 to 7.9)  5.9 (4.6 to 7.5) 4.0 (2.9 to 5.4) 4.5 (2.2 to 9.4) 
 OR1: Adjusted for age, sex and smoking status  
 OR2: Further adjustment for BMI, CVD and the number of comorbidities  
 OR3: The symptoms were adjusted for each other  
4.5 Discussion 
4.5.1 Main Findings  
The findings from this study of population-based data demonstrate that the presence of 
respiratory symptoms has more negative impact on patient’s HRQoL than the presence of 
airflow obstruction. GOLD Stage 0 patients had similar, although slightly better HRQoL 
across a number of different measures to symptomatic patients with airflow obstruction. In 
contrast, participants with airflow obstruction without symptoms consistently presented non-
significant differences from the normal population in their HRQoL.  
Additionally, upon further examination of patients’ perception of their health, the most 
important symptoms affecting quality of life appear to be dyspnoea and wheeze, with chronic 
cough having little independent impact.  
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4.5.2 Comparison with the Existing Evidence 
The present study was the first to examine the independent impact of chronic respiratory 
symptoms and airflow obstruction on HRQoL through classifying the participants in to three 
groups of “exposure” compared with the normal population. However, findings from this 
study are in line with previously published cross-sectional studies (94, 122, 129, 130), which 
also observed that lower quality of life scores were more strongly related to the respiratory 
symptoms than to the severity of COPD as measured using the GOLD fixed ratio criteria. On 
the other hand, Xie et al. (2005), in a Chinese context, found that only patients with both 
airflow obstruction and symptoms had higher risk of poor HRQoL, when patients with 
symptoms only and those with airflow obstruction only had a mild risk of poor HRQoL (131). 
Furthermore, the present study confirms the results of Voll-Aanerud et al. (126, 129, 130), 
who also found that dyspnoea and wheeze had a greater negative effect than other symptoms 
on the HRQoL and with Wheaton et al., study (122), which showed that wheeze but not 
cough was associated with poor HRQoL after adjustment for relevant confounders. However, 
they found that phlegm still had a significant effect on poor HRQoL (122). 
4.5.3 Strengths and Limitations  
This study has some limitations. First, the analysis was limited to those of white British and 
Irish ethnicity; therefore, the results may not be generalisable to other ethnic groups. The 
second limitation was the smaller number of patients in groups with airflow obstruction which 
suggests that caution needs to be considered in terms of interpreting some of the effect 
estimates. The strength of this study is centred on using a large national representative data 
from the HSE with the advantage of applying generalisability to the English population.  
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4.5.4 Implications for research and clinical practise  
Future longitudinal studies targeting this relevant group of patients with chronic respiratory 
symptoms in the absence of identified clear pathological origin are required. Such studies can 
contribute to better understanding of their prognosis, in particular to identify patients who 
may progress to formal diagnoses of COPD and those who may have a non-COPD treatable 
condition. In clinical practice, the importance of questioning the presence of respiratory 
symptoms (particularly dyspnoea and wheeze) is emphasised. This is simple, feasible and 
better describes patients’ quality of life than the severity of airflow obstruction. Furthermore, 
symptomatic patients without airflow obstruction must be investigated for any underlying 
respiratory and non-respiratory conditions and treated accordingly. As they are more likely to 
be obese, referral to weight management programmes might be beneficial. Although 
pulmonary rehabilitation is usually only available for patients with diagnosed respiratory 
conditions, perhaps this group of symptomatic patients might also benefit from pulmonary 
rehabilitation by improving their management of dyspnoea.  
4.5.5 Conclusion  
This study emphasises the significance of the impact of respiratory symptoms on patients’ 
quality of life, regardless of the presence of airflow obstruction, where FEV1 may not capture 
the entire picture of COPD. Consequently, those patients with symptoms without clear 
identified underlying pathology perhaps are more of a concern than those with a known cause, 
as they are recognised as having a similarly poor quality of life, which cannot be explained by 
impaired lung function. The cause for their breathlessness should be investigated and 
appropriately treated.  
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4.7 Supplementary Tables 
Table 19: Summary of the available evidence on the chapter’s topic 
Study ID Design Outcome Study population Gaps in knowledge  
Xie at al., 2005 
(131) 
9 years 
prospective cohort 
study in  
China 
  
 The relationship between 
baseline pulmonary function and 
HRQoL 9 years later  
 HRQoL was measured using the 
Chinese 35-Item Quality of Life 
Instrument  
 
 
 1,356 middle aged adults 
 Normal lung function was 
defined as: FEV1/FVC ratio 
≥ 0.70, FEV1 ≥ 80% 
predicted & FVC ≥80% 
predicted  
 The primary objective of this study was the effect 
of lung function on HRQoL and symptoms were 
included in the model as a confounder factor. 
However, the study population were further 
classified in to 4 groups normal, impaired 
pulmonary function only and impaired pulmonary 
function with chronic respiratory symptoms but this 
was a secondary objective and was briefly 
presented  
 Included asthma in symptomatic group  
 COPD was defined and classified using the GOLD 
criteria 
Voll-Aanerud et 
al., 2007 (126) 
Longitudinal 
population-based 
cohort study in 
Norway 
 The effect of incidence, 
remission, and persistence of 6 
respiratory symptoms (morning 
cough, chronic cough, phlegm 
cough, wheeze, dyspnea attacks, 
and dyspnea grade 2) on HRQoL 
compared to no symptoms  
 HRQoL was measured by the 
SF
5
-12 questionnaire 
3,786 subjects aged 15 to 70 
years  
Examined the negative impact of symptoms on HRQoL 
irrespective to the lung function  
Voll-Aanerud et 
al., 2008 (129) 
Cross sectional 
study, Norway 
 
 The association between 6 
respiratory symptoms and 
COPD severity (based on the 
GOLD criteria) with HRQoL 
compared to healthy subjects  
 HRQoL was measured by the 
SF-12 questionnaire 
2,306 subjects, aged 15 to 70  HRQoL was examined in relation to individual 
symptom, number of symptoms and to the COPD 
severity  
 COPD was defined and classified using the GOLD 
criteria 
 
                                                 
5
 Short-Form questionnaire 
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Study ID Design Outcome Study population Gaps in knowledge  
Voll-Aanerud et 
al., 2010 (130) 
Cross sectional 
study of the 
European 
Community 
Respiratory 
Health Study data 
 
 The association of respiratory 
symptoms with HRQoL in 
subjects with and without 
asthma or COPD  
 HRQoL was measured by the 
SF-36 questionnaire 
6,009 adults aged 20-44 years in  Asthma was not excluded 
 HRQoL was examined in relation to individual 
symptom and persistent symptoms in subjects with 
and without diagnosed asthma or COPD 
 COPD was defined and classified using the GOLD 
criteria 
De Oca et al., 
2012 (94) 
Cross sectional 
study in Latin 
America 
 The effect of the coexisting CB 
symptoms and COPD on 
patient’s perceptions of their 
HRQoL  
 HRQoL was measured by the 
SF-12 questionnaire 
 5,571 subjects, aged ≥40 
years and classified in to 2 
groups: COPD and non-
COPD and each group 
further classified into with 
and without CB groups 
 CB defined as; phlegm on 
most days at least 3 months 
per year for ≥ 2 years 
 Did not exclude asthma  
 COPD was defined and classified using the GOLD 
criteria 
 Although performed parallel analysis using the 
LLN but data was not shown  
Wheaton et al., 
2013 (122) 
Cross sectional 
study in the US 
 The association of impaired lung 
function and respiratory 
symptoms with the HRQOL 
 HRQOL was measured using 
questions on general health, 
physical health and mental 
health 
5,139 participants, aged 40–79 
years categorised into: 
 Normal lung function  
 Restrictive impairment  
 Mild obstruction  
 Moderate to severe 
obstruction 
And further classified according 
to their reported symptoms into:  
 Cough  
 Phlegm  
 Wheeze  
 Any symptoms  
 No symptoms  
 HRQoL was examined in relation to lung function 
category, individual symptom, any symptom and no 
symptom separately  
 COPD was defined and classified using the GOLD 
criteria 
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5 COPD GOLD STAGE 0 AND NEWLY 
DIAGNOSED COPD PATIENTS: HEALTH-
RELATED CHARACTERISTICS AND 
OUTCOMES−BIRMINGHAM COPD COHORT 
STUDY 
5.1 Abstract  
Introduction: Although the association between the presence of chronic respiratory 
symptoms and the development of COPD remains uncertain, these symptoms may have a 
relevant impact on patients’ health even in the absence of airflow obstruction. The aim of this 
study was to compare the health-related characteristics and health outcomes of GOLD Stage 0 
patients and those newly diagnosed with COPD, both groups identified through a COPD case-
finding trial in the UK.  
Methods: Cross-sectional analysis of baseline data from the Birmingham COPD Cohort 
Study including 281 GOLD Stage 0 patients and 215 new COPD patients. Characteristics and 
health outcomes of patient in both groups were compared using logistic regression analysis 
adjusted for age, sex, smoking status and comorbidity.   
Results: Compared to newly diagnosed COPD patients, GOLD Stage 0 patients were younger 
(mean age 62.3 versus 66.1 years, OR=0.9; 95% CI, 0.94 to 0.98), more likely to be never 
smokers (22.1% versus 15.3%, adjusted OR=4.3; 95% CI, 2.3 to 7.9) and more likely to be 
obese (43.8% versus 29.8%, adjusted OR=2.3; 95% CI, 1.3 to 4.0). GOLD Stage 0 patients 
showed possibly fewer exacerbation events, but similar overall patterns in HRQoL, healthcare 
utilisation, and exercise capacity to that reported by newly diagnosed COPD patients.  
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Conclusion: GOLD Stage 0 patients showed similar patterns of poor health outcomes to 
those diagnosed with COPD. Longitudinal studies are needed to better describe the long-term 
prognosis of GOLD Stage 0. 
5.2 Introduction  
Previous epidemiological studies have found that the prevalence of GOLD Stage 0 is 
relatively high (101). In the European Community Respiratory Health Survey, the prevalence 
of GOLD Stage 0 in the participating countries ranged from 7.2% in Australia to 23.7% in 
Spain (90), whilst the UK prevalence was found to be 9.8% (90). However, due to the 
uncertainty about the association between GOLD Stage 0 and the risk of development of 
COPD (9, 133), little attention has been directed to this condition compared with COPD 
(101).  
There are four published studies (Supplementary Table 29) that have examined the health 
outcomes of HRQoL (133), exacerbation events (101) and healthcare utilisation (9, 90) 
among GOLD Stage 0 patients, mostly compared with healthy controls (9, 90, 133). In the 
previous chapter 4, cross-sectional analyses of the Health Survey for England suggest that 
chronic respiratory symptoms, particularly dyspnoea and wheeze, are more important than 
airflow obstruction in affecting patients’ HRQoL. However, data were not available on other 
health-related outcomes such as healthcare utilisation, exacerbations and exercise capacity. In 
addition, those comparisons concern patients at all stages of COPD, some of whom may have 
had COPD for a long while and be in more advanced stages. It would be useful to compare 
patients identified contemporaneously from the same base population at the same point in 
time.  
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This will be the first study to examine the health-related characteristics of GOLD Stage 0 
patients with those newly identified with COPD. This study will also bring all different 
measures together to directly compare the health outcomes of GOLD Stage 0 patients with 
newly identified COPD patients.  
5.3 Methods  
5.3.1 Study Design  
Cross-sectional analysis of baseline data from the Birmingham COPD Cohort Study in the 
UK (134).  
5.3.2 Setting  
Participants in the Birmingham COPD cohort are drawn from two sources: (1) The Target 
COPD Case Finding Trial and (2) patients on the COPD registers of 71 participating general 
practices: 
5.3.2.1 The Target COPD Case Finding Trial  
The full protocol of the Birmingham COPD Case Finding Trial has been described elsewhere 
(135). Briefly, it was a pragmatic randomised controlled trial of COPD case finding 
intervention in 54 general practices in the West Midlands, UK (135). The patients targeted 
were identified as eligible if they fit the following criteria: registered with the participating 
practices, aged 40–79 years, and had no previous diagnosis of COPD (135). Thereafter, the 
eligible patients who positively responded to the respiratory symptom questions (chronic 
cough or phlegm for three or more months of the year for two or more years, wheeze in the 
last 12 months, or dyspnoea of MRC Grade two or above) were invited for spirometry testing 
(135). Patients were defined as having COPD using the GOLD/current NICE definition of 
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FEV1/FVC <0.7 (135). Later, patients who met the definition of GOLD Stage 0 (reported the 
presence of chronic respiratory symptoms but had normal lung function), as well as those 
newly identified with COPD within the study (reported the presence of chronic respiratory 
symptoms with demonstrated airflow obstruction), were further invited to take part in the 
linked Birmingham COPD Cohort Study (134). 
5.3.2.2 The Birmingham COPD Cohort Study 
The Birmingham COPD Cohort Study is a prospective primary care based cohort study in the 
West Midlands, UK (134). It includes patients with existing COPD on GP disease registers 
(prevalent cases), but also patients with respiratory symptoms, with (incident cases) and 
without airflow obstruction (GOLD Stage 0) (134).  
The eligible prevalent COPD patients were identified through standardised electronic searches 
of the COPD QoF register (COPD14) (134). The baseline assessment of this cohort was 
undertaken between May 2012 and June 2014 in 71 participating general practices (134).  
5.3.3 Patient included in this analysis   
The present study analysed the baseline data of the Birmingham COPD Cohort Study for 
GOLD Stage 0 patients, as well as those newly diagnosed with COPD. These two groups of 
patients were identified through the Birmingham COPD Case Finding Trial (135) and 
subsequently agreed to participate in the cohort study.  
5.3.4 Measurements and data collection  
Clinical assessment was undertaken at the patients’ practices by trained research assistants 
and included a wide range of clinical measures including anthropological measurements, 
blood pressure and heart rate, spirometry and exercise capacity (134). Spirometry was 
performed pre and post-bronchodilator (20 minutes after 400 micrograms salbutamol 
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administered through a spacer) using the Easy One spirometer (ndd, Switzerland) to attain 
three acceptable expiratory manoeuvres according to the ATS/ERS (2005) guidelines (136). 
Validated questionnaires were used to collect data on patient demographics, background, 
lifestyle, occupational history, coexisting comorbidities, respiratory symptoms, prescribed 
medications, healthcare utilisation, exacerbation events and HRQoL (COPD assessment test 
(CAT), EQ-5D (5 level version) and self-assessed general health). Parts of the questionnaires 
were self-completed, other parts interviewer-led as appropriate (134).  
5.3.5 Study Variable Definitions  
5.3.5.1 Exposure variables  
5.3.5.1.1 Smoking 
Patients were classified as never, current and ex-smokers according to their response to the 
question: Have you ever smoked a cigarette, cigar or pipe regularly? (Regularly means at 
least 1 cigarette/day or 7 cigarettes/ week for at least 6 months) (134). Pack years of smoking 
were calculated based on the cigarette history using the following equation: number of 
cigarettes per day multiplied by the number of years smoked divided by 20 (137) and further 
categorised into <5, 5-19, 20-49 and 50+ pack years.  
5.3.5.1.2 BMI 
Patient’s weight was measured using an electronic scale (Tanita BC-420SMA Body 
Composition Scale) and standing height was measured in metres using a portable Stadiometer 
(Leicester Height Monitor) by well-trained research assistants during the clinical assessment 
(134). BMI was calculated using the formula of (weight in kilograms divided by the square of 
the height in metres) (138) and categorised using the WHO/NICE cut-off points into: 
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underweight (BMI <18.5 kg/m²), normal (BMI= 18.5-24.9 kg/m²), overweight (BMI=25-29.9 
kg/m²) and obese (BMI ≥ 30 kg/m²) (139).  
5.3.5.1.3 Respiratory symptoms  
The presence of respiratory symptoms was assessed using a self-completed questionnaire 
(134). Cough and phlegm were defined by ‘their presence on most days for three or more 
consecutive months during the year for more than two consecutive years’, wheeze defined by 
‘ever had wheezing or whistling in the chest in the last twelve months’ and dyspnoea defined 
as Grade two and above of MRC Breathlessness Scale ‘troubled by shortness of breath when 
hurrying on the level ground or walking up a slight hill?’ (134).  
5.3.5.1.4 Coexisting comorbidities  
The presence of coexisting comorbid conditions was also self-reported. Cardiovascular 
comorbidity was defined by the presence of any cardiovascular diseases of coronary heart 
disease, heart failure, stroke, high blood pressure, or other heart problems ever diagnosed by a 
doctor.  
5.3.5.2 Health outcome variables  
5.3.5.2.1 Self-reported HRQoL 
Self-reported HRQoL was measured using the self-completed CAT score (140) as a disease 
specific HRQoL measure (Appendix G), and self-completed EQ-5D (5 level version) (141) 
(Appendix H) and a 5-point Likert scale of self-assessed general health as general HRQoL 
measures. Self-reported general health was assessed by the question, ‘How is your health in 
general?’ and classified as good to very good, fair or bad to very bad (134).  
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5.3.5.2.2 Self-reported exacerbation-like events  
Self-reported exacerbations were defined by an affirmative answer to one of the following 
questions: (1) In the last 12 months have you had one or more courses of oral steroids 
(prednisolone) for your lung problems? (2) In the last 12 months have you had one or more 
courses of antibiotics for your lung problems? (134). 
5.3.5.2.3 Self-reported healthcare utilisation  
Self-reported healthcare utilisation included hospital admissions and accident and emergency 
department (A & E) attendance over the last 12 months and the number of healthcare 
personnel consultations for lung disease in the past 14 days using the following questions: (1) 
In the last 12 months have you been admitted to hospital (spent at least one night) for your 
lung problems? (2) In the last 12 months have you been admitted to hospital (spent at least 
one night) for a reason other than your lung problems? (3) During the last 12 months did you 
ever attend casualty or A & E for your lung problems? (4) During the last 12 months did you 
ever attend as a patient at the casualty or A & E department of a hospital for a reason other 
than your lung problems? (4) Have you consulted healthcare personnel regarding your 
respiratory (lung) disease during the past 14 days? (134).  
5.3.5.2.4 Exercise capacity 
Exercise capacity was assessed by the one minute sit to stand test, it involves the number of 
complete sittings and standings undertaken by the patient over one minute, as counted by the 
research assistant during the clinical assessment (134). This test has been proved as a valid 
substitute to the six minute walking test in COPD patients (142).  
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5.3.6 Diagnostic criteria  
GOLD Stage 0 was defined by the presence of any of the above respiratory symptoms, with 
preserved lung function (post-bronchodilator FEV1/FVC ≥0.7) and free from self-reported 
asthma and other diagnosed respiratory diseases. New COPD cases were diagnosed through 
the Case Finding Trial using the GOLD/current NICE definition of post-bronchodilator 
FEV1/FVC <0.7. Patients with self-reported asthma were also excluded from the COPD 
group. Predicted lung function values were calculated using the Global Lung Initiative (GLI)-
2012 equations (143). These equations calculate predicted LLN spirometric indices for the 
entire age range (3-95 years) and for different ethnic and geographic groups all over the world 
(143, 144). These equations were derived based on 74,187 records from healthy non-smoking 
males and females from 26 countries across five continents (143) and therefore considered 
more generalisable across different population (143, 144). 
Patients with no post-bronchodilator spirometry data available because of reported spirometry 
contraindications (Table 20), inability to perform spirometry or reported a history of 
salbutamol allergy were excluded. Reversible airflow obstruction was defined using the 
GOLD/ATS definition of ‘a change of greater than 12% of the baseline FEV1 if this also 
exceeds 200 ml’ (6). Participants who had taken their bronchodilator medications four hours 
before the spirometry testing were excluded from the reversibility analysis.  
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Table 20: Spirometry contraindications (134)  
• Patient who had coughed up any blood in the last month prior to the study  
• Currently taking any medications for the treatment of tuberculosis within the last month 
• Being told by a Doctor or other health professional to have: 
 A heart attack in the last 3 months 
 A detached retina in the last 3 months?  
• Reported any major surgery on chest, abdomen, brain, ears or eyes, e.g. cataract surgery in the last 3 
months  
• Have been in hospital with severe angina in the last month        
5.3.7 Statistical analysis 
STATA v.13 was used in this analysis. Descriptive data were presented as mean and standard 
deviation (SD) or as median and interquartile range (IQR) for continuous variables and as 
frequency and percentage for categorical variables. Logistic regression was used to examine 
the significance of difference between patients groups and association was presented as ORs 
with 95% CI and p values. Age, sex, smoking status and comorbidity were defined as 
potential confounders.  
5.4 Results  
5.4.1 Patients recruitment  
Figure 7 summarises the selection procedure of patients included in this study. A total sample 
of 496 patients was included, 281 of whom met the definition of GOLD Stage 0 (56.7%), 
whilst 215 were newly diagnosed COPD patients (43.3%). Both patients’ subgroups identified 
through the Birmingham COPD Case Finding Trial and agreed to participate in the linked 
cohort study.  
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Figure 7: Flow diagram of patient recruitment procedure 
The Birmingham Case Finding Trial  
Participated in the cohort study  
(n=744) 
GOLD Stage 0 
patients (n=413) 
Excluded due 
to lacking of 
spirometry data 
(n=25) 
Included GOLD 0 
patients  
(n=281) 
Excluded with 
self-reported 
asthma 
(n=107) 
Newly identified  
COPD patients 
(n=331) 
Excluded due 
to lacking of 
spirometry data 
(n=29) 
Included 
Incident COPD 
patients  
(n=215) 
Excluded with 
self-reported 
asthma (n=87) 
Eligible patients invited to the linked 
cohort study (n=2,029)  
Incident COPD (n=793)  
GOLD 0 (n=1,236)   
Agreed to 
participate 
(n=950)  
Declined 
(n=489) 
Non-
responders 
(n=590) 
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5.4.2 Characteristics of participants and non-participants  
Compared to non-participants, those who participated were slightly older, more likely to be 
males and more likely to be of white ethnicity. However, the difference between both groups 
was not statistically significant (Table 21). 
Table 21: Univariable characteristics of participants and non- participants 
 Participants 
(n=744) 
Non-participants 
(n=1,285) 
 
Unadjusted 
OR 
p value  95% CI 
Age – mean (SD) 62.3 (9.6) 59.2 (10.9) 1.0 <0.0001 1.02 to 1.04 
Male sex ˡ 413 (55.5%) 667 (51.9%) 1.2 0.07 0.9 to 1.4 
White ethnicity²  477 (64.1%) 788 (61.3%) 1.1 0.2 0.9 to 1.4 
 Non-participants is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories:1=Female and 2=Non-white  
5.4.3 Comparison of the health-related characteristics between GOLD Stage 0 
patients and newly diagnosed COPD patients  
5.4.3.1 Socio-demographics 
Compared to the newly diagnosed COPD patients, GOLD Stage 0 patients were younger 
(mean age 62.3 versus 66.1 years, OR=0.9; 95% CI 0.94 to 0.98), more likely to be females 
(although not statistically significant), more likely to be never smokers (22.1% versus 15.3%, 
adjusted OR=4.3; 95% CI, 2.3 to 7.9) and ex- smokers (58.4% versus 47.9%, adjusted 
OR=3.7; 95% CI, 2.3 to 5.9) and less likely to be of white ethnicity (86.5% versus 87.9%, 
OR=0.4; 95% CI, 0.2 to 0.9) (Table 22).  
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Table 22: The adjusted socio-demographic characteristics of the study population 
 GOLD Stage 0 
(n=281)  
Newly diagnosed 
COPD (n=215) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Age −Mean (SD) 62.3 (10.3) 66.1 (8.8) 0.9 (0.94 to 0.98) - 
 
Sex
1 
 
Females  119 (42.3%)  81 (37.7%) 1.0 - 
Males  160 (56.9%) 131 (60.9%) 0.8 (0.6 to 1.2) - 
 
Ethnicity
2
  
Non-white  25 (9.0%)  7 (3.3%) 1.0 - 
White  243 (86.5%) 189 (87.9%) 0.4 (0.2 to 0.9) - 
 
Highest education level
3 
 
No formal qualification  79 (28.1%) 88 (40.9%) 1.0 1.0 
Primary level (GCSE)  68 (24.2%) 49 (22.8%) 1.5 (0.95 to 2.5) 1.1 (0.7 to 1.9) 
Secondary (A-level) 25 (8.9%)  9 (4.2%) 3.1 (1.4 to 7.0) 2.5 (0.9 to 6.1) 
Degree level or higher 54 (19.2%) 31 (14.4%) 1.9 (1.1 to 3.3) 1.6 (0.9 to 2.8) 
 
Currently in work  
 
106 (37.7%) 
 
58 (27.0%) 
 
1.7 (1.1 to 2.4) 
 
1.1 (0.7 to 1.8) 
 
Smoking status
4 
 
Current smoker  54 (19.2%)    76 (35.3%) 1.0 1.0 
Ex-smoker  164 (58.4%)   103 (47.9%)   2.2 (1.5 to 3.4) 3.7 (2.3 to 5.9) 
Never smoker  62 (22.1%)    33 (15.3%)   2.6 (1.5 to 4.6) 4.3 (2.3 to 7.9) 
 
Pack years smoking amongst smokers
5
  
<5  37 (13.2%)   9 (4.2%) 1.0 1.0 
5-19 73 (26.0%) 44 (20.5%) 0.4 (0.2 to 0.9) 0.4 (0.2 to 0.8) 
20-49 81 (28.8%) 77 (35.8%) 0.3 (0.1 to 0.6) 0.2 (0.1 to 0.5) 
50+ 52 (18.5%) 21 (9.8%) 0.6 (0.3 to 1.5)  0.6 (0.3 to 1.6)  
 Newly diagnosed COPD group is the reference for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 White ethnicity includes white British, Irish & other white backgrounds 
 Reference categories: 1=Female, 2=Non-white, 3= No formal qualification, 4= Current smoker and 5=<5 Pack years 
 *Adjusted for age, sex and smoking status 
 Smoking outcomes were adjusted only for age and sex 
5.4.3.2 Respiratory symptoms, BMI and coexisting comorbidities 
Overall, 63.7 % of GOLD Stage 0 patients and 73.0% of newly diagnosed COPD patients 
reported the presence of any of the relevant respiratory symptoms in the baseline cohort 
questionnaire. This had changed from their original status in the Case Finding Trial where all 
had reported relevant chronic symptoms. Dyspnoea was the most common symptom among 
GOLD Stage 0 patients (55.5%) followed by wheeze (37.7%). GOLD Stage 0 patients 
reported a similar distribution of chronic cough and phlegm to new COPD patients, although 
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wheeze was more common among COPD patients (37.7% versus 51.2%, adjusted OR=0.6; 
95% CI, 0.4 to 0.9). Dyspnoea was more frequently reported among COPD patients, but this 
was not statistically significant. GOLD Stage 0 patients were more likely to be obese than 
COPD patients (43.8% versus 29.8%, adjusted OR=2.3; 95% CI, 1.3 to 4.0). It is possible that 
GOLD Stage 0 patients were more likely to have diabetes and depression, however, the 
difference between groups was not statistically significant (Table 23).  
Table 23: The adjusted difference in respiratory symptoms, BMI and comorbidities by patients group 
 GOLD Stage 0 
(n=281) 
Newly diagnosed 
COPD (n=215) 
Unadjusted OR 
(95% CI) 
 
Adjusted OR* 
(95% CI) 
Self-reported respiratory symptoms 
Chronic cough     95 (33.8%)   75 (34.9%) 0.9 (0.6 to 1.4) 1.1 (0.7 to 1.7) 
Chronic phlegm     58 (20.6%)   57 (26.5%) 0.8 (0.5 to 1.2) 0.8 (0.5 to 1.4) 
Wheeze  106 (37.7%) 110 (51.2%) 0.6 (0.4 to 0.8) 0.6 (0.4 to 0.9) 
Dyspnoea
1 
(MRC grade 
≥ 2) 
156 (55.5%) 136 (63.3%) 0.8 (0.5 to 1.1) 0.8 (0.5 to 1.2) 
Any symptom  179 (63.7%) 157 (73.0%) 0.3 (0.1 to 0.9) 0.4 (0.1 to 1.02) 
BMI
2
  
Normal   41 (14.6%) 49 (22.8%) 1.0 1.0 
Underweight     2 (0.7%)   2 (0.9%) 1.2 (0.2 to 8.9) 0.4 (0.02 to 7.9) 
Overweight   87 (31.0%) 72 (33.5%) 1.4 (0.9 to 2.4) 1.4 (0.8 to 2.5) 
Obese 123 (43.8%) 64 (29.8%) 2.3 (1.4 to 3.8) 2.3 (1.3 to 4.0) 
Self-reported comorbidity 
Cardiovascular comorbidities 
CVDs  140 (49.8%) 117 (54.4%) 0.8 (0.6 to 1.2) 0.9 (0.6 to 1.4) 
High blood pressure  113 (40.2%)   95 (44.2%) 0.8 (0.6 to 1.2)  0.9 (0.6 to 1.3) 
Coronary heart disease  29 (10.3%)   21 (9.8%) 1.0 (0.6 to 1.8) 1.3 (0.7 to 2.5) 
Heart failure  17 (6.1%)   14 (6.5%) 0.9 (0.4 to 1.9)  1.1 (0.5 to 2.5) 
Stroke  14 (5.0%)   16 (7.4%) 0.6 (0.3 to 1.3)  0.8 (0.4 to 1.7) 
Other heart diseases  29 (10.3%)   20 (9.3%) 1.1 (0.6 to 1.9) 1.2 (0.6 to 2.3) 
Other comorbidities 
Cancer  30 (10.7%)  27 (12.6%) 0.8 (0.5 to 1.4) 0.9 (0.5 to 1.7) 
Diabetes  39 (14.0%)  23 (10.7%) 1.3 (0.8 to 2.3) 1.3 (0.7 to 2.2) 
Depression  81 (28.8%)  50 (23.3%) 1.3 (0.9 to 2.0) 1.2 (0.8 to 1.8) 
Number of comorbidities
3
 
No comorbidity    68 (24.2%)  53 (24.7%) 1.0 - 
1 comorbidity 108 (38.4%)  77 (35.8%) 1.1 (0.7 to 1.7) 1.2 (0.7 to 1.9) 
2 comorbidities   65 (23.1%)  54 (25.1%) 0.9 (0.6 to 1.6) 1.0 (0.6 to 1.8) 
≥ 3 comorbidities   40 (14.2%)  31 (14.4%) 1.0 (0.6 to 1.8) 0.96 (0.5 to 1.8) 
 Newly diagnosed COPD group is the reference for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories:1= MRC Grade 1, 2= Normal BMI and 3= No comorbidity 
 *Adjusted for age, sex and smoking status 
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5.4.3.3 FEV1 reversibility  
Compared to COPD patients, GOLD Stage 0 patients were less likely to have a significant 
post-bronchodilator FEV1% reversibility that might indicate the presence of asthma (6.9% 
versus 21.3%, OR=0.3; 95% CI, 0.2 to 0.5) (Table 24).  
Table 24: Univariable post-bronchodilator reversibility by patients group 
 GOLD Stage 0 
(n=275) 
Newly diagnosed 
COPD (n=204) 
Unadjusted 
OR 
p value 95% CI 
 
Reversible AFO 
 
19 (6.9%) 
 
41 (21.3%) 
 
0.3 
 
<0.0001 
 
0.2 to 0.5 
 Newly diagnosed COPD is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 Participants who had their bronchodilator medications 4 hours before the spirometry testing were excluded (11 newly 
diagnosed COPD and 6 GOLD Stage 0 patients) 
5.4.4 Comparison of the health outcome measures between GOLD Stage 0 patients 
and newly diagnosed COPD patients  
5.4.4.1 HRQoL 
As shown in Table 25 below, GOLD Stage 0 patients reported very similar HRQoL to newly 
diagnosed COPD patients across all measures, even after adjustment for the confounding of 
age, sex, smoking status and comorbidities.  
Table 25: The adjusted difference in HRQoL between patients group 
 GOLD Stage 0 
(n=281) 
Newly diagnosed 
COPD (n=215) 
Unadjusted OR  
(95% CI) 
Adjusted OR
1
 
(95% CI) 
Adjusted OR
2
 
(95% CI) 
 
Self-assessed general health
1− Number (%) 
Fair  82 (29.2%) 68 (31.6%) 0.9 (0.6 to 1.3) 0.9 (0.6 to 1.3) 0.9 (0.6 to 1.3) 
Bad/very bad  16 (5.7%)   8 (3.7%) 1.5 (0.6 to 3.6) 1.4 (0.5 to 3.4) 1.2 (0.5 to 3.1) 
 
EQ-5D Index value−Median (IQR) 
 0.84 (0.31) 0.84 (0.31) 0.7 (0.3 to 1.6) 0.8 (0.3 to 1.8) 0.9 (0.4 to 2.1) 
 
CAT score−Mean (SD) 
 13.3 (7.0) 13.5 (6.7) 1.0 (0.9 to 1.03) 1.0 (0.9 to 1.03) 0.9 (0.9 to 1.03) 
 Newly diagnosed COPD group is the reference for all comparisons 
 Reference categories: 1=Good to very good  general health 
 OR1: Adjusted for age, sex and smoking status  
 OR2: Adjusted for age, sex, smoking status and comorbidity (CVDs, diabetes & depression) 
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5.4.4.2 Exacerbation-like events  
Compared to new COPD patients, GOLD Stage 0 subjects were less likely to have 
exacerbation events (as defined by ever had two or more courses of oral steroids or antibiotics 
for lung problems), although the difference was at the margins of statistical significance 
(13.5% versus 19.5%, OR=0.6; 95% CI 0.4 to 1.1). The reporting of prescribed oral steroids 
and antibiotics of more than two courses was almost similar between subgroups (Table 26).  
Table 26: The adjusted difference in self-reported exacerbation events by patients group 
 GOLD Stage 0 
(n=281) 
Newly diagnosed 
COPD (n=215) 
Unadjusted OR  
(95% CI) 
Adjusted OR
1
 
(95% CI) 
Adjusted OR
2
 
(95% CI) 
 
Exacerbations in the last 12 months 
   38 (13.5%)   42 (19.5%) 0.7 (0.4 to 1.1) 0.6 (0.4 to 1.0) 0.6 (0.4 to 1.1) 
 
Prescribed steroids
1
 (≥ 2 courses)  
 270 (96.1%) 205 (95.4%) 2.2 (0.5 to 9.3) 2.0 (0.4 to 9.9) 1.8 (0.3 to 9.6) 
 
Prescribed antibiotics
1
 (≥ 2 courses)  
 251 (89.3%) 186 (86.5%) 1.5 (0.8 to 2.8) 1.8 (0.9 to 3.5) 1.8 (0.9 to 3.4) 
 Newly diagnosed COPD group is the reference for all comparisons  
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories: 1= one course 
 OR1: Adjusted for age, sex and smoking status  
 OR2: Adjusted for age, sex, smoking status and comorbidity (CVDs, diabetes & depression) 
5.4.4.3 Healthcare utilisation 
The difference between both patient subgroups in healthcare utilisation across different 
measures was small and not statistically different (Table 27).  
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Table 27: The adjusted difference in self-reported healthcare utilisation between patients group 
 GOLD Stage 0 
(n=281) 
Newly diagnosed 
COPD (n=215) 
Unadjusted OR  
(95% CI) 
Adjusted OR
1
 
(95% CI) 
Adjusted OR
2
 
(95% CI) 
 
All cause hospital admissions 
 19 (6.8%) 19 (7.6%) 0.7 (0.4 to 1.4) 0.7 (0.3 to 1.4) 0.7 (0.3 to 1.4) 
 
Hospital admissions due to lung problems 
   3 (1.1%)   3 (1.4%) 0.7 (0.2 to 3.7) 0.7 (0.1 to 3.4) 0.6 (0.1 to 3.2) 
 
Hospital admissions due to other health problems 
 16 (5.7%) 16 (7.4%) 0.7 (0.4 to 1.5) 0.7 (0.3 to 1.5) 0.7 (0.3 to 1.6) 
 
All cause A & E attendance 
 44 (15.7%) 43 (20.0%) 0.7 (0.5 to 1.2) 0.7 (0.4 to 1.1) 0.7 (0.4 to 1.1) 
 
A & E attendance due to lung problems 
   2 (0.7%)   1 (0.5%) 1.5 (0.1 to 16.6) 1.6 (0.1to 17.8) 1.5 (0.1 to 17.4) 
 
A & E attendance due to other health problems 
 43 (15.3%) 42 (19.5%) 0.7 (0.5 to 1.2) 0.7 (0.4 to 1.2) 0.7 (0.4 to 1.1) 
 
Number of consultations due to respiratory disease
1
 (≥ 2 times)  
   2 (0.7%)   0     
 Newly diagnosed COPD group is the reference for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories: 1=1 time 
 OR1: Adjusted for age, sex and smoking status  
 OR2: Adjusted for age, sex, smoking status and comorbidity (CVDs, diabetes & depression) 
5.4.4.4 Exercise capacity 
The mean of exercise capacity was also similar between both groups of patients (Table 28).  
Table 28: The adjusted difference in exercise capacity between patients group 
 GOLD Stage 0 
(n=281) 
Newly diagnosed 
COPD (n=215) 
Unadjusted OR  
(95% CI) 
Adjusted OR
1
 
(95% CI) 
Adjusted OR
2
 
(95% CI) 
 
Mean (SD) 
 
22 (7.9) 
 
21.6 (7.2) 
 
1.0 (0.9 to 1.03) 
 
1.1 (0.9 to 1.03) 
 
1.0 (0.9 to 1.03) 
 Newly diagnosed COPD group is the reference for all comparisons 
 OR1: adjusted for age, sex and smoking status  
 OR2: adjusted for age, sex, smoking status and comorbidity (CVDs, diabetes & depression) 
5.5 Discussion  
5.5.1 Main findings  
There were some important differences in the characteristics of patients in each of the 
categories. GOLD Stage 0 patients tended to be slightly younger and twice as likely to be 
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obese than newly diagnosed COPD patients identified contemporaneously from the same base 
population. Although less common than among the COPD patients, about 78% reported 
having ever smoked which could help to explain their symptoms. However, the symptoms 
amongst GOLD Stage 0 patients had a tendency to be slightly less severe than those newly 
diagnosed with COPD. Obesity might be another explanation for the presence of GOLD Stage 
0 symptoms. Obesity has been identified as one of the major aetiological factors for the 
presence of respiratory symptoms, particularly exertional dyspnoea independently of airflow 
obstruction (145-147). The main symptoms associated with obesity are usually dyspnoea 
(145) and wheeze (146), but an association with productive cough has been also observed 
(145).  
Although the importance of GOLD Stage 0 has been debated due to inconsistencies on 
whether such patients progress to develop COPD (133), in this study, this group of patients 
showed similar overall patterns cross-sectionally for outcome measures of HRQoL, healthcare 
utilisation and exercise capacity to that reported by patients newly identified with COPD. 
Thus, the presence of chronic respiratory symptoms—even in the absence of diagnosed 
airflow obstruction—could have a relevant impact on patients’ health, and the utilisation of 
healthcare system resources. Although exacerbation events were lower amongst GOLD Stage 
0 compared to COPD patients, both patient groups reported similar proportions of steroid and 
antibiotic prescriptions (indicative of acute respiratory events).  
5.5.2 Comparison with the existing evidence  
The present study supports the view that the presence of symptoms has a negative impact on 
affected patients’ health, through examining different health outcome measures amongst 
GOLD Stage 0 patients compared with those newly identified with COPD in a contemporary 
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and representative primary care population. Tan et al., (2014) study, was the only to compare 
cross-sectionally the exacerbation events between GOLD Stage 0 patients and those with 
COPD. Importantly, they found in line with this study that symptomatic patients had less 
frequent self-reported exacerbations than COPD patients (3.9% versus 8.2%, p<0.001) (101), 
but were seen to have a similar or even higher healthcare utilisation (68% versus 62%) (101). 
In the other studies (9, 90, 133), when compared to the normal population, GOLD Stage 0 
patients and newly identified COPD patients showed similar impairment in HRQoL (133), 
increased all cause and obstructive lung disease-related hospital admissions (9) and similar 
healthcare utilisation (90).  
5.5.3 Strengths and Limitations  
This study has some limitations. Firstly, the cross-sectional design does not allow inspection 
of longer-term prognosis between the two patient groups. Secondly, some of the study 
variables were self-reported and examined retrospectively, meaning they may be subject to 
recall bias. Another limitation is a lack of imaging data within the Birmingham COPD Cohort 
Study, meaning it is not possible to rule out the potential of the presence of other underlying 
pathology (such as emphysema or bronchiectasis), which could help to explain the presence 
of respiratory symptoms and their association with poor health outcomes among GOLD Stage 
0 patients. The strength of this study is its use of data with high quality measures from a 
prospective cohort study on a large representative sample of patients in the West Midlands, 
UK. Also patients in both groups were selected from the same underlying population at the 
same point in time, and therefore should be more comparable than having patients at different 
stages of COPD.  
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5.5.4 Implications for research and clinical practise  
This study has emphasised the need for further longitudinal studies on GOLD Stage 0 patients 
with the aim of better understanding their prognosis and to confirm whether the results 
observed cross-sectionally are reflected longitudinally. Furthermore, GOLD Stage 0 patients 
are more likely to be obese and in clinical practice they may benefit from weight management 
programmes and probably pulmonary rehabilitation programmes to improve their symptoms.  
5.5.5 Conclusion  
The impact of the chronic respiratory symptoms in the absence of airflow obstruction on 
patients and on the healthcare system should not be ignored. GOLD Stage 0 patients showed 
similar patterns of poor health outcomes to COPD patients and might also need to be 
identified and targeted with appropriate interventions. However, further longitudinal studies 
are needed to better understand their long-term prognosis.
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5.6 Supplementary Table  
Table 29: Summary of the available evidence on the chapter’s topic 
 
Study ID 
 
 
Design 
 
Outcome 
 
Sample size 
 
Population  
 
Comparator I 
 
Comparator II 
 
Gaps in knowledge  
Tan et al., 
2014 (101) 
A cross 
sectional 
multisite 
population-
based study-
Canada  
The 
prevalence of 
exacerbation 
events  
4,890 adults 
aged ≥ 40 
years  
 Non-COPD patients with “chronic 
cough or chronic phlegm not 
occurring during a cold and on 
most days for as much as 3 months 
each year for 2 years”, “the 
presence of episodes of wheezing 
or whistling in the chest associated 
with feeling of shortness of breath, 
in the past 1 year not occurring 
during a cold” and “troubled by 
shortness of breath when hurrying 
on the level or walking up a slight 
hill’ 
COPD patients, 
defined using the 
GOLD criteria  
 
 
 
 
None   Exacerbation was 
defined as “a period 
of worsening of 
breathing problems 
that got so bad that it 
interfered with usual 
daily activities or 
caused the individual 
to miss work”  
 Did not ask about 
antibiotic/steroids use  
Miravitlles 
et al., 2009 
(133) 
Cross-
sectional 
population-
based study- 
Spain 
HRQoL 4,274 adults 
aged 40–80 
years  
GOLD Stage 0 patients defined by 
the presence of chronic cough and 
sputum with normal spirometry 
Healthy reference 
group  
COPD patients 
(Stages 1-4), 
defined using the 
GOLD criteria  
 
The primary objective was 
to measure the prevalence 
and burden of 
undiagnosed COPD in the 
general population  
Ekberg-
Aronsson 
et al., 2008 
(9) 
23 years 
follow up 
study-Sweden 
Hospital 
admission 
rates  
 
22,044 
middle aged 
adults 
(mean=47.5 
years) 
Gold Stage 0 individuals reported 
“chronic productive cough for ≥ 3 
months for > 2 consecutive years” 
with FEV1/FVC >0.70 and 
FEV1>80% predicted  
Control group of 
asymptomatic 
smokers with 
normal lung 
function 
COPD patients, 
defined as  
FEV1/FVC <0.70 
with and without 
symptoms 
Asthma was not excluded 
among GOLD 0 patients 
and asthma-related 
hospital admissions were 
included in the analyses  
De Marco 
et al., 2004 
(90) 
Cross-
sectional 
study  
 
Healthcare 
resources 
utilisation  
18,000 young 
adults aged 
20-44 years 
GOLD Stage 0 patients reported 
“the presence of chronic cough+/-
phlegm usually in winter and on 
most days for as long as 3 months 
each year” with FEV1/FVC >70% 
Healthy control 
group  
COPD patients, 
defined using the 
GOLD criteria  
The primary focus was to 
measure the prevalence of 
COPD  
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6 COPD OVERDIAGNOSIS IN THE UK: THE 
BIRMINGHAM COPD COHORT STUDY 
6.1 Abstract 
Introduction: Overdiagnosis is a growing concern for a wide range of diseases including 
COPD. The aim of this study is to examine the magnitude of COPD overdiagnosis in the UK 
primary care settings and investigate the main factors associated with COPD overdiagnosis.  
Methods: Cross-sectional analysis of data on 1,473 GP diagnosed COPD patients aged 40 
years and over who participated in the Birmingham COPD Cohort Study-UK. Patients were 
classified as non-COPD or confirmed-COPD based on post-bronchodilator spirometry results. 
Characteristics were compared using logistic regression adjusted for age, sex and smoking 
status.  
Results: Based on GOLD/current NICE, LLN and NICE (2004) criteria, 13.7%, 28.1% and 
32.3% of participants were potentially overdiagnosed with COPD, respectively. A restrictive 
pattern of lung disease was observed in 18.9% of non-COPD patients by using the current 
NICE definition. Compared to confirmed-COPD, non-COPD patients were more likely to be 
females (52.2% versus 35.4%, OR=2.0; 95% CI, 1.5 to 2.7), never smokers (22.9% versus 
13.8%, OR=2.4; 95% CI, 1.5 to 3.9), obese (39.3% versus 31%, OR=1.6; 95% CI, 1.1 to 2.4), 
have multiple comorbidities (23.9% and 16.4% with three or more comorbidities respectively, 
OR=1.7; 95% CI, 1.1 to 2.7) but have less FEV1 reversibility (10% versus 21.4%, OR=0.4; 
CI, 0.2 to 0.7). Although not statistically significant, non-COPD participants reported more 
diagnosed coronary heart disease (18.4% versus 14.2%), asthma (47.3% versus 38.7%), 
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diabetes (18.9% versus14.2%) and depression (21.4% versus 16.8%). Applying the LLN 
definition made a little difference to these characteristics.  
Conclusion: COPD overdiagnosis is common. Female sex, obesity and restrictive lung 
function were identified as potential explanations for COPD overdiagnosis. A follow-up 
assessment to examine for the possibility of physiological spirometry variability is 
recommended.  
6.2 Introduction  
In recognition of the increasing burden of COPD in the UK, both diagnosed and undiagnosed, 
two key initiatives were established (148). Firstly, NICE published its guidelines for COPD 
management (148); which included the recommendation that COPD diagnosis should be 
confirmed only with spirometry (148). Secondly, the introduction of QOF section to the new 
General Medical Services contract, in which General Practices would receive extra payments 
for providing a high standard care for COPD patients and for creating detailed patients 
registers including documented spirometry data, annual reviews and treatment plans (73, 148, 
149). Since then, an increase in the prevalence of registered diagnoses of COPD and in the 
prescription of inhaler medications have been observed (148). Furthermore, most COPD 
research is usually focused on COPD under diagnosis in primary care, but less is known about 
COPD overdiagnosis and its consequences, particularly the potential for overtreatment.  
A correct diagnosis of COPD is essential because of the therapeutic and prognostic 
consequences on diagnosed patients and on the healthcare system (60). The inappropriate use 
of COPD medications to treat patients who do not have the disease exposes them to 
potentially harmful adverse effects of these medications (62, 63). For example, ICS have been 
associated with an increased risk of pneumonia (64, 65) and LABAs may cause adverse 
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cardiovascular effects (61, 66). This is of particular concern as patients at higher risk for 
receiving a false diagnosis of COPD (e.g. those with undiagnosed heart conditions) are those 
who may be at higher risk for these adverse effects (61). Moreover, available evidence 
suggests that symptomatic patients misdiagnosed with COPD are more likely to have higher 
hospital admission rates and have more diagnostic tests than correctly diagnosed COPD 
patients indicating missed opportunities for intervention (61) and an increased cost to the 
NHS (68). Consequently, patients are suffering from chronic respiratory symptoms because of 
other underlying causes and not receiving the appropriate management (60, 62). 
There are a number of studies which suggest that COPD is overdiagnosed in the UK and 
elsewhere (36, 60, 62, 68, 72, 73, 80, 150-153) (Table 30). However, evidence is limited on 
the most important factors leading to COPD overdiagnosis, particularly the patient’s clinical 
and lung function-related factors. This study will be the first to examine the magnitude of 
COPD overdiagnosis and overtreatment in UK primary care settings using three different 
criteria to define COPD. It will also examine the main factors associated with COPD 
overdiagnosis, by comparing the clinical and lung function-related characteristics of 
“overdiagnosed” patients and those with confirmed COPD diagnosis using two criteria. The 
secondary aim of this study is to compare the health outcomes of “overdiagnosed” patients 
and confirmed COPD patients. 
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Table 30: Summary of available evidence on COPD overdiagnosis 
Study ID Setting Outcome Sample size Rate of COPD 
overdiagnosis 
Factors associated with 
COPD overdiagnosis 
Gaps in knowledge  
Van Dijk et al., 
2015 (36)  
Cross-sectional 
population-based 
study-Canada 
The clinical relevance of 
the GOLD and LLN 
criteria on patient-
reported outcomes of 
symptoms, health status, 
disability, exacerbations 
and cardiovascular 
comorbidity 
4,882 people 
aged ≥ 40 
years  
 
 
Was not 
measured 
Have not been examined The main focus was to 
compare the clinical relevance 
of the GOLD and the LLN 
criteria  
Ghattas et al., 
2013 (68) 
Retrospective cohort 
study-US 
The prevalence of COPD 
overdiagnosis among 
underserved population  
80 people 
aged ≥ 40 
years  
42.5%   Less smoking exposure 
 Asthma  
 Small sample size 
 Targeted specified 
population  
 Used the GOLD criteria 
only to define COPD 
 
Buffels et al., 
2012 (80)  
Prospective cohort 
study-Belgium  
The diagnostic accuracy 
of COPD in primary care 
312 patients 
aged > 40 
years 
28.6%  Have not been examined Used the GOLD criteria only  
Melbye et al., 
2011 (150) 
General practice-
based study-Norway  
The agreement between 
spirometry findings and 
GPs diagnosis of COPD  
74 registered 
COPD 
patients aged 
≥ 40 years  
25.8% Have not been examined Used the GOLD criteria only 
to define COPD 
Small sample size  
Jones et al., 2008 
(72) 
 
Cross-sectional study 
in primary care 
practices-UK 
The diagnostic accuracy 
of COPD registers in 
general practices 
580 patients 27.2%   Restrictive function 
 Asthma  
Used the former NICE (2004) 
criteria only  
Walters et al., 
2011 (60) 
Cross-sectional study 
in primary care 
practices- Australia 
The misclassification of 
COPD  
341 patients 31%  Obesity  
 Self-reported allergic 
rhinitis and hay fever  
 Age, sex and smoking 
status  
 Respiratory symptoms  
 Restrictive function 
Used the GOLD criteria only  
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Study ID Setting Outcome Sample size Rate of COPD 
overdiagnosis 
Factors associated with 
COPD overdiagnosis 
Gaps in knowledge  
Bolton et al., 
2005 (73) 
Questionnaire based 
survey-UK 
The agreement between 
the diagnostic label of 
COPD in primary care 
and the study’s 
spirometric results  
 
125 GP-
diagnosed 
COPD 
patients 
without 
spirometry, 
aged ≥ 40 
years  
31%  Restrictive function 
 Asthma 
Used the NICE (2004) criteria 
only  
Sichletidis et al., 
2007 (151) 
 
Prospective study in 
general practices-
Greece 
The validity of COPD 
diagnosis in general 
practices  
319 diagnosed 
COPD 
patients, aged 
≥ 40 years  
 
49.8%  Restrictive function 
 Asthma 
Used the GOLD criteria only  
Zwar et al., 2011 
(62)  
Conducted in a 
context of a 
randomised 
controlled trial-
Australia. 
The practitioner, practice 
and patients-related 
factors that affect the 
agreement between 
COPD diagnostic label 
and the study’s 
spirometry results  
 
445 COPD 
patients aged 
40-80 years.  
 
42.2%  Younger age  
 Multiple comorbidities  
 Restrictive function 
 Asthma 
Used the GOLD criteria only  
Ta´lamo et al., 
2007 (152)  
PLATINO study of 
COPD prevalence in 
Latin America  
The agreement between 
prior diagnostic label 
and the study’s 
spirometry findings 
 
237 COPD 
patients aged 
≥ 40 years 
63.7%  Spirometry underuse 
 Restrictive function 
 Female sex 
 Less smoking exposure 
Used the GOLD criteria only  
Centurion et al., 
2012 (153) 
 
Multi-centre study-
US 
The utility of 
confirmatory spirometry 
for COPD diagnosis in 
patients hospitalised 
with exacerbation  
 
36 adults age 
≥18 years 
admitted with 
COPD 
exacerbations 
28%  High BMI Used the LLN criteria only  
Small sample size 
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6.3 Methods and Materials  
6.3.1 Study design/setting 
Cross-sectional analysis of baseline assessment data from the Birmingham COPD Cohort 
Study, a prospective primary-care based cohort study in the West Midlands-UK (134). The 
baseline assessment was undertaken between May 2012 and June 2014, across 71 
participating general practices (134). 
6.3.1.1 Patient recruitment  
As mentioned in the previous chapter (section 5.3.2.2), prevalent COPD patients participated 
in the Birmingham COPD Cohort Study were identified through a standardised electronic 
search of the COPD QoF register (COPD14) of the participating general practices (134). 
Thereafter, GPs reviewed the search results and identified eligible patients who were 
registered with COPD diagnosis, aged 40 years and over and able to give a written consent 
(134). At the GP’s discretion, patients with terminal illness, unable to give informed consent 
or with other social factors (e.g. recent bereavement) were excluded (134). All of the 
identified eligible patients were invited by their GPs to participate in the study, with a 
maximum of two reminders sent to non-respondents (134). Information on how the COPD 
diagnosis was made and the date of diagnosis was not obtained (134).  
6.3.2 Measurements and data collection  
Clinical assessment was undertaken at the patients’ practices by trained research assistants 
and included a wide range of clinical measures (134). Spirometry was performed pre and 
post-bronchodilator according to the ATS/ERS guidelines (136). Validated questionnaires 
were used to collect data on patient demographics, lifestyle, coexisting comorbidities, 
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respiratory symptoms, prescribed medications, healthcare utilization, exacerbation events and 
HRQoL (134).  
6.3.3 Study variables definitions  
6.3.3.1 Exposure variables  
Exposure variables of smoking, BMI, self-reported respiratory symptoms and self-reported 
coexisting comorbidities were examined using the same measures and definitions detailed in 
Chapter 5 (Section 5.3.4.1). 
6.3.3.2 Health outcome variables 
Health outcomes examined in this study included; self-reported HRQoL, self-reported 
exacerbation-like events, self-reported healthcare utilisation and a measured exercise capacity. 
All were assessed using the same measures and definitions detailed in Chapter 5 (Section 
5.3.4.2).  
6.3.4 Diagnostic criteria 
6.3.4.1 Confirmation of COPD diagnosis  
The diagnosis of COPD was confirmed using three different criteria: the current NICE/the 
GOLD committee criteria of post-bronchodilator FEV1/FVC ratio <0.7 (6, 7), the former 
NICE (2004) criteria of FEV1/FVC<70% and FEV1<80% (154) and the LLN criteria of ‘post-
bronchodilator FEV1/FVC ratio falls below the 5
th
 percentile of the predicted values for 
patient’s age, height, sex and ethnicity, with a reference to healthy non-smoker population’ 
calculated using the GLI-2012 equations (143).  
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Patients with no post-bronchodilator spirometry data available because of reported spirometry 
contraindications, inability to perform spirometry or reported history of salbutamol allergy 
were excluded from this study.  
6.3.4.2 Reversible airflow obstruction 
Reversible airflow obstruction was defined using the GOLD/ATS definition of ‘a post 
bronchodilator increase of the baseline FEV1 of more than 12% if this also exceeds 200 ml’ 
(6). Participants who had taken their bronchodilator medications four hours prior to 
spirometry testing were excluded from the reversibility analysis.  
6.3.4.3 Restrictive lung function pattern  
Restrictive lung function is ‘a condition in which the total lung capacity is reduced, on the 
basis of an abnormally low vital capacity in combination with a normal or high FEV1/FVC 
ratio’ (144). It was measured as FVC below 80% predicted and FEV1/FVC ratio equal to or 
higher than 70% (155) and secondly as FVC% predicted below the LLN but FEV1/FVC% 
predicted within or higher than the LLN (156). All predicted lung function values were 
calculated using the GLI equations.  
6.3.5 Statistical analyses 
STATA v.13 was used for all statistical analyses. Descriptive data of patients with and 
without COPD, were presented as mean and SD or as median and IQR for continuous 
variables and as frequency and percentage for categorical variables. Logistic regression was 
used to examine the patient-related factors associated with COPD overdiagnosis and 
presented as ORs with 95% CI and p values adjusted for age, sex, smoking status and 
cardiovascular comorbidities.  
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6.4 Results  
6.4.1 Patient recruitment  
From the QOF register of 71 participating general practices, 6,383 diagnosed COPD patients 
were identified as eligible and invited to participate in the cohort study. Of those, 2,014 
(31.6%) did not respond after two reminders, 2,171 (34.0%) agreed to participate and 2,198 
(34.5%) declined. Amongst those patients who agreed to the invitation, 1,558 gave written 
consent and were assessed. 85 patients (5.5%) were excluded from this study due to missing 
post-bronchodilator spirometry data (Figure 8).  
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Figure 8: Flow diagram of patient recruitment procedure  
6.4.2 Characteristics of participants and non-participants  
Compared to non-participants, those who participated were more likely to be males (57.1% 
versus 46.5%, OR=1.6; 95% CI, 1.4 to 1.8) and more likely to be of white ethnicity (70.2% 
versus 67.4%, OR=1.5; 95% CI, 1.1 to 2.2). However, the mean age was similar (Table 31).  
 
 
Eligible "COPD patients" invited to participate 
(n=6,383)  
Non-responders 
(n=2,014) 
 Declined 
(n=2,198) 
Agreed to participate 
(n=2,171)  
Participated "COPD patients" 
(n=1,558) 
Included patients (n=1,473) 
Final diagnosis 
Confirmed COPD 
(n=1,272) 
No COPD 
(n=201) 
 
Excluded patients (n=85) 
● Reported spirometry 
contraindications (n=19)  
● Reported allergy to salbutamol 
(n=28)  
● Unable to perform spirometry 
(n=38) 
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Table 31: Univariable characteristics of participants and non-participants 
 Participants 
(n=1,558) 
Non-participants 
(n=4,825) 
 
Unadjusted OR p value  95% CI 
Age – Mean (SD)   68.5 (9.9)   69.3 (11.4) 1.0 0.007 1.0 to 1.1 
Male sex ˡ     890 (57.1%) 2,246 (46.5%) 1.6 <0.0001 1.4 to 1.8 
White ethnicity²  1,094 (70.2%) 3,253 (67.4%) 1.5 0.03 1.1 to 2.2 
 Non- participants is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories:1=Female and 2=Non-white 
6.4.3 Magnitude of COPD overdiagnosis 
6.4.3.1 Prevalence of COPD overdiagnosis 
A total of 1,473 registered GP-diagnosed COPD patients were included in this study, the 
prevalence of COPD overdiagnosis amongst them varied according to the criteria being 
applied. Using the current NICE/GOLD criteria, 201 patients (13.7%, 95% CI; 0.12 to 0.16) 
did not meet the definition of COPD. With the LLN criteria, 413 participants (28.1%, 95% 
CI; 0.26 to 0.30) did not have COPD; similarly, using the former NICE (2004) criteria, 458 
participants (32.3%, 95% CI; 0.30 to 0.35) did not meet the criteria (Figure 9).  
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Figure 9: Rate of COPD overdiagnosis based on three different definitions 
6.4.3.2 Consequence of COPD overdiagnosis: medication prescriptions  
Although 77.6% of patients without COPD were prescribed inhaled medications, this was 
lower than those with confirmed COPD (88.5%). Some respiratory medications were 
significantly less likely to be prescribed for non-COPD compared with confirmed COPD 
participants: Combinhaler (31.8% versus 56.8%, p<0.0001), LAMA (28.9% versus 50.6%, 
p<0.0001) and SABA (69.2% versus 76.4%, p=0.03). However, both sets of patients had 
similar levels of prescribed single ICS, LABA and SAMA (Table 32). 
Table 32: Prescribed respiratory medications by lung function group using the current NICE criteria 
Prescribed respiratory medications  Non-COPD (n=201) Confirmed COPD (n=1,272) P value 
Combinhaler   64 (31.8%)   723 (56.8%) <0.0001 
LAMA   58 (28.9%)    643 (50.6%) <0.0001 
SABA  139 (69.2%)    972 (76.4%) 0.03 
ICS   11 (5.5%)     45 (3.5%) 0.18 
LABA   12 (6%)     77 (6.1%) 0.96 
SAMA     9 (4.5%)      62 (4.9%) 0.81 
Any of the above inhaler medication  156 (77.6%) 1,126 (88.5%) <0.0001 
 Confirmed COPD group is the reference for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 ICS: inhaled corticosteroids. Combinhaler: ICS combined with one of the other inhalers. LABA: long-acting beta2 
agonist. LAMA: long-acting muscarinic antagonist. SABA: Short-acting beta2 agonists. SAMA: short-acting muscarinic 
antagonists 
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6.4.4 Comparing the clinical and lung function related characteristics of non-
COPD and confirmed COPD groups using the current NICE criteria 
6.4.4.1 Clinical characteristics  
6.4.4.1.1 Socio-demographics 
Table 33 below presents the socio-demographic characteristics of participants potentially 
overdiagnosed with COPD based on the current NICE criteria. Compared to confirmed COPD 
patients, non-COPD participants were slightly younger (although not statistically significant), 
more likely to be females (52.2% versus 35.4%, OR=2.0; 95% CI, 1.5 to 2.7) and more likely 
to be never smokers (22.9% versus 13.8%, OR=2.4; 95% CI, 1.5 to 3.9).  
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Table 33: The adjusted socio-demographic characteristics by lung function group using the current NICE 
criteria 
 Non-COPD 
(n=201) 
 
Confirmed COPD 
(n=1,272) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Age −Mean (SD) 67.2 (10.8) 69.5 (9) 1.0 (0.9 to 1.0)  
 
Sex
1
  
Males   96 (47.8%) 822 (64.6%)  1.0  
Females  105 (52.2%) 450 (35.4%)  2.0 (1.5 to 2.7)  
 
Ethnicity
2
  
White  180 (89.6%) 1, 141 (89.7%) 1.1 (0.5 to 3.0)  
Non-white  5 (2.6%)  37 (3.0%) 1.0  
 
Highest education level
3 
 
No formal qualification  108 (53.7%)  695 (54.6%) 1.0 1.0 
Primary level (GCSE)   34 (16.9%) 196 (15.4%) 1.1 (0.7 to 1.7) 1.0 (0.7 to 1.6) 
Secondary (A-level)  7 (3.5%)  43 (3.4%) 1.1 (0.5 to 2.4) 1.0 (0.4 to 2.3) 
Degree level or higher   8 (4.0%)  82 (6.5%) 0.6 (0.3 to 1.3) 0.6 (0.3 to 1.3) 
 
Currently in work  
 
36 (17.9%) 
 
203 (16.0%) 
 
1.2 (0.8 to 1.7 ) 
 
1.0 (1.0 to 1.1 ) 
 
Smoking status
4 
 
Current smoker  42 (20.9%)   343 (27%)    1.0 1.0 
Ex-smoker  107 (53.2%)   727 (57.2%)   1.2 (0.8 to 1.8) 1.5 (1.0 to 2.2) 
Never smoker   46 (22.9%)   175 (13.8%)   2.2 (1.4 to 3.4) 2.4 (1.5 to 3.9) 
 
Pack years smoking amongst smokers
5
  
<5   18 (8.9%)  80 (6.3%) 1.0 1.0 
5-19  40 (19.9%) 187 (14.7) 0.9 (0.5 to 1.8) 0.8 (0.4 to 1.5) 
20-49  61 (30.3%) 496 (39.1%) 0.5 (0.3 to 1.0) 0.5 (0.3 to 0.8) 
50+  33 (16.4%) 106 (8.3%) 1.3 (0.7 to 2.6) 1.2 (0.6 to 2.3) 
 Confirmed COPD group is the reference for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 White ethnicity includes white British, Irish & other white backgrounds 
 Reference categories: 1=male, 2=non-white, 3= no formal qualification, 4= current smoker and 5=<5 pack years 
 *Adjusted for age, sex and smoking status 
 Smoking outcomes were adjusted only for age and sex 
6.4.4.1.2 Respiratory symptoms, BMI and coexisting comorbidities 
There was little difference in the frequency of reported respiratory symptoms between the two 
groups (Table 34). However, compared with confirmed COPD participants, those without 
COPD were more likely to be obese (39.3% versus 31%, adjusted OR=1.6; 95% CI, 1.1 to 
2.4) and have multiple comorbidities (23.9% and 16.4% with three or more comorbidities 
respectively, adjusted OR=1.7; 95% CI, 1.1 to 2.7). Although not statistically significant, non-
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COPD participants reported more doctor-diagnosed coronary heart disease (18.4% versus 
14.2%), asthma (47.3% versus 38.7%), diabetes (18.9% versus 14.2%) and depression (21.4% 
versus 16.8%).  
Table 34: The adjusted difference in respiratory symptoms, BMI and comorbidities by lung function 
group using the current NICE criteria 
 Non-COPD 
(n=201) 
Confirmed COPD 
(n=1,272) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
 
Self-reported respiratory symptoms  
Chronic cough  107 (53.2%)    645 (50.7%) 1.2 (0.8 to 1.6) 1.3 (0.9 to 1.8) 
Chronic phlegm    77 (38.3%)    519 (40.8%) 0.8 (0.6 to 1.1) 0.9 (0.6 to 1.3) 
Wheeze  141 (70.1%)    918 (72.2%) 0.8 (0.6 to 1.2) 0.8 (0.6 to 1.2) 
Dyspnoea
1
 (MRC grade 2)   49 (24.4%)    276 (21.7%) 1.0 (0.5 to 1.3) 1.0 (0.6 to 1.6) 
Dyspnoea
1
 (MRC 3-5)  112 (55.7%)    722 (56.8%) 0.9 (0.6 to 1.7) 0.8 (0.5 to 1.3) 
Any symptom  173 (86.1%) 1,120 (88.1%) 0.5 (0.2 to 1.4) 0.5 (0.2 to 1.4) 
 
BMI
2
  
Normal 38 (18.9%) 313 (24.6%) 1.0 1.0 
Underweight   3 (1.5%)   29 (2.3%) 0.9 (0.3 to 2.9) 0.9 ( 0.3 to 3.1) 
Overweight 66 (32.8%) 468 (36.8%) 1.2 (0.8 to 1.8) 1.2 (0.8 to 1.9) 
Obese 79 (39.3%) 394 (31%) 1.7 (1.1 to 2.5) 1.6 (1.1 to 2.4) 
 
Self-reported comorbidity  
Cardiovascular comorbidities 
CVD  116 (57.7%) 710 (55.8%) 1.02 (0.7 to 1.4) 1.2 (0.9 to 1.7) 
High blood pressure    89 (44.3%) 556 (43.7%) 0.9 (0.7 to 1.3) 1.0 (0.8 to 1.4) 
Coronary heart disease   37 (18.4%) 180 (14.2%) 1.3 (0.9 to 2.0) 1.5 (0.9 to 2.3) 
Heart failure   17 (8.5%)    87 (6.8%) 1.2 (0.7 to 2.1) 1.4 (0.8 to 2.4) 
Stroke  16 (8%)    96 (7.5%) 1.03 (0.6 to 1.8) 1.1(0.6 to 1.9) 
Other heart diseases  19 (9.5%) 106 (8.3%) 1.2 (0.7 to 1.96) 1.2 (0.7 to 2.1) 
Respiratory comorbidities 
Asthma   95 (47.3%) 492 (38.7%) 1.3 (0.9 to 1.8) 1.1 (0.8 to 1.6) 
Hay fever  32 (15.9%) 199 (15.6%) 1.0 (0.7 to 1.5) 0.9 (0.6 to 1.3) 
Tuberculosis     3 (1.5%)   48 (3.8%) 0.4 (0.1 to 1.2) 0.3(0.1 to 1.1) 
Other comorbidities 
Cancer  19 (9.5%) 157 (12.3%) 0.7 (0.4 to 1.2) 0.8 (0.5 to 1.3) 
Diabetes  38 (18.9%) 180 (14.2%) 1.4 (0.9 to 2.0) 1.3 (0.9 to 2.0) 
Depression  43 (21.4%) 214 (16.8%) 1.4 (0.9 to 2.0) 1.1 (0.7 to 1.6) 
Number of comorbidities
3
 
No comorbidity  45 (22.4%) 330 (25.9%) 1.0 1.0 
1 comorbidity 59 (29.4%) 429 (33.7%) 1.0 (0.7 to 1.5) 1.1 (0.7 to 1.7) 
2 comorbidity 49 (24.4%) 304 (24%) 1.2 (0.8 to 1.8) 1.3 (0.8 to 2.0) 
≥ 3 comorbidity 48 (23.9%) 209 (16.4%) 1.7 (1.1 to 2.6) 1.7 ( 1.1 to 2.7) 
 Confirmed COPD group is the reference for all comparisons 
 Values presented are numbers with percentages unless otherwise stated 
 CVD includes high blood pressure, coronary heart disease, heart failure, stroke or any other heart problems 
 Reference categories:1= MRC 1, 2= normal BMI and 3= no comorbidity 
 *Adjusted for age, sex and smoking status 
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6.4.4.2 Lung function-related characteristics 
According to spirometric measurements at the cohort baseline assessment, approximately 
18.9% of non-COPD participants had restrictive lung function. 69.6% reported the presence 
of respiratory symptoms with normal lung function (met the definition of GOLD Stage 0), 
whereas, 2.5% were asymptomatic with normal lung function (Table 35). Post-bronchodilator 
FEV1 reversibility was less likely amongst non-COPD participants than confirmed COPD 
participants (10% versus 21.4%, OR=0.4; 95% CI, 0.2 to 0.7) (Table 35).  
Table 35: Univariable spirometry findings by lung function group using the current NICE criteria 
 Non-COPD 
(n=201) 
 
Confirmed 
COPD (n=1,272) 
Unadjusted 
OR 
P value 95% CI 
Restrictive lung function    38 (18.9%) 0    
“GOLD Stage 0”  140 (69.6%) 0    
Asymptomatic with normal PFT      6 (3.0%)    0    
 
Post-bronchodilator AFO reversibility 
   
 
Non-COPD 
(n=170)
1 
Confirmed 
COPD (n=907)
2 
   
Reversible AFO  17 (10%)  194 (21.4%) 0.4 0.001 0.2 to 0.7  
 Confirmed COPD is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 PFT=pulmonary function test  
 1=Excluding 28 participants who had their bronchodilator medications 4 hours prior to the spirometry 
 2=Excluding 352 participants who had their bronchodilator medications 4 hours prior to the spirometry 
6.4.4.3 Potential explanations for COPD overdiagnosis using the current NICE definition 
Being female, a never smoker, having obesity and having multiple comorbidities were the 
main clinical factors significantly associated with COPD overdiagnosis. However, when 
further adjusted for each another, the reported multiple comorbidities of more than three 
conditions no longer remained significant, although the point estimate remained the same 
(Table 36).  
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Table 36: Adjusted clinical factors associated with COPD overdiagnosis based on the current NICE 
criteria  
 Non-COPD 
(n=201) 
 
Confirmed 
COPD (n=1,272) 
Unadjusted OR 
(95% CI) 
Adjusted OR
1 
(95% CI) 
Adjusted OR
2 
(95% CI) 
Female sex  105 (52.2%) 450 (35.4%) 2.0 (1.5 to 2.7) - 1.8 (1.3 to 2.5) 
Never smoker 46 (22.9%)   175 (13.8%)   2.2 (1.4 to 3.4) 2.4 (1.5 to 3.9) 2.5 (1.5 to 4.1) 
Obesity  79 (39.3%) 394 (31%) 1.7 (1.1 to 2.5) 1.6 (1.1 to 2.4) 1.6 (1.01 to 2.4) 
≥ 3 comorbidities  48 (23.9%) 209 (16.4%) 1.7 (1.1 to 2.6) 1.7 (1.1 to 2.7) 1.6 (0.9 to 2.6) 
 Confirmed COPD is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 OR1 adjusted for age, sex and smoking status 
 OR2 adjusted for age, sex, smoking status, BMI and number of comorbidities 
6.4.5 Comparing the health outcome measures between non-COPD and confirmed 
COPD using the current NICE definition 
There were no statistically significant differences between non-COPD participants and those 
with confirmed COPD for HRQoL, healthcare utilisation or exercise capacity (Table 37). 
However, compared with the confirmed COPD group, non-COPD participants reported 
significantly fewer exacerbation events (50.2% versus 58.1%, OR=0.6; 95% CI, 0.5 to 0.9) 
but were more likely to report antibiotics and steroids prescriptions of two courses or more 
(Although not statistically significant) (Table 37).  
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Table 37: The adjusted difference in health outcome measures by lung function group using the current 
NICE criteria 
 Non-COPD 
(n=201) 
 
Confirmed COPD 
(n=1,272) 
Unadjusted OR  
(95% CI) 
Adjusted OR* 
(95% CI) 
 
HRQoL 
Self-assessed general health
1
  
Fair    91 (45.3%)  575 (45.2%) 1.0 (0.7 to1.3) 1.0 (0.7 to 1.4) 
Bad/very bad    23 (11.4%)  166 (13.1%) 0.8 (0.5 to 1.4) 0.9 (0.5 to 1.6) 
EQ-5D Index value − Median (IQR) 
 0.71 (0.34) 0.74 (0.28)  0.8 (0.4 to 1.5) 0.8 (0.4 to 1.5) 
CAT score−Mean (SD) 
 19.2 (8.4)    20 (8.8) 1.0 (0.9 to 1.0) 1.0 (0.9 to1.0) 
 
Self-reported exacerbation events  
Exacerbations in the last 12 
months  
101 (50.2%)   739 (58.1%) 0.7 (0.5 to 0.9) 0.6 (0.5 to 0.9) 
Prescribed steroids
2
 (≥ 2 
courses) 
164 (81.6%) 1,004 (78.9%) 1.1 (0.7 to 1.7) 1.2 (0.8 to 1.9) 
Prescribed antibiotics
2
 (≥ 2 
courses) 
164 (81.6%)    971 (76.3%) 1.2 (0.8 to 1.8) 1.2 (0.8 to 1.8) 
 
Self-reported healthcare utilisation  
All-cause hospital 
admissions 
30 (14.9%) 203 (16%) 0.9 (0.6 to 1.4) 1.0 (0.7 to 1.6) 
Hospital admissions due to 
lung problems 
  8 (4%)   87 (6.8%) 0.6 (0.3 to 1.2) 0.7 (0.3 to 1.4) 
Hospital admissions due to 
other health problems 
24 (11.9%) 132 (10.4%) 1.2 (0.8 to 1.9) 1.3 (0.8 to 2.1) 
All cause A & E attendance 46 (22.9%) 268 (21.1%) 1.1 (0.8 to 1.6) 1.2 (0.8 to 1.7) 
A & E attendance due to 
lung problems 
11 (5.5%)   81 (6.4%) 0.9 (0.4 to 1.6) 0.8 (0.4 to 1.7) 
A & E attendance due to 
other health problems 
39 (19.4%) 206 (16.2%) 1.2 (0.8 to 1.8)  1.3 (0.8 to 1.9) 
Number of consultations due to respiratory disease
3
 
1 time  13 (6.5%) 83 (6.5%) 1.0 1.0 
≥ 2 times    5 (2.5%) 30 (2.4%) 1.1 (0.3 to 3.2) 1.1 (0.3 to 3.4) 
 
Exercise capacity (sit to stand test)−Mean (SD) 
 18.7 (6.8) 17.9 (6.0) 1.0 (1.0 to 1.1) 1.0 (1.0 to 1.1) 
 Confirmed COPD is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 Reference categories: 1=good/very good general health, 2= one course and 3=1 time 
 *Adjusted for age, sex, smoking status and cardiovascular comorbidity 
6.4.6 The implications of applying the LLN criteria  
By applying the LLN criteria to define COPD in place of the current NICE/GOLD criteria 
(Table 38), broadly similar patterns observed except that there was no longer any difference in 
the sex distribution but there were now more ex-smokers in the non-COPD group than 
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confirmed COPD (59.1% versus 55.8%, adjusted OR=1.7; 95% CI, 1.3 to 2.3) and non-COPD 
patients were less likely to have severe dyspnoea of MRC grades 3-5 (51.3% versus 58.6%, 
adjusted OR=0.7; 95% CI 0.5 to 0.9). Although the difference in post-bronchodilator FEV1 
reversibility between groups was not statistically significant, the effect was in the same 
direction as with the current NICE criteria. Among the overdiagnosed group, a larger 
proportion had restrictive lung function than with using the current NICE criteria (31.5% 
versus 18.9%) and a larger proportion had reversible airflow obstruction (16.3% versus 10%). 
This resulted in a smaller proportion (53.8% versus 69.6%) who reported symptoms with no 
lung function abnormality (i.e. COPD GOLD Stage 0) (Table 38).  
Table 38: The adjusted difference in clinical and spirometry-related characteristics by lung function 
group using the LLN criteria 
 Non-COPD 
(n=413) 
Confirmed COPD 
(n=1,059) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
 Clinical factors 
Age −Mean (SD) 70.2 (9.8) 68.7 (9.2) 1.0 (1.0 to 1.03) - 
Sex
1
  
Male 246 (59.6%) 672 (63.5%) 0.9 (0.7 to 1.1) - 
Female  167 (40.4%) 387 (36.5%) 1.0 - 
Ethnicity
2
  
White  367 (88.9%) 953 (90%) 1.2 (0.6 to 2.5) - 
Non-white   10 (2.4%)  32 (3.1%) 1.0 - 
Highest education level
3
  
No formal qualification  217 (52.5%) 585 (55.2%) 1.0 1.0 
Primary level   69 (16.7%) 161 (15.2%) 1.2 (0.8 to 1.6) 1.3 (0.9 to 1.8) 
Secondary level   16 (3.9%)  34 (3.2%) 1.3 (0.7 to 2.3) 1.4 (0.8 to 2.6) 
Degree level or higher   23 (5.7%)  67 (6.3%) 0.9 (0.6 to 1.5) 1.0 (0.6 to 1.6) 
Currently in work  57 (13.8%) 182 (17.2%) 0.8 (0.6 to 1.1) 0.9 (0.7 to 1.3) 
Smoking status
4
  
Current smoker  72 (17.4%)   313 (29.7%) 1.0 1.0 
Ex-smoker 244 (59.1%) 590 (55.8%) 1.8 (1.3 to 2.4) 1.7 (1.3 to 2.3) 
Never smoker  86 (20.8%) 134 (12.4%) 2.8 (1.9 to 4.1) 2.6 (1.8 to 3.8) 
Pack years smoking amongst smokers
5
  
<5  36 (8.7%)   62 (5.9%) 1.0 1.0 
5-19  69 (16.7%) 158 (14.9%) 0.8 (0.5 to 1.2) 0.8 (0.5 to 1.3) 
20-49 132 (32%) 425 (40.1%) 0.5 (0.3 to 0.8) 0.6 (0.4 to 0.9) 
50+   59 (14.3%)   79 (7.5%)  1.3 (0.8 to 2.2) 1.2 (0.7 to 2.1) 
BMI
6
  
Normal   70 (16.9%) 281 (26.5%) 1.0 1.0 
Underweight   5 (1.2%)  27 (2.5%) 0.7 (0.3 to 2.0) 0.9 (0.4 to 2.6) 
Overweight  140 (33.9%) 393 (37.1%) 1.4 (1.0 to 2.0) 1.4 (1.0 to 1.9) 
Obese  165 (40%) 308 (29.1%) 2.2 (1.6 to 3.1) 2.2 (1.6 to 3.0) 
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 Non-COPD 
(n=413) 
Confirmed COPD 
(n=1,059) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Respiratory symptoms  
Chronic cough 215 (52.1%) 536 (50.6%) 1.1 (0.9 to 1.4) 1.3 (1.0 to 1.6) 
Chronic phlegm 155 (37.5%) 440 (41.5%) 0.8 (0.6 to 1.1) 0.9 (0.7 to 1.2) 
Wheeze 279 (67.6%) 779 (73.6%) 0.7 (0.6 to 0.9) 0.8 (0.6 to 1.1) 
Dyspnoea
7
 (MRC grade 2) 103 (24.9%) 222 (21.5%) 0.9 (0.6 to 1.3) 0.9 (0.6 to 1.3) 
Dyspnoea (MRC grade 3-5)
 
212 (51.3%)  621 (58.6%) 0.7 (0.5 to 0.9) 0.7 (0.5 to 0.9) 
Any symptom 363 (88.0%) 985 (93.0%) 0.5 (0.4 to 0.8) 0.8 (0.4 to 1.9) 
Self-reported comorbidity  
Cardiovascular comorbidities 
CVDs 241 (58.4%) 584 (55.1%) 1.2 (0.9 to 1.5) 1.1 (0.9 to 1.5) 
High blood pressure 194 (47%) 450 (42.5%) 1.2 (0.9 to 1.5) 1.2 (0.9 to 1.5) 
Coronary heart disease  69 (16.7%) 148 (14%) 1.2 (0.9 to 1.7) 1.2 (0.9 to 1.7) 
Heart failure  36 (8.7%)  68 (6.4%) 1.4 (0.9 to 2.2) 1.4 (0.9 to 2.0) 
Stroke  28 (6.8%)  84 (7.9%) 0.9 (0.5 to 1.3) 0.9 (0.6 to 1.4) 
Other heart diseases  35 (8.5%)  90 (8.5%) 1.0 (0.7 to 1.5) 1.0 (0.6 to 1.5) 
Respiratory comorbidities 
Doctor diagnosed asthma 173 (41.9%) 413 (39%) 1.1 (0.9 to 1.5) 1.1 (0.9 to 1.4) 
Hay fever   65 (15.7%) 165 (15.6%) 1.0 (0.8 to 1.4) 1.0 (0.7 to 1.4) 
Tuberculosis  11 (2.7%)  40 (3.8%) 0.7 (0.4 to 1.4) 0.6 (0.3 to 1.3) 
Other comorbidities 
Cancer  51 (12.3%) 125 (11.8%) 1.1 (0.7 to 1.5) 1.0 (0.7 to 1.5) 
Diabetes  73 (17.7%) 145 (13.7%) 1.4 (1.0 to 1.9) 1.3 (0.9 to 1.7) 
Depression  74 (17.9%) 183 (17.3%) 1.1 (0.8 to 1.5) 1.1 (0.8 to 1.6) 
Number of comorbidities
8
 
No comorbidity 100 (24.2%) 275 (26%) 1.0 1.0 
1 comorbidity 117 (28.3%) 370 (34.9%) 0.9 (0.6 to 1.2) 0.9 (0.6 to 1.2) 
2 comorbidity 108 (26.2%) 245 (23%) 1.2 (0.9 to 1.7) 1.2 (0.9 to 1.7) 
≥ 3 comorbidity  88 (21.3%) 169 (16%)  1.4 (1.01 to 2.0) 1.4 (1.0 to 2.0) 
 Lung function-related factors 
Restrictive lung function 130 (31.5%) 308 (29.1%) 1.1 (0.7 to 1.7)  
“GOLD Stage 0”  222 (53.8%) 0   
Asymptomatic with normal 
PFT 
  8 (1.9%) 0   
Post-bronchodilator reversibility 
 Non-COPD 
(n=332)
9
  
Confirmed COPD 
(n=740)
10
  
  
Reversible AFO   54 (16.3%) 157 (21.2%) 0.7 (0.5 to 1.02)  
 Confirmed COPD is the reference group 
 Values presented are numbers with percentages unless otherwise stated 
 White ethnicity includes white British, Irish & other white backgrounds 
 Reference categories: 1=Female, 2=Non-white, 3= No formal qualification, 4= Current smoker, 5=<5 Pack years, 
6=Normal BMI, 7=MRC Grade 1 and 8=No comorbidity  
 *Adjusted for age, sex and smoking status 
 PFT=pulmonary function test  
 9=excluding 81 non-COPD participants who had their bronchodilator medications 4 hours prior to the spirometry testing 
 10=excluding 319 confirmed COPD participants who had their bronchodilator medications 4 hours prior to the 
spirometry testing 
137 
 
6.5 Discussion 
6.5.1 Main findings and comparison with the existing evidence  
6.5.1.1 Magnitude of COPD overdiagnosis  
Using data from a unique primary care cohort of COPD patients, this study shows that 13.7% 
were potentially overdiagnosed with COPD based on the current NICE criteria 
(approximately one in every seven diagnosed patients). Published prevalence rates from the 
UK using the former NICE criteria are similar to the rate of 32.3% observed in this study, 
where 5 to10 years ago rates of 31% (73) and 27.2% (72) were reported. Overdiagnosis in the 
UK however does appear to be less of a problem than in some other countries. Even in more 
recent international studies, most of which used the GOLD criteria (equivalent to the current 
NICE definition), a rate of 25.8% was reported in Norway (150), 28.6% in Belgium (80) and 
49.8% in Greece (151). In the US, the figure has been found to be 42.5% amongst the 
uninsured population (68) and 28% amongst patients admitted to hospital with a diagnosis of 
COPD exacerbation by using the LLN criteria (153). In Australia, rates of 31% (60) and 
42.2% have been reported (62). In Latin America, a rate of 63.7% was reported (152). 
However, the current NICE/GOLD definition of COPD is controversial as it does not account 
for normal age related airflow limitation (39) and may overestimate the COPD prevalence by 
up to 50% in older people (40). If the LLN criterion is used, which may be accepted in future 
guidelines; up to one-third of patients will be classified as overdiagnosed.  
6.5.1.2 Consequences of COPD overdiagnosis 
Overdiagnosis has consequences such as over treating individuals with normal spirometry 
with COPD medications, thus exposing them to the adverse effects, as well as the unnecessary 
cost to those patients and to the national healthcare systems (62). In this study, by excluding 
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participants who had shown FEV1 reversibility indicating asthma (10%), around 68% of non-
COPD individuals were potentially over treated with bronchodilators. This accords with 
previous observations from a survey of GP practices in South West England (72). A 
previously published study in Belgium observed that 49% of GPs prescribed ICS to all of 
their COPD patients irrespective of the guidelines (157).  
6.5.1.3 Clinical factors associated with COPD overdiagnosis  
There is a lack of published information on the clinical factors associated with COPD 
overdiagnosis. In this study, using the current NICE definition, non-COPD participants were 
more likely to be females, never smokers, obese and with multiple comorbidities. These 
findings are in line with the few published studies that found a significant association of 
COPD overdiagnosis with multiple comorbidities (62), obesity (60, 153), female sex (152), 
and with less smoking exposure (68, 152) by using the GOLD criteria.  
Female sex was found to be associated with higher restrictive lung function pattern than male 
sex (158). Published studies (158, 159) have also shown that males and females perceive and 
report symptoms differently (158) and females are more likely to report symptoms than males 
(160). Furthermore, female sex found to be associated with a higher risk for comorbidities of 
diabetes, heart failure and depression than male sex (161).  
Obesity is also one of the etiological factors of restrictive lung function (85), it also causes 
exertional dyspnoea and reduced exercise capacity (146) and obese patients usually have 
limited expiratory flow (60) despite normal airway function (162). Previously published 
studies have shown a negative association between increased BMI and obstructive lung 
function (146, 163) but a positive association with restrictive lung function (145). However, 
the assessment of COPD in obese patients remains challenging in primary care (145), due to 
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the presence of dyspnoea (147), which is usually the main symptom of COPD but also can be 
caused by obesity (147). This usually leads to overdiagnosis, over dosing of obese patients 
with bronchodilators (163) and missed opportunities to appropriately manage obesity induced 
dyspnoea (163). Published evidence (162, 163) have reported a higher prescription of inhaled 
bronchodilators among obese patients despite the absence of diagnosed COPD or asthma. 
There is a lack of supporting evidence on the use of bronchodilators in treating dyspnoea 
unrelated to airflow obstruction (146).  
The presence of self-reported diabetes was also more common among overdiagnosed patients 
in this study, which is also known to be one of the aetiological factors of restrictive lung 
function (164).  
6.5.1.4 Lung function-related factors associated with COPD overdiagnosis  
When using the current NICE definition, approximately 19% of non-COPD participants 
showed restrictive patterns of lung disease, 10% had FEV1 reversibility indicating asthma and 
71% had normal spirometry. Of the latter, 2.5% did not report the presence of any symptom 
and the rest reported the presence of symptoms and met the definition of GOLD Stage 0. 
Although other studies reported a range of values for spirometry related factors amongst 
misdiagnosed COPD patients, the present study was broadly consistent. Restrictive lung 
function was reported at about 4% (72, 73, 151), 18% to 20% (62, 152), up to 37% (60). Post-
bronchodilator reversibility (indicating asthma) ranged from about 4% to 22.5% (62, 68, 72, 
73, 151). However, the present study identified more subjects without lung function 
abnormalities compared with other studies which reported rates of 16% to 56% (60, 62, 72, 
151, 152).  
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Although non-COPD participants were more likely to report previous asthma, this might be 
explained by reporting of childhood asthma as they showed less airflow obstruction 
reversibility and therefore COPD overdiagnosis in this study cannot be explained by current 
misdiagnosed asthma.  
6.5.1.5 Difference in health outcome measures 
There are little published data on the health outcomes of patients overdiagnosed with COPD. 
In the present study, there was no evidence of a difference between the groups in their 
HRQoL, healthcare utilisation or exercise capacity. This indicates that those patients are ill 
with other underlying conditions but not with COPD. These findings were in line with 
Walters et al., (2011) study, which also found a non-significant difference in the frequency of 
respiratory-related emergency department attendance or hospital admission between both 
patient subgroups (60).  
6.5.2 Strengths and Limitations  
The limitations of this study include a lack of data on the date of COPD diagnosis and how it 
was diagnosed, whether based on spirometry or only on smoking history and clinical 
symptoms. However, the quality of spirometry performed in the Birmingham COPD cohort 
was found to be exceptionally high. It was performed by well-trained research assistants with 
real-time and post-assessment quality assurance (134, 135). Another limitation is the 
exclusion of homebound patients and those with end stage COPD. However, this study has 
much strength, using data from a prospective cohort study on a large sample of different 
stages COPD patients from 71 participating practices in the West Midlands that were 
purposively selected to provide a study population that comprised different ethnicities, 
socioeconomic backgrounds and rural/urban patterns and broadly representative of the 
region’s primary care COPD patients (134).  
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6.5.3 Implications for research and clinical practise  
The prevalence of COPD overdiagnosis reported by this study is considerable and requires 
more attention, given the impact on patients’ health and on the healthcare system. However, 
the current diagnostic criteria of COPD remain controversial and need to be superseded by 
more restructured criteria. In clinical practise, the diagnosis of COPD should be confirmed 
only by the post-bronchodilator spirometry rather than relying upon the nonspecific 
respiratory symptoms and smoking history. GPs need to pay more attention to differential 
diagnoses of respiratory symptoms, particularly dyspnoea and consider coexisting 
comorbidities and restrictive lung diseases, especially with the presence of obesity.  
With the high rates of obesity, which may account for much of the overdiagnosis, 
interventions to reduce weight and improve physical activity could help in improving 
patients’ symptoms. Furthermore, evidence on COPD overdiagnosis is limited. Therefore, 
future longitudinal research aiming at exploring the factors which contribute to overdiagnosis 
and also examine for physiological lung function variability would be advised. An economic 
analysis is also required to estimate the extra expenditure of the NHS resources on the 
unnecessary over medicalisation.  
6.5.4 Conclusion  
COPD overdiagnosis is common in UK primary care settings. Subsequently, inappropriate 
use of respiratory medications occurs with potential risk to patients and unnecessary waste of 
the national healthcare system resources. The true underlying causes of reporting respiratory 
symptoms need to be identified and managed appropriately. In particular, obesity, restrictive 
lung function, undiagnosed heart disease or other comorbidities. A follow-up lung function 
assessment is also recommended to examine for the potential reversal of lung function values 
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between obstructed and non-obstructed patterns due to daily and seasonal physiological 
variations.  
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7 DISCUSSION AND CONCLUSION  
7.1 Background and context 
In 2001, the GOLD committee included an additional “at risk” stage in the description of 
COPD patients with a view to considering early interventions (90). Patients in this stage 
(known as COPD GOLD Stage 0) were included because they had relevant chronic 
respiratory symptoms (86), and were thought to be ‘at risk’ of developing COPD in the future 
(19). However, in 2006, GOLD Stage 0 was subsequently excluded due to lack of supporting 
evidence regarding its progression to diagnosed COPD (91). However, it remains an open 
area of debate, because there are many patients in the population (especially amongst 
smokers) with such symptoms (87, 135, 165). Furthermore, it is known that a certain 
proportion of patients in primary care with a formal diagnosis of COPD may not meet the 
spirometric criteria (72), but have relevant respiratory symptoms and therefore may fit the 
criteria for “GOLD Stage 0”. It is possible that these patients represent a group at risk of 
developing COPD, although it is also possible that they may have other conditions which 
could explain their symptoms. This thesis uses a range of primary and secondary data sources 
to provide further evidence to help clarify these questions. 
7.2 Key findings 
7.2.1 Risk of developing COPD among individuals with GOLD Stage 0 symptoms 
The systematic review in chapter 2 showed evidence on that there are relatively few published 
studies in this area and that they are heterogeneous in design, populations and outcomes 
measured. There are a mixture of cohort studies and small cross-sectional studies. However, 
there are some useful conclusions which can be tentatively drawn. Individuals with GOLD 
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Stage 0 symptoms appear to show faster decline in FEV1 than the normal population (86, 93, 
99, 116, 119), although risk of development of COPD is not consistent across studies (19, 86, 
89, 93, 98, 116, 117). GOLD Stage 0 symptoms are not always stable over time. Development 
of COPD and FEV1 decline appears to be associated with persistence of GOLD Stage 0 
symptoms (93, 98, 116), and the inconsistent cohort findings may reflect this phenomenon. 
Persistence of symptoms was associated with persistent smoking and among males, older 
females and males with metabolic syndrome (93) (Chapter 3).  
7.2.2 Prognosis of individuals with GOLD Stage 0 symptoms 
The systematic reviews in chapter 3 again identified few studies which explored the prognosis 
of GOLD Stage 0 patients. In two of the four relevant cohort studies, GOLD Stage 0 
participants had a similar risk of mortality to patients with COPD GOLD Stage 1 (95), and 
current smoking GOLD Stage 0 participants had similar risks to those with GOLD Stage 2 
(103). Across four studies (9, 90, 100, 101), healthcare use among GOLD Stage 0 patients 
was found to be similar to those with established COPD. In one cross-sectional study (102), 
GOLD Stage 0 participants reported poorer functioning than their diagnosed counterparts. 
None of these studies accounted for the instability of GOLD Stage 0 symptoms over time, and 
therefore the effects may even be underestimated.  
These findings were explored in more depth in cross-sectional analyses of the 2010 HSE 
(Chapter 4) and of data from the Birmingham COPD Cohort (Chapter 5). Analyses of the 
Birmingham COPD Cohort also showed that patients with GOLD Stage 0 symptoms had 
similar consumption of healthcare resources to those newly identified with COPD, but also 
reported similar quality of life, exercise capacity and exacerbation-like events.  
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The HSE analyses allowed examination of three groups of participants. In addition to the 
normal population, a “GOLD Stage 0” group and a group which fitted COPD criteria, there 
was a group of participants without symptoms but recorded as having airflow obstruction only 
(AFO only). There was a gradient of effect from normal through to patients with “COPD”. 
The “GOLD Stage 0” group was again quite similar to the “COPD” group in terms of quality 
of life, and even appeared to have worse anxiety and depression. The AFO only group, 
however, was much more similar to the normal population.  
Exploration of the importance of different symptoms showed that dyspnoea and wheeze were 
more strongly associated with poor quality of life than chronic productive cough.  
In general, the prognosis, quality of life and healthcare utilisation of GOLD Stage 0 patients is 
quite similar to those with milder COPD. 
7.2.3 Health related characteristics of GOLD Stage 0 patients  
The clinical characteristics of GOLD Stage 0 patients were explored in several primary 
analyses (Chapters 4-6). There were some important differences in the characteristics of 
patients in each of the categories. Overall, GOLD Stage 0 patients were of older age 
compared to the normal population (Chapter 4) but younger than diagnosed COPD patients 
(Chapter 5). A similar gradient was observed with smoking exposure. Furthermore, compared 
with diagnosed COPD patients, GOLD Stage 0 patients were more likely to be female, obese 
and have multiple comorbidities. Across all analyses, they were more likely to report 
cardiovascular diseases, high blood pressure, diabetes and depression, although this was not 
statistically significant. Additionally, they were less likely to show reversibility when tested 
spirometrically, suggesting that asthma is not more common in GOLD Stage 0 patients.  
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Obesity is a major aetiological factor of the presence of respiratory symptoms, particularly 
exertional dyspnoea (145-147). Moreover, obesity is a major contributor to the functional 
capacity restriction (145, 146, 163). However, the potential interrelationships between 
obesity, airflow obstruction, and respiratory symptoms or exercise limitations are not fully 
understood (145).  
7.2.4 COPD overdiagnosis in the UK primary care setting  
The work in chapter 6 identified a substantial proportion of patients in primary care with a 
diagnosis of COPD who did not meet the required spirometric criteria. The magnitude of 
COPD overdiagnosis varied according to the criteria being used; 13.7%, 28.1% and 32.3% 
using the current NICE, the LLN and the former NICE criteria, respectively. Previous UK 
studies which used the former NICE criteria (72, 73), reported comparable rates of 
overdiagnosis. It is also noteworthy that the extent of diagnosis varies substantially with the 
COPD criteria used. The current NICE criterion, which employs the fixed ratio, apparently 
diminishes the proportion of people thought to be overdiagnosed. However, these criteria 
themselves are suggested to be too inclusive (39, 40) and therefore the actual extent of 
overdiagnosis may be far greater. Consequently, patients are suffering from symptoms and 
not receiving the appropriate treatment which has several implications of missed opportunities 
(60, 62), increased cost to the NHS, false lifelong disease labels and the side effects of 
inappropriate medications (68). 
Patients who were overdiagnosed were more likely to be female, never smokers, obese and 
possibly have multiple comorbidities. Exploration of the overdiagnosed revealed that 
approximately 70% met the GOLD Stage 0 criteria, 19% had a restrictive pattern of lung 
function (which could be related to the excess obesity) and 2.5% were asymptomatic with 
normal lung function. 10% had reversible airflow obstruction, but this was significantly lower 
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than those with confirmed COPD, and therefore it is unlikely that misdiagnosed asthma would 
explain the findings. It is also possible that some of these overdiagnosed patients might have 
undiagnosed heart disease, but this was not measured. The features of the overdiagnosed 
group are very similar to the GOLD Stage 0 patients in the previous chapters. Quality of life, 
exacerbations, exercise capacity and healthcare utilisation were similar between the confirmed 
and the overdiagnosed groups. This may indicate that many of those patients are ill but not 
necessarily with COPD.  
7.3 Strengths and limitations  
This thesis has some limitations. First, the cross-sectional design of the primary analyses 
(Chapters 4-6) has limitation in terms of causality. Second, most of the study populations 
were of white ethnicity; therefore, the results may not be generalisable to patients of other 
ethnicities. The presence of doctor-diagnosed comorbidity was self-reported and therefore, 
there is a potential for under or overdiagnosed chronic disease among GOLD Stage 0 patients. 
Another limitation is a lack of imaging data, thus it is not possible to rule out the possibility of 
the presence of underlying respiratory or cardiac pathology, which could explain the presence 
of respiratory symptoms and their association with poor health outcomes. The strengths of 
this thesis are centred on the first systematic reviews of literature on COPD GOLD Stage 0 
carried out to the high standards of the Cochrane collaboration. Secondly, the use of a large 
national representative data from the HSE with the advantage of applying generalisability to 
the English population. Thirdly, the use of data from the Birmingham prospective COPD 
Cohort Study on a large sample of patients from 71 participating practices in the West 
Midlands.  
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7.4 Implication for research 
Although this thesis was based on cross-sectional studies, it can be used as a platform for 
future prospective population-based studies to confirm the cross-sectional findings and 
explore the prognosis of GOLD Stage 0. There is still a big gap in knowledge on this 
condition. Further work is needed to determine the main factors affecting the persistence of 
GOLD Stage 0 symptoms over time– smoking seems important so can we target smoking 
cessation to these people. Moreover, future studies examining GOLD Stage 0 must account 
for the instability of its symptoms. The relationship between the GOLD Stage 0 symptoms, 
obesity, diabetes and restrictive spirometry function also warrants further investigations. 
Studies investigating the effect of reducing obesity by targeted weight intervention on 
reducing patients’ symptoms are also needed.  
7.5 Implication for clinical practice  
This thesis emphasises the importance of questioning the presence of respiratory symptoms 
even in the absence of airflow obstruction. There may be no clear management pathways, but 
their health seems to be as poor as patients with mild COPD. Initially, persistence of 
symptoms should be established. For those patients with persistent symptoms who do not 
meet criteria for obstruction, alternative causes of their symptoms should be investigated. 
Furthermore, GOLD Stage 0 patients with persistent symptoms and frequent exacerbation 
may need to be identified and targeted for COPD screening. Clinicians should also consider 
other strategies to treat symptomatic patients, including weight management interventions and 
pulmonary rehabilitation rather than focusing on labelling patients falsely with a diagnosis of 
COPD. Moreover, further improvement in the use and interpretation of spirometry in 
diagnosing COPD in primary care is needed. Lastly, the desire to strengthen smoking 
cessation support programmes in clinical practice is always beneficial.  
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7.6 Conclusion  
The findings from this thesis emphasise that the presence of respiratory symptoms is an 
epidemiologically and clinically relevant regardless of the presence of lung function 
abnormalities. People with GOLD Stage 0 symptoms have similar poor quality of life and 
healthcare consumption when compared to those with mild COPD. It is still uncertain whether 
this group will develop COPD or whether they are ill because they have other conditions, or 
whether the lung function criteria for defining COPD is rather arbitrary. Some GOLD Stage 0 
patients showed similar characteristics to COPD patients but others may have other conditions 
(e.g. obesity and restrictive lung disease) responsible for their symptoms. It is therefore 
important to further investigate GOLD Stage 0 through longitudinal studies. Such works 
would also help in developing management guidelines aiming at improving patients’ quality 
of life, reduce the risk of misdiagnosis and reduce the inappropriate consumption of 
healthcare resources.  
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APPENDICES 
8 APPENDIX A: A SYSTEMATIC REVIEW 
PROTOCOL  
8.1 Step 1: the Review’s Topic 
8.1.1 Background and Rationale for the Topic 
8.1.1.1 Definition of COPD 
COPD is a heterogeneous disease consisting of a number of chronic respiratory disorders that 
progress gradually into air flow obstruction (AFO) as a consequence of different disease 
mechanisms (4); therefore, there is more than one definition for COPD (4) .The widely used 
definition is that of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
which defines COPD as “a common preventable and treatable disease, . . . characterized by 
persistent airflow limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and the lung to noxious particles or gases. 
Exacerbations and co morbidities contribute to the overall severity in individual patients”(6, 
7).  
8.1.1.2 Classification of COPD  
The GOLD guidelines, published in 2001, aimed to provide a standard global framework for 
COPD prevention, severity staging, diagnosis and management (86, 87) . The GOLD 
guidelines classified five stages of COPD severity based on post-bronchodilator spirometric 
lung function measurements, as summarised in Table 39. 
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Table 39: 2001 GOLD classification of COPD severity (69, 73) 
 
Gold Stage 
 
Characteristics 
Post-bronchodilator spirometry Chronic respiratory 
symptoms 
(cough, sputum production) 
GOLD Stage 0 (At risk) Normal spirometry  
(FEV1/FVC > 0.70) 
+ 
GOLD Stage I (Mild COPD) FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
± 
GOLD Stage II (Moderate COPD) FEV1/FVC < 0.70 
FEV1 < 80% but ≥ 50% predicted 
± 
GOLD Stage III (Severe COPD) FEV1/FVC < 0.70 
FEV1 < 50% but ≥ 30% predicted 
± 
GOLD Stage IV (Very Severe 
COPD) 
FEV1 ≤ 30% predicted or FEV1 < 
50% predicted plus chronic 
respiratory failure
6
 
± 
FEV1: forced expiratory volume in one second. FVC: forced vital capacity 
 
8.1.1.3 GOLD Stage 0 
Many components of the original GOLD guidelines and staging system are controversial (86), 
particularly COPD GOLD stage 0, which defines individuals who have preserved normal lung 
function (FEV1/FVC > 70%) but chronic respiratory symptoms (such as cough and sputum 
production) as being “at risk” of developing COPD in the future (86). The main idea behind 
the inclusion of this stage was to allow for early intervention, before the progression to stage 
1 or even more advanced stages of COPD (90). However, due to limited epidemiological 
studies and a lack of supporting evidence regarding the progression from GOLD stage 0 to 
stage 1 COPD, GOLD stage 0 has been excluded from GOLD staging of COPD since 2006 
(91). Meanwhile, the significance of the public health message that chronic respiratory 
symptoms are abnormal and that their underlying causes must be identified remains 
unchanged (91).  
                                                 
6Respiratory failure is defined as “arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without 
arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level” .  
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8.1.1.4 Areas of Arguments on GOLD Stage 0 
The main areas of disagreement regarding GOLD stage 0 COPD are whether this stage exists 
or not (87) and by what means subjects with normal pulmonary function (no obstruction) can 
be classified as COPD and included in GOLD staging (87). The data from preceding surveys 
have shown that a large proportion of patients with abnormal pulmonary function do not 
report respiratory symptoms (87). On the other hand, a large proportion of patients with 
normal lung functions do report respiratory symptoms (87). Another area of debate is that 
regarding the respiratory symptoms essentially required to define Gold Stage 0, most previous 
studies have used the following definition of chronic bronchitis: “the presence of productive 
cough for 3 months in two successive years in a patient in whom other causes of chronic 
cough, have been excluded” (94). Some other studies have suggested a more sensitive 
definition of GOLD Stage 0 by including a wider range of respiratory symptoms (cough, 
phlegm, wheeze, breathlessness) that happen on a recurrent basis (87).  
8.1.1.5 The Scoping Search on GOLD Stage 0: Existing Literature  
There is a wide range of views and some contradictory opinions from relevant studies that 
exist on the risk factors and prognosis of GOLD stage 0. Some studies have found GOLD 
stage 0 to be associated with an increased risk of developing COPD in the future (98, 99), a 
higher utilisation of health care (90), lower HRoQL and increased risk of long-term mortality 
(87), especially among smoking males (103). Furthermore, some studies have found that the 
presence of chronic respiratory symptoms increases the risk of mortality in all stages of 
COPD, including stage 0 patients with preserved lung function (95). Two studies by de Marco 
et al and one by Pelkonen et al have concluded that chronic cough and phlegm predict an 
increased risk of developing COPD, independent of smoking behaviours (98, 99), due to the 
significant risk of respiratory symptoms in excessive FEV1 decline (86, 99, 119). In their 
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study, Mannino et al have shown that respiratory symptoms with normal lung function are 
associated with functional restriction and poor health status to a similar degree as moderate 
COPD (85). On the other hand, in their analysis of data collected over 15 years of the course 
of three surveys in The Copenhagen City Heart Study, Vestbo and Lange have concluded that 
GOLD Stage 0 “is of little help in identifying subjects at risk of COPD” (86). They state that 
GOLD Stage 0 lacks any predictive prognostic value (even though it was associated with 
excess FEV1 decline), and that it does not considerably increase the risk of developing AFO 
later in life (86).  
8.1.2 Rationale for a systematic review 
To the best of knowledge, there has as of yet been no systematic review studying GOLD 
Stage 0 and assessing the natural history of this group of patients. Therefore, this proposed 
systematic review will be the first to gather the available literature on GOLD Stage 0.  
8.1.3 Review aims and Questions  
The proposed systematic review aims to: 
a. Draw together the currently available literature on Gold Stage 0 and provide an 
evidence-based summary. 
b. Identify the scope for further research on COPD Gold stage 0. 
These aims will be achieved by answering the following questions: 
1. Are people who have chronic respiratory symptoms but normal lung function at a 
higher risk of developing COPD compared to people who do not? 
2. What is the prognosis of patients with chronic respiratory symptoms but normal lung 
function compared to established COPD patients? 
3. What are the main factors that can affect the prognosis of patients with chronic 
respiratory symptoms but normal lung function? 
154 
 
8.1.4 Selection Criteria for Considering Studies for this Review 
Although, the term GOLD Stage 0 does not officially exist, it will be used in this review to 
refer to the study population (instead of using its long definition every single time). 
Furthermore, the term chronic bronchitis (CB) may be also used to refer to GOLD Stage 0. 
Table 40 below summarises the PECOS components of the review’s questions: 
8.1.4.1 Population 
This review will particularly include studies that have assessed middle-aged and elderly 
populations (40 years and above) who have chronic respiratory symptoms but preserved 
normal lung function. Studies of younger age groups will be included if self-reported asthma 
was excluded, due to the potential of diagnostic bias by misclassification of bronchial asthma 
as COPD. 
8.1.4.2 Exposure 
For questions 1 and 2, studies should include any chronic respiratory symptoms as cough, 
phlegm, dyspnoea and wheeze, which occur on a frequent basis. (This is defined in some 
studies as more than three consecutive months a year for two consecutive years (95), although 
it may not always be defined this way). For questions 3, studies which measure any factors 
that affect the prognosis of GOLD Stage 0 patients such as age, sex, ethnic group, smoking 
status, passive smoking, body mass index (BMI), biomarkers, occupational exposure, FEV1 
predicted and comorbidity. Studies of genetic factors and childhood respiratory infection will 
not be included. 
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8.1.4.3 Comparator 
For question 1, studies that compared GOLD Stage 0 to normal population (asymptomatic 
with normal lung function) will be included. For question 2, studies that compared GOLD 
Stage 0 to clinically diagnosed COPD patient’s stages 1+ will be included. 
8.1.4.4 Outcome 
For question 1, the outcome of interest is the decline in FEV1% and development of COPD. 
For question 2 and 3, any outcome, it will include: mortality, symptoms exacerbation and 
hospitalisation, health care utilisation, development of comorbidities and HRQOL. 
8.1.4.5 Study Design 
For questions 1 and 2, ideally cohort studies will be included as a reliable 
prognostic/aetiological systematic review necessitates an accurate cohort of patients at the 
same stage of their disease (115). However, cross-sectional studies will also be considered, 
due to the likelihood of limited cohort studies on GOLD Stage 0. For question 3, only cohort 
studies will be included. 
8.1.4.6 Types of Publication  
The proposed review will include all relevant studies for which full text is available, 
regardless of their publication status. There will be no language or time restrictions, relevant 
grey literature will be included and also conference abstracts and ongoing studies will be 
included if the full article can be obtained (authors will be contacted for full articles). 
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Table 40: PECOS components of the review questions 
Question 
components 
(PECOS) 
Q1: GOLD Stage 0 
and the risk of 
developing COPD  
Q2: Prognosis of 
GOLD Stage 0  
Q3: Prognostic 
factors of GOLD 
Stage 0 
Exclusion 
Criteria 
Population People aged ≥40 
years with normal 
lung function 
People aged ≥40 
years with normal 
lung function 
People aged ≥40 
years with chronic 
respiratory 
symptoms and 
normal lung 
function 
Studies of 
younger age 
groups unless 
asthma excluded 
“Exposure” Any chronic 
respiratory 
symptoms  
 
Chronic respiratory 
symptoms  
Any; for e.g. age, 
sex, ethnic group, 
smoking status, 
passive smoking, air 
pollutions, BMI, 
biomarkers, 
occupational 
exposure, FEV1 
predicted and 
comorbidity  
 Genetic 
factors 
 Childhood 
respiratory 
infections 
 
 
Comparator “Normal 
population” 
COPD patients with 
or without chronic 
respiratory  
None  
Outcome 
 
Decline in FEV1% 
and development of 
COPD 
Any outcome; for 
e.g. mortality, 
HRQOL, 
exacerbation and 
healthcare utilisation  
Any outcome 
 
 
Study Design Ideally cohort 
studies, but case-
control studies and 
cross-sectional 
studies might be 
considered 
Ideally cohort 
studies, but case-
control and cross-
sectional studies will 
be considered 
Cohort studies 
 
Reviews, 
editorials, case 
series and 
reports 
Types of 
Publication  
All relevant studies with available full text, regardless of their publication status 
 
 
8.2 Step 2: Search strategy and identifying relevant literature 
8.2.1 Selection of Relevant Databases to Search  
8.2.1.1 Identifying Ongoing Systematic Reviews 
Initially, the following databases will be searched and checked for both existing and ongoing 
systematic reviews on COPD GOLD stage 0 and to identify the nature and numbers of 
significant studies on this topic: the Database of Abstracts of Reviews of Effects (DARE), the 
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Cochrane Database of Systematic Reviews (CDSR), the Centre for Reviews and 
Dissemination (CRD) and the International Prospective Register of Systematic Reviews 
(PROSPERO), MEDLINE, EMBASE and websites of the National Institute for Health and 
Clinical Excellence (NICE) and the NIHR Health Technology Assessment (NIHR HTA) 
Programme. 
8.2.1.2 Search for Relevant Literature 
The following sources will be searched: 
8.2.1.2.1 Bibliographic Electronic Databases 
MEDLINE and EMBASE via Ovid, MEDLINE in process, CINAHL, Web of Sciences, 
PubMed and Cochrane (Wiley) Central will be accessed and searched through the University 
of Birmingham library catalogue. 
8.2.1.2.2 Searching the Internet 
Searches will also be conducted on selected websites such as GOLD, NICE, ERS and ATS 
for conferences abstracts over the last two years. 
8.2.1.2.3 Searching Reference Lists 
Reference lists of relevant studies will also be searched in order to identify other significant 
studies that can be included. 
8.2.1.2.4 Searching Other Sources 
This will include searching for grey literature, which is not usually included in the main 
databases. However, much of this literature can be searched and accessed via SIGLE (System 
for Information on Grey Literature), ETHOS library, ZETOC library, and Conference 
Proceedings Citation Index- Science (CPCI-S) within Web of Sciences. 
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8.2.1.2.5 Seeking Experts’ Input 
In order to ensure a comprehensive literature search, advice and support from information 
specialists and expert librarians will be sought throughout the proposed systematic review 
period.  
8.2.1.2.6 Hand searching of a selection of relevant journals  
If advised by the review team 
8.2.1.3 Search Strategy 
8.2.1.3.1 Search Term Combinations for Electronic Databases 
In order to maximise the sensitivity of the search to obtain the largest possible number of 
relevant studies, the following steps will be taken: 
a. Identification and inclusion of a comprehensive list of key search terms for each 
component of the question and a range of synonyms with spelling alterations.  
b. Identification of relevant MeSH terms by looking at the keywords recommended 
at the end of abstracts of relevant studies and searching for how they are indexed 
in the database. 
c. Combination of simple key terms and the MeSH terms selected previously. 
The following (Table 41) shows an example of search term combinations for the MEDLINE 
(Ovid) database; 
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Table 41: Questions components and search terms 
Population: Patients aged 40 and over with chronic respiratory symptoms but normal lung function (GOLD Stage 0) 
Key terms MeSH terms Search term 
combinations 
GOLD Stage 0 
Respiratory symptoms 
Respiratory disease$ 
Cough  
Phlegm  
Dyspnoea 
Wheeze  
Chronic bronchitis 
exp chronic respiratory tract disease 
exp bronchitis 
 
 
O
R
 
(c
a
p
tu
re
s 
P
o
p
u
la
ti
o
n
) 
Exposure: Risk factors  
Key terms MeSH terms 
O
R
 
(c
a
p
tu
re
s 
E
x
p
o
su
re
) 
Risk factors  
Determinant$ 
Cohort 
Epidemiological studies 
exp risk factors  
exp epidemiologic studies 
 
exp predictive value 
Comparator: COPD Stages 1+ 
Key terms MeSH terms 
O
R
 
(c
a
p
tu
re
s 
C
o
m
p
a
ra
to
r)
 
Chronic obstructive lung disease 
Global initiative for obstructive lung 
disease 
GOLD stages 
 
exp pulmonary disease 
exp chronic obstructive lung disease 
exp pulmonary disease, chronic obstructive 
[classification, complications, aetiology, mortality] 
Outcome: Prognosis of GOLD Stage 0 
Key terms MeSH terms 
O
R
 
(c
a
p
tu
re
s 
o
u
tc
o
m
e)
 
Prognosis  
Predict$  
Prognos$ 
course 
Predictive value 
Outcomes 
Exp cohort studies 
exp disease progression 
exp mortality 
exp follow-up studies 
 
AND combines all the question components 
Adapted from (166) 
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8.2.1.4 Identifying Relevant Studies 
The search for a literature will be conducted by the first reviewer and the screening for 
eligibility of inclusion will be conducted independently by two reviewers. The searching will 
be done over three stages, as follows: 
Stage1: Searching databases and other previously mentioned sources using key and MeSH 
terms combinations, importing obtained records to EndNoteX7 reference software and 
eliminating duplicates. 
Stage2: Screening the searched literatures’ titles and abstracts against the predefined 
inclusion/exclusion criteria. 
Stage 3: A detailed assessment of the full text of potentially significant studies yielded from 
the initial screening, as well as questionable studies about which the final judgment cannot be 
made through title and abstract screening alone. If a final decision on the eligibility of 
questionable studies cannot be made, or in cases of disagreement between the two reviewers, 
a third reviewer will be consulted. However, to avoid major disagreement between the two 
reviewers, the review’s eligibility criteria was first piloted on some studies (n=14) (Table 42). 
Excluded studies will be listed and documented with the reasons for exclusion. A Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (167) schematic flow 
diagram will be used to report different phases of identifying relevant literature to be 
included.  
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Table 42: Piloting some studies against the selection criteria 
Study ID 
 
The population The exposure The outcomes The study design Comments 
Mannino et al., 2005 
 
Adult subjects 
aged 43–66 years 
 Chronic respiratory symptoms 
 Pack-years of smoked cigarettes  
 Age, sex and race 
 BMI 
 Education level 
The predictive risk of 
abnormal lung function on the 
subsequent mortality 
11 years cohort study This study categorised 
the participants according 
to the Pre-BD spirometry  
Antonelli-Incalzi et 
al., 2003 
 
Individuals aged 
73±6 years  
 Sex, age 
 Living condition  
 Comorbidity  
The correlation between 
different GOLD stages of 
COPD and changes in health 
status 
Cross-sectional study  
Stroband et al., 
2007 
45–75 years old 
patients  
 Chronic respiratory symptoms  
 Smoking and ≥10 pack-years of 
smoked cigarette  
The variation in inflammatory 
biomarkers between COPD 
patients with and without 
respiratory symptoms of 
chronic bronchitis  
Cross-sectional study  
Tsushima et al., 
2005 
 
No selection 
criteria were 
applied (general 
population health 
survey)  
 Chronic respiratory symptoms  
 Smoking  
 Demographic data, lifestyle and 
past medical histories 
The clinical difference 
between GOLD stage 0 and 
normal individuals 
Cross-sectional study  Young age groups 
included 
 The exclusion of 
bronchial asthma 
relied only on self-
reported 
questionnaires 
without testing for 
reversibility 
Vestbo and Lange, 
2002 
Subjects aged 20 
years or above  
 Age sex 
 Smoking  
 * Changes in smoking habits 
(smoking cessation) 
Decline in FEV1 and 
Progression from stage 0 to 
COPD 1+ 
 
Prospective 15 years 
cohort study 
Stavem et al., 2005 Healthy males 
aged 40- 59 years 
(have no other 
comorbidities 
including severe 
pulmonary 
diseases) 
 
 Respiratory symptoms 
 BMI 
 Age 
 Serum cholesterol and BP  
 Smoking habits 
 Physical fitness  
Risk of mortality in GOLD 
stage 0 compared with GOLD 
stages I and II  
Occupational 8 years 
cohort study 
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Study ID 
 
The population The exposure The outcomes The study design Comments 
Aronsson et al., 
2005 
 
Subjects aged 27-
61 years 
 Chronic respiratory symptoms 
 Smoking 
 Age  
 Sex 
 Comorbidity 
Over-all mortality risks in 
GOLD stages 0–4 and the 
influence of chronic 
respiratory symptoms on 
mortality risks  
 
The study analysed 
previously collected data 
from 18 years health 
screening survey in 
Sweden, then 
prospectively followed 
up all participants 
through the national 
registers to assess the 
total mortality 
 
Shin et al., 2005 Adults aged 40–
69 years 
 Chronic respiratory symptoms 
 Sex 
 Age  
 Smoking 
Relationship between chronic 
respiratory symptoms and 
deterioration in lung function 
 
Cross-sectional study  
Pelkonen et al., 2006 Men aged 40 to 
59 years 
 Chronic bronchitis 
 Smoking 
 Age  
 
The effect of chronic 
bronchitis on lung function 
and the risk of mortality  
Cohort study  
de Marco et al., 
2004 
Young adults 
aged 20–44 years 
 Chronic cough and phlegm 
 Childhood respiratory infection 
 Smoking 
 Asthma  
 Occupational exposure 
 Socioeconomic class 
 Sex 
 Age  
 
Shared common risk factors 
and difference in health care 
utilisation between stage 0 and 
more advanced stages of 
COPD  
 
Cross sectional analysis 
of data from the 
European Community 
Respiratory Health 
Survey (ECRHS)  
Classification bias of 
asthma as COPD 
de Marco et al., 
2007 
Young adults 
aged 20–44 years 
 Chronic cough and phlegm  
 Sex 
 Age 
 Smoking habits  
 Educational level 
The incidence of COPD 
among young adults and the 
value of chronic cough and 
phlegm as independent 
predictors of COPD 
ECRHSII  Classification bias of 
asthma as COPD 
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Study ID 
 
The population The exposure The outcomes The study design Comments 
Albers et al., 2007 Adults aged 20-70 
years with no 
history of COPD, 
asthma or other 
chronic 
respiratory 
disease 
 Early respiratory symptoms 
 Age 
 Gender 
 Pack years  
 Smoking behaviour  
The predictive value of 
chronic respiratory symptoms, 
lung function below normal 
range and reversibility  
Prospective 5 years 
cohort study 
 
Cerveri et al., 2003 Individuals aged  
20–44 years 
 Respiratory symptoms 
 Asthma 
 Socioeconomic status 
 Smoking habits 
 Age  
 Gender 
The prevalence and 
characteristic of chronic cough 
and phlegm 
Multicentre cross-
sectional survey 
The assessment and 
characterisation of the 
respiratory symptoms 
was done by using simple 
screening questionnaire 
without performing 
spirometry 
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8.3 Step 3: Data extraction and management 
The data extraction will be done independently by the two reviewers. The form will be 
adapted from the STOBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) checklist (110, 111) (Appendix C). It puts the primarily emphasis on 
population, exposure/comparator, outcomes and study designs. The form will be piloted first 
on some papers and then if no modification is required, it will be used to collect data from the 
identified eligible studies. In cases of discrepancy between the two reviewers, the third 
reviewer will be consulted. The author of the primary study may be contacted at this stage for 
any missing data. 
8.4 Step 4: Methodological Quality Assessment  
Assessment of the quality of studies to be included in the proposed review will be performed 
independently by the two reviewers. Because of lack of consensus comprehensive critical 
appraisal tool of observational studies, the assessment forms were generated from two key 
quality assessment tools of non-randomised studies; QUIPS tool (Appendix D) will be used 
for included cohort studies (112) and Newcastle Ottawa tool (Appendix E) for cross sectional 
studies (113). According to the Cochrane Collaboration recommendations (107) a scale rating 
will not be generated as the rating system does not always reflect the validity of the study 
finding. The risk of bias will be judged by yes, no, partly and unclear for each perspective.  
8.5 Step 5: Data synthesis and analysis 
There are clear difficulties involved with a formal meta-analysis of prognostic systematic 
reviews. These challenges are mainly attributed to the high risk of publication bias, the 
methodological quality and the reporting quality of the primary observational studies to be 
included in the systematic review (114, 115). Furthermore, the results of a meta-analysis of a 
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systematic review of prognostic studies are usually misleading and not convincing even when 
the meta-analysis is conducted with great precision (108, 115, 168), except when the 
individual patients data (IPD) can be accessed and used for synthesis (115) which might not 
be feasible. Therefore, this review will be a descriptive review and will not consider a meta-
analysis.  
8.6 Step 6: Protocol Registration and Plan of Dissemination 
Once finalised and agreed upon by the review team, the protocol will be registered with 
PROSPERO. After completion, both the protocol and the systematic review will be submitted 
for publication and will also be presented and disseminated through seminars and conference 
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9 APPENDIX B: LIST OF THE SEARCH TERMS 
USED IN THE SYSTEMATIC REVIEWS   
Table 43: Search terms for systematic reviews 1, 2 and 3 
 Search term  
1 “gold stage 0”.mp. 
2 chronic respiratory symptoms.mp. 
3 bronchitis.mp. 
4 exp bronchitis/ 
5 exp cough/ 
6 cough.mp. 
7 exp mucus 
8 phlegm.mp. 
9 exp dyspnea/  
10 Dyspnea.mp. 
11 Wheeze.mp. 
12 exp wheezing/ 
13 epidemiology.mp. 
14 exp epidemiology/ 
15 exp cohort studies/ 
16 cohort.mp. 
17 exp cross-sectional studies/ 
18 cross-sectional.mp. 
19 exp case-control Studies/ 
20 Case-control.mp. 
21 copd.mp. 
22 exp pulmonary disease, chronic obstructive/ 
23 airflow obstruction.mp. 
24 exp airway obstruction/ 
25 FEV1 decline.mp. 
26 predict$.mp. 
27 exp Prognosis/ 
28 prognosis.mp. 
29 prognos$.mp. 
30 outcome.mp. 
31 age.mp. 
32 sex.mp. 
33 exp smoking/ 
34 smoking.mp. 
35 BMI.mp. 
36 ethnicity.mp. 
37 comorbidity.mp. 
38 biomarkers.mp. 
39 air pollution.mp. 
40 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
41 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
42 21 or 22 or 23 or 24 or 25  
43 40 and 41 and 42   
44 26 or 27 or 28 or 29 or 30 
45 40 and 41 and 44 
46 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39  
47 13 or 14 or 15 or 16 
48 26 or 27 or 28 or 29  
49 40 and 46 and 47 and 48   
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10 APPENDIX C: STRENGTHENING THE REPORTING OF 
OBSERVATIONAL STUDIES IN EPIDEMIOLOGY CHECKLIST 
(STROBE)  
 
No Item Recommendation 
 
 
1 
 
Study ID  
 
The title, author, year and journal 
 
Methodology 
2 Study design Present key elements of study design  
 
3 Setting Describe the study locations, periods of recruitment, exposure, follow-up, and data collection 
4 Participants a) Cohort study: Give the eligibility criteria, sources and methods of selection of participants and methods of follow-up/ for 
matched cohort studies, the matching criteria and number of exposed and unexposed 
Cross-sectional study: Give the eligibility criteria, and the sources and methods of selection of participants  
b) Sample size: Explain how the study size was arrived at 
 
5 Variables a) Clearly define all exposures, predictors, potential confounders, and diagnostic criteria 
b) For each variable of interest, give sources of data and methods of measurement 
c) Describe comparability of assessment methods if there is more than one group 
 
6 Outcome measures a) Define outcomes of interest 
b) Describe statistical methods used to control for confounding 
c) Describe statistical methods used to examine subgroups and interactions 
d) Describe statistical methods used to deal with missing data  
e) Cohort study: Describe methods used to address loss to follow-up  
f) Cross-sectional study: Describe the analytical methods taking account of sampling strategy 
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No Item Recommendation 
 
 
Results 
7 Participants a) Report numbers of individuals at each stage of study; numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
b) Give reasons for non-participation at each stage 
 
8 Variables a) Give the demographic, clinical and social characteristics of the study participants 
b) Give information on exposures and potential confounders 
c) Indicate the number of participants with missing data for each variable of interest 
d) Adjustment and justification of potential confounders 
e) Cohort study: Summarise follow-up time (average and total amount) 
 
9 Outcome data a) Report the outcome measures 
b) Addressed potential sources of bias 
c) Cohort study: Report numbers of outcome events over time/ attrition rate 
d) Cross-sectional study: Report numbers of outcome events or summary measures 
 
Source:(110) 
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11 APPENDIX D: QUALITY IN PROGNOSIS STUDIES (QUIPS) TOOL  
 
Summary of the Bias Domains, Prompting Items, and Ratings of the QUIPS Tool (112) 
 
Variable 
Bias Domains 
1. Study 
Participation 
2. Study Attrition 3. Prognostic Factor 
Measurement 
4. Outcome 
Measurement 
5. Study 
Confounding 
6. Statistical Analysis 
and Reporting 
Optimal study or 
characteristics of 
unbiased study 
The study sample 
adequately 
represents the 
population 
of interest 
The study data 
available (i.e., 
participants not lost to 
follow-up) adequately 
represent the study 
sample 
The PF is measured in 
a similar way for all 
participants 
The outcome of 
interest is measured in 
a similar way for all 
participants 
 
Important potential 
confounding factors 
are appropriately 
accounted for 
The statistical analysis 
is appropriate, and all 
primary outcomes are 
reported 
Prompting items and 
considerations† 
a. Adequate 
participation in the 
study by eligible 
persons 
a. Adequate response 
rate for study 
participants 
a. A clear definition 
or description of the 
PF is provided 
a. A clear definition 
of the 
outcome is provided 
a. All-important 
confounders are 
measured 
a. Sufficient 
presentation of data 
to assess the adequacy 
of the analytic 
strategy 
 b. Description of the 
source population or 
population of interest 
b. Description of 
attempts to collect 
information on 
participants who 
dropped out 
b. Method of PF 
measurement is 
adequately valid and 
reliable 
b. Method of outcome 
measurement used is 
adequately valid and 
reliable 
b. Clear definitions of 
the important 
confounders measured 
are provided 
b. Strategy for model 
building is appropriate 
and is based on a 
conceptual framework 
or model 
 c. Description of the 
baseline study sample 
c. Reasons for loss to 
follow-up are 
provided 
c. Continuous 
variables are reported 
or appropriate cut 
points are used 
c. The method and 
setting of outcome 
measurement is the 
same for all study 
participants 
c. Measurement of all 
important 
confounders is 
adequately valid and 
reliable 
c. The selected 
statistical model 
is adequate for the 
design of the study 
 d. Adequate 
description of the 
sampling frame and 
recruitment 
d. Adequate 
description of 
participants lost to 
follow-up 
d. The method and 
setting of 
measurement of PF is 
the same for all study 
participants 
 
 d. The method and 
setting of confounding 
measurement are 
the same for all study 
participants 
d. There is no 
selective reporting of 
results 
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 e. Adequate 
description of the 
period and place of 
recruitment 
e. There are no 
important differences 
between participants 
who completed the 
study and those who 
did not 
e. Adequate 
proportion of the 
study sample has 
complete data for the 
PF 
 e. Appropriate 
methods are used 
if imputation is used 
for missing 
confounder data 
 
 
 f. Adequate 
description of 
inclusion and 
exclusion criteria 
 f. Appropriate 
methods of imputation 
are used for missing 
PF data 
 f. Important potential 
confounders are 
accounted for in the 
study design 
 
     g. Important potential 
confounders are 
accounted for in the 
analysis 
 
Ratings       
High risk of bias The relationship 
between the PF and 
outcome is very likely 
to be different for 
participants and 
eligible 
nonparticipants 
The relationship 
between the PF and 
outcome is very likely 
to be different for 
completing and 
non-completing 
participants 
The measurement of 
the PF is very likely 
to be different for 
different levels of the 
outcome of interest 
The measurement of 
the 
outcome is very likely 
to be different related 
to the baseline level of 
the PF 
The observed effect of 
the PF on the outcome 
is very likely to be 
distorted by another 
factor related to PF 
and outcome 
The reported results 
are very 
likely to be spurious 
or biased 
related to analysis or 
reporting 
Moderate risk of bias The relationship 
between the PF and 
outcome may be 
different for 
participants and 
eligible 
nonparticipants 
The relationship 
between the PF and 
outcome may be 
different for 
completing and non-
completing 
participants 
The measurement of 
the PF may be 
different for different 
levels of the outcome 
of interest 
The measurement of 
the 
outcome may be 
different related to the 
baseline level of the 
PF 
The observed effect of 
the PF 
on outcome may be 
distorted 
by another factor 
related to 
PF and outcome 
The reported results 
may be 
spurious or biased 
related to 
analysis or reporting 
Low risk of bias The relationship 
between the PF and 
outcome is unlikely 
to be different for 
participants and 
eligible 
nonparticipants 
The relationship 
between the PF and 
outcome is unlikely to 
be different for 
completing and non-
completing 
participants 
The measurement of 
the PF is unlikely to 
be different for 
different levels of the 
outcome of interest 
The measurement of 
the outcome is 
unlikely to be 
different related to the 
baseline level of the 
PF 
The observed effect of 
the PF on outcome is 
unlikely to be 
distorted by another 
factor related to PF 
and outcome 
The reported results 
are unlikely to be 
spurious or biased 
related to analysis or 
reporting 
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12 APPENDIX E: NEWCASTLE-OTTAWA 
SCALE  
 
Selection: (Maximum 5 stars) 
1) Representativeness of the sample: 
a) Truly representative of the average in the target population. * (all subjects or 
random sampling) 
b) Somewhat representative of the average in the target population. * (non-random 
sampling) 
c) Selected group of users. 
d) No description of the sampling strategy. 
2) Sample size: 
  a) Justified and satisfactory. * 
  b) Not justified. 
3) Non-respondents: 
  a) Comparability between respondents and non-respondents characteristics is established, 
and the response rate is satisfactory. * 
  b) The response rate is unsatisfactory, or the comparability between respondents and non-
respondents is unsatisfactory. 
  c) No description of the response rate or the characteristics of the responders and the non-
responders. 
4) Ascertainment of the exposure (risk factor): 
  a) Validated measurement tool. ** 
  b) Non-validated measurement tool, but the tool is available or described.*  
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  c) No description of the measurement tool. 
Comparability: (Maximum 2 stars) 
1) The subjects in different outcome groups are comparable, based on the study design or 
analysis. Confounding factors are controlled. 
  a) The study controls for the most important factor (select one). * 
  b) The study control for any additional factor. * 
Outcome: (Maximum 3 stars) 
1) Assessment of the outcome: 
  a) Independent blind assessment. ** 
  b) Record linkage. ** 
  c) Self report. * 
  d) No description. 
2) Statistical test: 
  a) The statistical test used to analyze the data is clearly described and appropriate, and the 
measurement of the association is presented, including confidence intervals and the 
probability level (p value). * 
  b) The statistical test is not appropriate, not described or incomplete. 
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13 APPENDIX F: METHODOLOGICAL QUALITY OF INDIVIDUAL 
COHORT STUDIES INCLUDED IN THE SYSTEMATIC REVIEWS  
 
Table 44: Risk of bias assessment for the included cohort studies (systematic review 1) 
Bias Domain Description Judgment 
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, 
2
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Study participation Adequate participation in the study by eligible persons Y Y  Y  Y Y Y Y Y 
Description of the source population or population of interest Y Y  Y  Y Y Y Y Y 
Description of the baseline study sample Y Y  Y  Y Y Y Y Y 
Adequate description of the period and place of recruitment Y Y  Y  Y Y Y  Y Y 
Adequate description of inclusion and exclusion criteria Y Y  Y  Y Y Y Y Y  
Study attrition Adequate response rate for study participants U Y  Y  Y Y Y Y Y 
Description of attempts to collect information on participants who dropped out N N  N  Y N N N N 
Reasons for loss to follow-up are provided N N  N  N N N Y N 
Adequate description of participants lost to follow-up N N  N  P
7
  P  N  Y  N 
There are no important differences between participants who completed the study and those 
who did not 
U  U  U  U U U Y U 
                                                 
7 Only the number of lost to follow up was reported 
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Bias Domain Description Judgment 
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Outcome measurement 
 
A clear definition of the outcome is provided Y Y  Y  Y Y Y Y Y 
Method of outcome measurement used is adequately valid and reliable P
8
  P  P  P  N  P  Y P 
The method and setting of outcome measurement is the same for all study participants Y  Y  Y  Y  Y Y Y Y 
Study confounding All-important confounders are measured Y Y  Y  Y  Y Y Y Y 
Clear definitions of the important confounders measured are provided Y Y  Y  Y  Y Y Y Y 
Important potential confounders are accounted for in the analysis  
 
Y Y  Y  Y  Y Y Y Y 
Statistical analysis and 
reporting 
Sufficient presentation of data to assess the adequacy of the analytic strategy Y Y  Y  Y Y Y Y Y 
The selected statistical method is adequate for the design of the study Y Y  Y  Y  Y Y Y Y 
There is no selective reporting of results Y Y  Y Y  Y  Y  Y Y  
(Y=yes, N=no, P=partly, U=unclear) 
 
 
 
 
 
 
 
 
 
 
 
                                                 
8 Only pre-BD spirometry was performed 
175 
 
Table 45: Risk of bias assessment for the included cohort studies (systematic review 2) 
Bias Domain Description Judgment 
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Study participation Adequate participation in the study by eligible persons Y Y Y   Y  Y  Y  
Description of the source population or population of interest Y Y Y  Y  Y  Y  
Description of the baseline study sample Y Y Y  Y  Y  Y  
Adequate description of the period and place of recruitment Y Y Y  Y  Y  Y  
Adequate description of inclusion and exclusion criteria 
 
Y Y Y  Y  Y  N  
Study attrition Adequate response rate for study participants Y Y Y  Y  Y  N  
Description of attempts to collect information on participants who dropped out N  N  Y   Y  N  N 
Reasons for loss to follow-up are provided Y  Y  Y  Y  Y  N 
Adequate description of participants lost to follow-up P
9
  P  Y  N  N  N 
There are no important differences between participants who completed the study and 
those who did not 
U  
 
U  
 
Y  U  U  N 
Outcome measurement 
 
A clear definition of the outcome is provided Y  Y  Y  Y  Y  Y  
Method of outcome measurement used is adequately valid and reliable Y  Y  U  Y  Y  Y  
The method and setting of outcome measurement is the same for all study participants Y  Y  
  
Y  Y  
 
Y  Y  
                                                 
9 Only the number of lost to follow up was reported 
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Bias Domain Description Judgment 
 
 
 
Study ID: (authors, year) 
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Study confounding All-important confounders are measured Y  Y  N  Y  Y  Y  
Clear definitions of the important confounders measured are provided Y Y N  Y  Y  P  
Important potential confounders are accounted for in the analysis  Y  Y   N  Y  Y  Y  
Statistical analysis and reporting Sufficient presentation of data to assess the adequacy of the analytic strategy Y Y Y  Y  Y  Y  
The selected statistical method is adequate for the design of the study  Y  Y  P  Y  Y  P  
There is no selective reporting of results 
 
 P  P  Y  Y  U  U  
(Y=yes, N=no, P=partly, U=unclear) 
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Table 46: Risk of bias assessment for the included cohort studies (systematic review 3) 
Bias Domain Description Judgment 
 
 
 
 
Study ID: (authors, year) 
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Study participation Adequate participation in the study by eligible persons N  Y 
Description of the source population or population of interest N  Y 
Description of the baseline study sample P  Y 
Adequate description of the period and place of recruitment Y  Y 
Adequate description of inclusion and exclusion criteria 
 
Y  Y 
Study attrition Adequate response rate for study participants U  Y 
Description of attempts to collect information on participants who dropped out N  N 
Reasons for loss to follow-up are provided Y  Y 
Adequate description of participants lost to follow-up N  Y  
There are no important differences between participants who completed the study and those who did not 
 
U  Y 
Prognostic Factor (PF) 
Measurement 
A clear definition or description of the PF is provided P  Y  
Method of PF measurement is adequately valid and reliable P  Y  
The method and setting of measurement of PF is the same for all study participants Y  Y  
Adequate proportion of the study sample has complete data for the PF Y  Y  
Outcome measurement 
 
A clear definition of the outcome is provided Y  Y 
Method of outcome measurement used is adequately valid and reliable Y  Y 
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Bias Domain Description Judgment 
 
 
 
 
Study ID: (authors, year) 
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The method and setting of outcome measurement is the same for all study participants 
 
Y  Y 
Study confounding All-important confounders are measured Y  Y 
Clear definitions of the important confounders measured are provided Y  Y 
Important potential confounders are accounted for in the analysis  
 
Y  Y 
Statistical analysis and 
reporting 
Sufficient presentation of data to assess the adequacy of the analytic strategy P  Y 
The selected statistical method is adequate for the design of the study P  Y 
There is no selective reporting of results 
 
Y  Y 
(Y=yes, N=no, P=partly, U=unclear)
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14 APPENDIX G: COPD ASSESSMENT TEST 
(CAT) 
 
 
 
 
 
 
 
 
 
 
 
 
I never cough 0 1 2 3 4 5 I cough all the time 
I have no phlegm (mucus) in my chest at 
all 
0 1 2 3 4 5 My chest is completely full of phlegm 
My chest does not feel tight at all 0 1 2 3 4 5 My chest feels very tight 
When I walk up a hill or one flight of stairs 
I am not breathless 
0 1 2 3 4 5 When I walk up a hill or one flight of stairs 
I am breathless 
I am not limited doing any activities at 
home 
0 1 2 3 4 5 I am very limited doing activities at home 
I am confident leaving home despite my 
lung condition 
0 1 2 3 4 5 I am not confident leaving my home 
because of my lung condition 
I sleep soundly 0 1 2 3 4 5 I don’t sleep soundly because of my lung 
condition 
I have lots of energy 0 1 2 3 4 5 I have no energy at all 
180 
 
15 APPENDIX H: EQ-5D (5 LEVEL VERSION) 
 
MOBILITY 
I have no problems in walking about        
I have slight problems in walking about      
I have moderate problems in walking about       
I have severe problems in walking about       
I am unable to walk about         
SELF-CARE 
I have no problems washing or dressing myself      
I have slight problems washing or dressing myself      
I have moderate problems washing or dressing myself     
I have severe problems washing or dressing myself      
I am unable to wash or dress myself        
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
I have no problems doing my usual activities      
I have slight problems doing my usual activities      
I have moderate problems doing my usual activities      
I have severe problems doing my usual activities      
I am unable to do my usual activities        
PAIN / DISCOMFORT 
I have no pain or discomfort         
I have slight pain or discomfort        
I have moderate pain or discomfort       
I have severe pain or discomfort        
I have extreme pain or discomfort        
ANXIETY / DEPRESSION 
I am not anxious or depressed        
I am slightly anxious or depressed        
I am moderately anxious or depressed       
I am severely anxious or depressed        
I am extremely anxious or depressed        
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16 APPENDIX I: COPD OVERDIAGNOSIS 
CONFERENCE ABSTRACT (ORAL 
PRESENTATION AT SAPC, POD AND THE 
ERS CONFERENCES) 
Halima Buni, Rachel Jordan, Peymane Adab, Alexandra Enocson, Kar Keung Cheng. 
European Respiratory Journal 46 (suppl 59):OA3288 · September 2015  
Introduction: Overdiagnosis is a growing concern for a wide range of diseases. We aimed to 
assess the magnitude of COPD overdiagnosis in the UK primary care settings and examine 
the characteristics of patients potentially overdiagnosed with COPD.  
Methods: We analysed data on 1,473 GP diagnosed COPD patients aged 40 years and over 
who participated in the Birmingham COPD cohort study-UK. Patients were classified as non-
COPD or confirmed-COPD based on post-bronchodilator spirometry results. Characteristics 
were compared using logistic regression adjusted for age, sex and smoking status.  
Results: Based on GOLD, LLN (GLI-2012 equations) and NICE 2004 definitions, 13.7%, 
28.1% and 32.3% of participants were potentially overdiagnosed with COPD respectively. 
Restrictive pattern of lung disease was observed in 18.9% of non-COPD. Compared to 
confirmed-COPD, non-COPD were younger (mean age 67.2 versus 69.5 years, OR 0.98; 95% 
CI 0.96 - 0.99), more likely to be female (52.2% versus 35.4%, OR 0.5; CI 0.4 - 0.7), never 
smokers (22.9% versus 13.8%, OR 2.2; CI 1.4-3.4), obese (39.3% versus 31%, OR 1.7; CI 1.1 
- 2.5), with multiple comorbidities (23.9% versus 16.4%, OR 1.7; CI 1.1 - 2.6) and showed 
less FEV1 reversibility (10% versus 21.4%, OR 0.4; CI 0.2 - 0.7). Non-COPD participants 
were more likely to report previous asthma (47.3% versus 38.7%), coronary heart diseases 
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(18.4% versus 14.2%), diabetes (18.9% versus 14.2%) and depression (21.4% versus 16.8%). 
But the difference between groups was insignificant.  
Conclusion: Overdiagnosis was common. We identified female sex, obesity, restrictive lung 
pattern and multiple comorbidities as potential predictors for COPD overdiagnosis but 
recommend a follow-up assessment for spirometry variability.
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